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Abstract 
Cytokines and their downstream signalling components play a major role in regulating blood 
and immune cell development and function.  Perturbed cytokine signaling has been implicated 
in deficiencies as well as proliferative disorders and cancers involving those cells.  Amongst 
the cytokine signaling components, Colony-stimulating factor 3 receptor (CSF3R) and Janus 
kinase 3 (JAK3) exert important and distinctive roles. CSF3R is crucial for myelopoiesis with 
a key role in neutrophil production and function. Inactivating mutations in CSF3R lead to 
neutropenia, while activating mutations are associated with myeloid malignancies. JAK3 plays 
an essential role in lymphoid development, with inactivating mutations in JAK3 causing severe 
combined immunodeficiency (SCID), whereas activating JAK3 mutations are associated with 
lymphoid malignancies.  
Zebrafish is well suited to model blood and immune cell development and its disruption, and 
possesses conserved CSF3R and JAK3 homologues. Both had been previously studied in 
zebrafish, but much remained to be learnt about their roles in development and disease. 
Therefore, the aims of this dissertation were: (i) to investigate the role of CSF3R signalling in 
zebrafish myelopoiesis, and generate a model of neutropenia; and (ii)   to investigate the role 
of JAK3 in zebrafish lymphopoiesis and generate models of SCID and lymphoid malignancy. 
Anti-sense morpholinos were used to target the genes encoding the two zebrafish ligands for 
CSF3R, csf3a and csf3b, with both shown to contribute to early myelopoiesis and myeloid cell 
migration during development. In contrast, csf3b contributed to the migration of myeloid cells 
in response to wounding whereas csf3a had a redundant role. However, both csf3a and csf3b 
were required for emergency responses. Genome editing was used to create mutants of 
zebrafish csf3r based on those identified in neutropenia patients. Zebrafish homozygous for 
 XVII 
 
these csf3r mutant alleles possessed reduced number of neutrophils from embryonic through 
to adult stages. They also showed defective neutrophil migration, were more susceptible to 
bacterial infections and failed to respond to CSF3. These fish therefore represent a bone fide 
model of neutropenia unresponsive to CSF3. 
Genome editing was utilised to create mutants of zebrafish jak3 similar to those observed in 
human SCID. These mutants showed reduced numbers of T cells during embryogenesis, which 
continued in larval stages, when NK cells were also observed to be decreased, whereas B cells 
were not affected. This has the hallmarks of the T-B+NK- SCID observed in humans carrying 
inactivating JAK3 mutations. Genome editing was also employed to introduce a specific 
constitutively-activating mutation observed in human T cell lymphoma and other 
hematopoietic malignancies, A573V, into zebrafish Jak3. Zebrafish carrying even one copy of 
the constitutively-activating Jak3 A573V allele displayed elevated T cell numbers during 
embryonic hematopoiesis, which continued into adulthood. The numbers of B cells and NK 
cells were unchanged, but hematopoietic precursors were increased in the adult kidney, 
consistent with a lymphoproliferative disorder. 
This study has extended our knowledge about the role played by CSF3R in myelopoiesis and 
in emergency responses. In addition, the essential contribution of distinct JAK3 mutations to 
two functional distinct diseases - immunodeficiency and lymphoproliferative disorder-was 
shown to be conserved in zebrafish. It is anticipated that the immunodeficient zebrafish model 
may be useful for performing transplantation and other studies, while the lymphoproliferative 
zebrafish model may be applied to the identification of new therapeutics. 
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The following gene and protein nomenclature conventions were used in this study, based on 
the recommendations of ZFIN.  
Example: granulocyte-colony stimulating factor “CSF3R” 
 
Species    Gene  Protein 
Homo sapiens (Humans)   CSF3R  CSF3R 
Gallus gallus (Chicken)   CSF3R  CSF3R 
Mus musculus (Mouse)   Csf3r  Csf3r 
Danio rerio (Zebrafish)   csf3r  Csf3r 
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Chapter 1: Introduction 
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   Hematopoiesis and immunity 
Hematopoiesis, the generation of blood and immune cells, initiates during embryogenesis and 
continues throughout life (Zambidis et al. 2005). Hematopoiesis progresses through several 
distinct waves of development. In mammals, the primitive wave occurs in the extraembyonic 
yolk sac and later in the allantois and placenta, leading to the transient production of primitive 
erythrocytes, important for tissue oxygenation during embryonic growth and development 
(Orkin & Zon 2008), and macrophages including those that populate the developing brain 
(Prinz & Priller 2014; Rieger & Schroeder 2012; Zambidis et al. 2005). Following this is a 
transient intermediate wave of hematopoiesis, which generates erythroid-myeloid progenitors 
(EMP) within fetal blood islands that produce several cell lineages (Bertrand et al. 2007; 
McGrath et al. 2011). The definitive wave commences later in development with the generation 
of hematopoietic stem cells (HSCs) in the aorta-gonad-mesonephros region (Ivanovs et al. 
2011; Medvinsky & Dzierzak 1996; Müller et al. 1994) and placenta (Gekas et al. 2005; 
Ottersbach & Dzierzak 2005) able to give rise to all other blood cell types. These HSCs migrate 
to the fetal liver, thymus and spleen and then ultimately to the bone marrow, where they 
underpin sustained lifelong hematopoiesis (Jagannathan-Bogdan & Zon 2013). 
HSCs can generate both additional HSCs and daughter cells that become progressively 
restricted to specific cell lineages, with different models proposed to describe this complex 
process (Ema, Morita & Suda 2014). In the classical model (Doulatov et al. 2012; Ema, Morita 
& Suda 2014), the multipotent hematopoietic progenitor cells (HPCs) yield common myeloid 
progenitor (CMP) and common lymphoid progenitor (CLP) cells that are restricted to the 
myeloid and lymphoid lineages, respectively (Figure 1.1).  
CMPs differentiate to megakaryocyte-erythroid progenitors (MEPs) or granulocyte-
macrophage progenitors (GMPs). MEPs differentiate via megakaryoblasts to yield 
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2 
 
megakaryocytes (thrombocytes) or via proerythroblasts to yield erythrocytes. GMPs 
differentiate via myeloblasts into granulocytes (basophils, neutrophils and eosinophils) or 
monocytes, which develop into macrophages and myeloid dendritic cells (Baker, Rane & 
Reddy 2007; Rosenbauer & Tenen 2007). These fully differentiated cells have specialised 
roles. Platelets are involved in blood clotting and wound healing, whereas erythrocytes are 
important for O2 and CO2 transport (Rieger & Schroeder 2012). Basophils are responsible for 
allergic and inflammatory responses with additional roles in blood clotting and parasitic 
infections (Karasuyama et al. 2011). Eosinophils are associated with parasitic infections and 
also contribute to allergic reactions (Jacobsen et al. 2012).  Neutrophils defend against bacterial 
and fungal pathogens and are associated with other inflammatory reactions (Mócsai 2013). 
Macrophages have roles in removing the harmful pathogens and dead cell debris by 
phagocytosis (Hume 2008), and consist of two subsets, M1 and M2. M1 macrophages have 
important functions in promoting T helper (Th1) responses, inhibiting cell proliferation and 
mediating tumoricidal activity (Mantovani et al. 2002; Mills 2012), whereas M2 macrophages 
promote Th2 responses and mediate cell proliferation and tissue repair (Mantovani et al. 2002; 
Mills 2012).  
CLPs generate the various lymphoid lineages, including T lymphocytes, B lymphocytes, 
Natural killer (NK) cells and dendritic cells. (Mansson et al. 2009; Rosmarin, Yang & Resendes 
2005). T cells form the principal cellular component of the adaptive immune response and 
include T-helper (TH) cells, cytotoxic T (TC) cells, memory T cells and regulatory T (TREG) 
cells (Andersen et al. 2006). TH cells can be further sub-classified into TH1, TH2, TH9, TH17 
and T follicular helper (TFH) cells (Kaplan, Hufford & Olson 2015).  TH cells have important 
roles in antigen presentation, B cell activation and immune response regulation, including 
activation of TC cells and macrophages (Zhu & Paul 2008). TC cells destroy infected or 
damaged cells and cancer cells (Andersen et al. 2006). Memory T cells are of three types: 
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effector memory T cells (TEM), central memory T cells (TCM) and tissue-resident memory T 
cells (TRM) (Mueller et al. 2013; Sallusto, Geginat & Lanzavecchia 2004). Memory T cells 
have functions in adaptive immunity and can recall responses against previously encountered 
pathogens (Sallusto, Geginat & Lanzavecchia 2004). Lastly, TREG cells tolerate T cells to self-
antigens and prevent auto-immunity (Josefowicz, Lu & Rudensky 2012). 
B cells can be classified as plasma B cells and memory B cells (Yoshida et al. 2010). Memory 
B cells are dormant cells that arise by B cell differentiation and have secondary antibody 
response, while plasma cells are terminally differentiated B cells that produce antibodies to 
provide immune protection (Yoshida et al. 2010). NK cells form part of the innate immune 
system, identifying tumors and virally infected cells and marking them for destruction (Vivier 
et al. 2008). NK cells are closely related to T cells and secrete factors, which stimulate T cells, 
macrophages and dendritic cells (Vivier et al. 2008).  Dendritic cells act to stimulate B and T 
cell lymphocytes (Banchereau & Steinman 1998; Hume 2008). There are also a myriad of 
additional lymphocyte populations, such as NK-T cells, and innate lymphoid cells (Montalvillo 
et al. 2014; Nau, Altmayer & Mattner 2014).  
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Figure  1.1:  Definitive  hematopoiesis  
Schematic  representation  of  definitive  hematopoiesis.  Hematopoietic  stem  cells  (HSCs)  self-­
renew  or  generate  HPC  that  undergo  lineage  commitment  to  generate  the  complete  repertoire  
of  blood  and  immune  cells.  HPC  differentiate  to  CMP  and  CLP.  CMP  yield  MEP,  which  give  
rise   to   erythrocytes   and   megakaryocytes,   and   GMPs   that   differentiate   into   basophils,  
eosinophils,  neutrophils,  macrophages  and  dendritic  cells.  CLPs  give  rise  to  all  the  lymphoid  
cells  lineage  consisting  of  T  and  B  lymphocyte  and  NK  cells.  HSC:  hematopoietic  stem  cell,  
HPC:   hematopoietic   progenitor   cell,   CMP:   common   myeloid   progenitor,   CLP:   common  
lymphoid   progenitor,   MEP:   myeloid-­erythroid   progenitor,   GMP:   granulocyte-­macrophage  
progenitor.  Adapted  from  (de  Bruin,  Voermans  &  Nolte  2014).  
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   Cytokine receptor signalling  
   Cytokines 
Cytokines are low molecular weight polypeptides that are involved in cell-cell communication, 
being secreted in response to a range of stimuli. These extracellular signalling proteins act on 
target cells by binding to cognate cell surface receptors that mediate downstream intracellular 
signalling events that result in modulation of gene expression (Baker, Rane & Reddy 2007).   
   Cytokine receptors 
Cytokines act via specific cell-surface receptors divided into ‘Class I’ and ‘Class II’ families. 
These receptors are usually composed of a multi-subunit complex consisting of a unique 
ligand-binding subunit and a distinct signal-transducing subunit. Cytokine receptor chains 
typically comprise an extracellular domain, a transmembrane domain and an intracellular 
domain (Schenk & Snaar-Jagalska 1999). The extracellular domain can possess a number of 
different motifs, such as Immunoglobulin (Ig) and fibronectin type III (FNIII) domains, but all 
contain a conserved motif of 200 amino acids required for ligand-receptor interactions, known 
as the cytokine receptor homology domain (CHD) (Bazan 1990). The CHD contains two 
fibronectin type III (FNIII) folds, each comprising approximately 100 amino acids, and a hinge 
region that connects these modules (Bazan 1990). The CHD of Class I cytokine receptors 
typically contain two conserved cysteine pairs in the N-terminal fold and a conserved 
tryptophan-serine-X-tryptophan-serine (W-S-X-W-S) motif, where X refers to any amino acid 
residue, located in the C-terminal fold. In contrast, the Class II cytokine receptors have a 
different arrangement of cysteines and lack the W-S-X-W-S motif (Baker, Rane & Reddy 
2007). The intracellular domain of cytokine receptors contains two conserved Box 1 and Box 
2 motifs that are important for signalling. 
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   Intracellular signaling pathways 
   JAK-STAT pathway 
Ligand binding initiates cytokine receptor aggregation that concomitantly activates 
intracellular tyrosine kinases called Janus Kinases (JAKs), which are associated with the 
membrane proximal Box 1 and Box 2 regions of the cytokine receptor signaling chain (Rane 
& Reddy 2000). JAKs are relatively large proteins with a molecular weight of ~ 120-140 kDa, 
which are encoded by mRNA transcripts from 4.4 to 5.4 kb in length (Ortmann et al. 2000). 
Four members of this family, have been identified in mammals: JAK1, JAK2, JAK3 and 
tyrosine kinase 2 (TYK2). JAK1, JAK2 and TYK2 are ubiquitously expressed, whereas JAK3 
shows more restricted expression in myeloid and lymphoid cells (Rane & Reddy 1994; Sharfe 
et al. 1997; Witthuhn et al. 1994). Different cytokine receptors have distinct preferences for 
specific JAKs to mediate downstream signalling (Table 1.1). Cytokine binding induces 
conformational changes allowing trans-phosphorylation of residues at multiple sites in the 
activation loop within the kinase domain, including the KEYY sequence (Ihle 1995; Saharinen, 
Takaluoma & Silvennoinen 2000), which is crucial for JAK kinase activity and subsequent 
downstream intracellular signalling (Feng et al. 1997; Gauzzi et al. 1996; Liu et al. 1997).  
The JAKs undergo trans-phosphorylation that subsequently induces tyrosine phosphorylation 
of the receptor, creating docking sites for Src-homology 2 (SH2) containing signalling proteins, 
including the cytoplasmic transcription factors called Signal Transducer and Activator of 
Transcription (STATs) (Figure 1.2). The STAT family consists of seven members (STAT 1-4, 
5A, 5B and 6), with each functioning downstream of specific cytokine receptors. JAKs 
phosphorylate STAT proteins recruited to the activated receptor complexes. Consequently, 
phosphorylated STATs form either homodimers or heterodimers (Baker, Rane & Reddy 2007; 
Winston & Hunter 1996) that dissociate from the receptor complex through increased affinity 
towards the SH2 domains within other STATs (Rane & Reddy 2000). These STAT dimers 
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translocate to the nucleus and regulate the expression of target genes by binding to specific 
DNA sequences within their regulatory regions (Ghoreschi, Laurence & O'Shea 2009). These 
genes are involved in a number of important processes, including differentiation, survival and 
proliferation (Horvath 2000). 
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Figure  1.2:  Cytokine  receptor  signalling  
Schematic  representation  of  signalling  pathways  emanating  from  the  cytoplasmic  domain  of  
activated   cytokine   receptors.  Cytokines   bind   extracellularly   to   their   corresponding   cytokine  
receptor  causing  conformational  changes  that  activate  JAKs  bound  to  the  cytoplasmic  domain,  
which   become   auto-­phosphorylated   and   in   turn   phosphorylate   tyrosine   residues   on   the  
receptor,   which   act   as   docking   sites   for   STATs   and   other   signaling   proteins.   STATs   are  
phosphorylated   by   JAKs,   and   then   dimerize   and   translocate   to   the   nucleus   to   enable  
transcription  of  target  genes  that  produces  the  relevant  cellular  response.  Signaling  is  regularly  
regulated  by   tyrosine  phosphatases,  such  as  SHP-­1/2,  SOCS  and  PIAS  proteins.  Adapted  
from  (Harrison  2012).    
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   The RAS-MAPK pathway 
The RAS-MAPK pathway is initiated by the recruitment of a GRB2/SOS complex by direct 
docking to tyrosine-phosphorylated receptor chains or via intermediates such as SHC (Katz, 
Amit & Yarden 2007; Shaw & Cantley 2006). This complex recruits RAS, which is bound to 
GDP in its inactive state, and promotes the exchange of GDP to GTP to activate RAS. The 
activated RAS binds to and activates RAF, which in turn phosphorylates the MAPK kinases, 
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MEK1 and MEK2 (Katz, Amit & Yarden 2007). These dual-specificity kinases recognize and 
phosphorylate the threonine and tyrosine residues of different downstream MAPKs, 
particularly ERK1 and ERK2, which then phosphorylate various nuclear transcription factors 
to alter their transcriptional activity to induce specific cellular responses, notably including 
proliferation (Downward 2003; Katz, Amit & Yarden 2007).  
   The PI3K/AKT pathway 
Phosphatidylinositol-3 kinases (PI3Ks) are activated by cytokine receptor stimulation typically 
through docking of the regulatory subunit of PI3K, p85, to tyrosine residues on the activated 
receptor (Blalock et al. 1999). This results in the recruitment of the catalytic subunit of PI3K, 
p110, to this complex. Alternatively, PI3K can be induced by activated RAS, which mediates 
the membrane localization and activation of the p110 subunit (Rodriguez-Viciana et al. 1994). 
Upon activation, PI3K converts phosphatidylinositol-4,5-phosphate (PIP2) into 
phosphatidylinositol-3,4,5-trisphosphate (PIP3), which recruits a subset of signalling protein 
with pleckstrin homology (PH) domains like AKT and PDK1 (Fresno Vara et al. 2004). The 
activated AKT regulates several targets, including Forkhead to mediate transcriptional changes 
underpinning cell growth, survival and proliferation (Datta, Brunet & Greenberg 1999). 
   Negative regulators  
As part of the complex signalling cascades used by cytokines to elicit their biological effects, 
rapid and efficient attenuation of signalling is also required to prevent pathologic side effects. 
Some of the negative regulators of cytokine signalling include SH2 domain-containing protein-
tyrosine phosphatases (SHP-1 and SHP-2), SH2-containing 5’-Inositol Phosphatase (SHIP), 
the Protein Inhibitors of Activated STAT (PIAS) families and Suppressor of Cytokine 
Signalling (SOCS). 
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SHP-1 is predominantly expressed in hematopoietic cells and along with SHP-2 regulates 
signalling pathway by binding to the receptor complex via their SH2 domain, deactivating 
receptor associated kinases like JAKs through dephosphorylation (Haque et al. 1998; Migone 
et al. 1998; Weiss & Schlessinger 1998). Similarly, SHIP is also widely expressed in 
hematopoietic cells, and negatively regulates the cytokine and growth factor receptor-mediated 
signalling, especially AKT activation, impacting on cell survival (Helgason et al. 1998; Liu et 
al. 1999; Yasukawa, Sasaki & Yoshimura 2000). In contrast, the PIAS family of proteins act 
by binding to activated STAT dimers and inhibiting their DNA binding activity (Liu et al. 
1998). In humans, there are four PIAS family members, PIAS1 and PIASy that inhibit STAT1, 
PIAS3 that inhibits STAT3, and PIASx that inhibits STAT4 (Shuai 2006). 
Eight mammalian SOCS proteins have been identified, SOCS1-7 and CISH (Cytokine-
inducible SH2-containing protein), most of which are found in hematopoietic tissues. These 
proteins inhibit cytokine signalling through three distinct mechanisms: (i) directly binding to 
the receptor-associated JAK thereby blocking its activity (Endo et al. 1997; Greenhalgh & 
Hilton 2001; Naka et al. 1997) (ii) competing with other signalling molecules for binding to 
phosphotyrosine residues of the receptor (Dalpke et al. 2008) and (iii) targeting receptor 
complexes and associated signalling proteins for proteasomal degradation (Sasaki et al. 1999; 
Yoshimura, Naka & Kubo 2007). Their expression is typically induced by cytokine receptor 
signalling, especially for SOCS1, SOCS2, SOCS3 and CISH (Tamiya et al. 2011; Yoshimura 
1998). 
   Cytokine receptor signalling in hematopoiesis and hematopoietic diseases 
Cytokine receptor signalling via various colony-stimulating factors (CSFs), interleukins (ILs), 
interferons (IFNs), erythropoietin (EPO) and thrombopoietin (TPO) (Mansson et al. 2009; 
Metcalf 1998; Orelio et al. 2008; Robb 2007) plays a critical role in regulating the development 
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and function of blood cells and the immune system in both basal and emergency situations. 
Class I cytokines can be grouped into five subtypes on the basis of their receptor complex 
through which they signal: (i) a single receptor chain (EPO, CSF3), (ii) complex with GP130 
receptor (IL-6, IL-11), (iii) complex with IL-3βc receptor subunit (IL-3, IL-5, CSF2), (iv) 
complex with IL2Rγc subunit or  IL2Rγc related receptor subunits (IL-2, IL-4, IL-7, IL-9, IL-
15 and IL-21) and (v) cytokines signalling through two or more subunits (IFNα/β, IFNγ) 
(Baker, Rane & Reddy 2007; Ihle et al. 1995) (Table 1.1). 
Hematopoietic cytokines have distinct functional roles in hematopoietic differentiation. For 
example, EPO has key roles in embryonic and emergency erythropoiesis, with EPO and 
erythropoietin receptor (EPOR) null mice displaying severe anemia leading to embryonic 
lethality (Lin et al. 1996; Wu et al. 1995). Similarly, TPO has important role in megakaryocyte 
proliferation, with deletion of TPOR resulting in thrombocytopenia (Kieran et al. 1996). IL-6 
and IL-11 are functionally related cytokines sharing the common GP130 subunit. IL-6 has 
multiple functions with key role in B cell differentiation and myelopoiesis (Kishimoto et al. 
1992). Whilst IL-11 has an important role in early hematopoiesis (Musashi et al. 1991a; 
Musashi et al. 1991b) and erythropoiesis with additional functions in myelopoiesis and 
lymphopoiesis (Anderson et al. 1992; Quesniaux et al. 1992). IL-5 acts primarily on 
eosinophils, basophils and their progenitors (Goodall et al. 1993; Sanderson 1992). Finally, 
members of the IL-2R family (IL-2, IL-4, IL-7, IL-9 and IL-15) are involved in T, B and NK 
cell development and function (Rochman, Spolski & Leonard 2009; Yamane & Paul 2012).  
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Table  1.1:  Specificity  of  different  hematopoietic  cytokines  and  their  receptor  
complexes  for  downstream  JAKs  
Summary  of  class  I  and  class  II  cytokines,  their  receptor  and  the  partnering  tyrosine  kinases  
downstream.  EPO:  erythropoietin,  EPOR:  erythropoietin   receptor,  CSF3:  colony-­stimulating  
factor,  CSF3R:  colony-­stimulating  factor  receptor,  CT-­1:  cardiotrophin,  CT-­1R:  cardiotrophin  
receptor,   IL:   interleukin,   IL-­R:   interleukin   receptor,   LIF:   leukemia   inhibitory   factor,   LIFR:  
leukemia  inhibitory  factor  receptor,  OSM:  oncostatin  M,  OSMR:  oncostatin  M  receptor,  IFN:  
interferon,  IFN-­R:  interferon  receptor.  JAK3  has  been  highlighted  in  green,  which  is  one  of  the  
genes  of  interest  in  this  study.  Adapted  from  (O'Sullivan  et  al.  2007)  
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Due to the importance of cytokine signalling in the development and function of these blood 
and immune cell lineages, disruptions in cytokine receptor-signalling components are also 
associated with disease.  
Benign erythrocytosis is characterised by increased levels of red blood cells with normal levels 
of serum erythropoietin (Arcasoy, Harris & Forget 1999; Youssoufian et al. 1993). This disease 
is caused by a nonsense mutation in the EPO receptor leading to deletion of 70 carboxy-
terminal amino acids (de La Chapelle, Träskelin & Juvonen 1993) or a frameshift mutation 
resulting in deletion of 64 carboxy-terminal amino acids (Sokol et al. 1995). These deletions 
cause disruption of the binding site for the negative regulator SHP-1, and results in constitutive 
activation of EPOR and leading to enhanced production of red blood cells (Arcasoy, Harris & 
Forget 1999; Kralovics et al. 1997; Noguchi et al. 2008). 
Severe Combined Immunodeficiency (SCID) is a primary immunodeficiency characterized by 
profound lymphopenia. In X-linked SCID, the IL-2Rγc chain, the common signalling 
component of the receptors for IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 is mutated, thereby 
failing to initiate normal signalling (Giri et al. 1994; Kimura et al. 1995; Leonard 1994; 
Noguchi et al. 1993; Russell et al. 1993; Russell et al. 1995). This causes an absence of T and 
NK cells with non-functional B cells. Furthermore, ligand specific receptor mutations such as 
IL-15/IL-2Rβ, have been found to cause another form of SCID with low T cells, normal B cells 
and no NK cells (Gilmour et al. 2001). 
A variety of hematological proliferative disorders and malignancies are associated with 
mutations affecting the downstream JAK-STAT pathway. TEL-JAK2 fusion proteins have 
been associated with lymphoid (ALL) and myeloid atypical (CML) malignancies (Lacronique 
et al. 1997). These are caused by fusion of the helix-loop-helix oligomerisation domain of the 
transcription factor TEL to the catalytic JH1 domain of JAK2, leading to constitutive activation 
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of the complex and downstream signalling molecules including STAT proteins leading to 
unrestrained proliferation. In addition, activating mutations in the SH2 domain of STAT3 and 
STAT5B have been identified in patients with NK/T-cell lymphoma (NKTCL) (Küçük et al. 
2015), and STAT5B SH2 mutations in the patients with γδ-T-cell lymphomas (Bandapalli et 
al. 2014). These mutations are associated with increased phosphorylation of protein and 
stimulating proliferative signals for NK cell production. Silencing of the SOCS1 gene by 
aberrant DNA methylation contributes to B-cell neoplasm and myelodysplastic syndrome 
(MDS) (Brakensiek et al. 2005; Weniger et al. 2006), while inactivating mutations in SOCS1 
and SOCS3 have been found in a variety of cancers, including lymphoma (Baus & Pfitzner 
2006).  
   Colony-stimulating factor 3 receptor in health and disease 
   Colony-stimulating factor 3 and its receptor 
Granulocyte colony-stimulating factor (G-CSF), now officially designated as colony-
stimulating factor 3 (CSF3) is encoded by the CSF3 gene, consists of 5 exons and is located on 
human chromosome 17 (q11.2-q12). The encoded CSF3 protein is 207 amino acids and 
becomes glycosylated before being secreted. CSF3 is a major extracellular regulator of 
granulopoiesis (Roberts 2005). CSF3 promotes mobilization of hematopoietic precursor cells 
from bone marrow into the blood (Petit et al. 2002), stimulating the proliferation and 
maturation of myeloid progenitor cells into neutrophilic granulocytes (Demetri & Griffin 1991; 
Kato 2016), as well as also promoting neutrophil survival and functions (Basu et al. 2002; Kato 
2016; Liu et al. 1996). These functions include arachidonic acid release, superoxide anion 
generation, production of leukocyte alkaline phosphate (LAP) and antibody-dependent cellular 
cytotoxicity (ADCC) (Avalos et al. 1990; Kawano et al. 2017; Lopez et al. 1983; Morishita et 
al. 1987; Sato et al. 1988; Teillaud 1998; Van der Kolk et al. 2002). Many tissues are capable 
of producing CSF3 but only in response to infection and inflammation (Cebon et al. 1994; 
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Kavgaci et al. 2002). Various recombinant forms of this cytokine are widely used clinically to 
overcome neutropenic conditions (Ward 2007), as well as in mobilising hematopoietic stem 
cells from bone marrow into the blood for harvesting prior to transplantation (Roberts 2005). 
CSF3 acts via a specific cell surface receptor, Granulocyte Colony-Stimulating Factor Receptor 
(GCSF-R) or Colony-Stimulating Factor 3 Receptor (CSF3R). The CSF3R gene is located on 
human chromosome 1p32-35, consisting of 17 exons scattered over a locus of 16.5 kb (Inazawa 
et al. 1991). The mature CSF3R protein is composed of an extracellular N-terminal Ig domain, 
a CHD domain containing four conserved cysteine residues and a W-S-X-W-S motif, three 
FNIII domains, a transmembrane domain, and cytoplasmic region containing conserved 
sequences termed Box 1, Box 2 and Box 3, as well as four tyrosine residues (Y704, Y729, 
Y744 and Y764) that become phosphorylated upon ligand-receptor binding (Liongue & Ward 
2014; Nguyen-Jackson, Zhang & Watowich 2012) (Figure 1.3). CSF3R forms homodimers 
upon ligand binding through interactions of the Ig-like domain of the first receptor subunit to 
the CHD domain of the second receptor subunit forming a 2:2 crossover receptor complex 
(Tamada et al. 2006).  
The membrane-proximal Box 1 and Box 2 regions of CSF3R are essential for mitogenic signal 
transduction, whereas the membrane-distal Box 3 homology region appears to have a 
regulatory role. CSF3R, like other members of the class I cytokine receptors, lacks intrinsic 
kinase activity (Layton & Hall 2006) but activates multiple intracellular tyrosine kinases, 
including JAK1, JAK2, TYK2 (Marino & Roguin 2008; Nicholson et al. 1994; Shimoda et al. 
1997; Shimoda et al. 1994; Tian et al. 1996), and the SRC kinases, LYN and HCK (Corey et 
al. 1994; Futami et al. 2011). These activate downstream signalling cascades, including STAT 
transcription factors (particularly STAT1, STAT3 and STAT5)  (de Koning et al. 1996; Marino 
& Roguin 2008; Tian et al. 1994; Tian et al. 1996; Ward et al. 1999a), the phosphatidyl inositol 
3-kinase (PI3-K)-AKT pathway (Dong & Larner 2000; Furmento et al. 2016; Hunter & Avalos 
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1998; Souza et al. 2013) and the RAS-MAPK pathway via SHC and GRB2 (Bashey, Healy & 
Marshall 1994; Furmento et al. 2016; Nicholson et al. 1995). Members of the SOCS family 
(particularly SOCS3 and CISH), and various phosphatases (such as SHP-1, SHP-2 and SHIP-
1) serve to negatively regulate the CSF3R (Sampson, Zhu & Corey 2007; Ward et al. 1998b).  
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Figure  1.3:  Structure  of  the  CSF3R  
The  extracellular  domain  of  CSF3R  contains  an  immunoglobulin  (Ig)-­like  domain  (red  oval),  a  
cytokine  receptor  homology  domain  (CHD)  (two  orange  ovals),  with  four  conserved  cysteine  
(C)  residues  (four  thin  black  lines)  and  a  conserved  W-­S-­X-­W-­S  motif  (a  thick  black  line),  and  
three  fibronectin  type  III  (FNIII)-­like  domains  (three  green  hexagons).  The  intracellular  domain  
mediates  downstream  signal  transduction  and  contains  the  conserved  Box  1,  Box  2  and  Box  
3   motifs   (grey   boxes),   and   four   tyrosine   (Y704,   Y729,   Y744   and   Y764)   residues.   The  
intervening  transmembrane  domain  is  denoted  by  a  blue  rectangle.  Adapted  from  (Liongue  &  
Ward  2014).  
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   CSF3R mutations 
A variety of mutations affecting the CSF3R gene have been reported contributing to a range of 
hematopoietic diseases, including neutropenias, myelodysplasia (MDS), acute myeloid 
leukemia (AML) and chronic neutrophilic leukemia (CNL) (Liongue & Ward 2014). Based on 
the location of the CSF3R mutations these can be categorized into distinct categories (Figure 
1.4). 
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Figure  1.4:  CSF3R  perturbations  in  disease  
Schematic   representation   of   the   CSF3R   showing   the   important   subdomains   and   residues  
conserved   among  other   cytokine   receptors.   The   relative   positions   of   various   categories   of  
mutation   are   indicated   on   both   sides   of   the   receptor,   along   with   the   respective   clinical  
manifestations   of   these   perturbations.   Abbreviations:   Ig   –   immunoglobulin-­like;;   CHD   –  
cytokine   receptor   homology   domain;;   CNL   –   chronic   neutrophilic   leukemia;;   MDS   –  
myelodysplastic  syndrome;;  AML  –  acute  myeloid  leukemia.  Adapted  from    (Liongue  &  Ward  
2014).  
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   “Crippling” extracellular mutants 
Approximately 10% of severe congenital neutropenia (SCN) or chronic idiopathic neutropenia 
(CIN) patients are non-responsive to CSF3 therapy and studies show that these patients harbour 
CSF3R extracellular domain mutations (Liongue & Ward 2014; Ward 2007). This category of 
mutations are called ‘crippling’ mutations because they block activation, often impacting on 
the function of the co-expressed wild-type receptors in a dominant manner (Liongue & Ward 
2014; Ward 2007). The first identified mutation of this type was P206H, where one of the 
conserved prolines located between the two folds of the CHD domain was disrupted, thereby 
perturbing the configuration of the ligand-receptor complex. This in turn affected the 
intracellular signalling pathways, where it suppressed activation of co-expressed wild-type 
receptors in a dominant-negative manner (Ward et al. 1999b). Two frame-shift mutations in 
the extracellular domain, S299Gfs*29 and S296Gfs*29, caused by 182 bp and 191 bp deletions 
in the CSF3R gene, respectively, introduced premature stop codons causing truncation from 
the W-S-X-W-S motif (Druhan et al. 2005; Sinha et al. 2003). A CIN-associated frameshift 
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mutation S601Afs*177 that truncates the extracellular domain of the receptor after the 
fibronectin domains has also been reported (Papadaki et al. 2004). 
Recent studies have demonstrated SCN caused by bi-allelic loss-of-function CSF3R mutations. 
One carried an allele intronic mutation, c.998-2A>T that skips exon 9, resulting in a frameshift 
in FNIII domain and the other carried a nonsense (W547*) mutation that truncated the 
extracellular domain of CSF3R (Klimiankou et al. 2015). Similarly, an infant carrying a 
compound heterozygous mutation G316fs*322 and G415fs*432 resulted in frameshift causing 
a premature stop codon (Järvinen et al. 2013; Triot et al. 2014). Finally, three children from the 
same family carried a homozygous missense mutation R308C, which hampered N-
glycosylation of CSF3R resulting in aberrant cell surface localization and disrupted 
downstream signalling (Järvinen et al. 2013; Triot et al. 2014).  
   “Activating” mutants 
A series of CSF3R mutations affecting the transmembrane domain and adjacent residues of the 
encoded receptor have been reported in a variety of myeloid malignancies. These mediate 
stabilization of transmembrane helix-helix interactions resulting in ligand-independent 
activation of the receptor and downstream signalling cascades analogous to similar mutations 
found in the CSF2R and thrombopoietin receptor (TPOR) (D'Andrea & Gonda 2000; Ding et 
al. 2004; Forbes et al. 2002). 
An activating mutation, W341C, in the FNIII domain of CSF3R has been reported in an AML 
patient (Zhang et al. 2017). This mutation mediated formation of intermolecular cysteine 
disulfide bonds leading to receptor self-dimerization. CSF3R W341C occurs as a compound 
mutation with an additional truncation mutation W791X in the intracellular domain present on 
the same allele (Maxson et al. 2013; Zhang et al. 2017). This CSF3R W341C/W791X 
compound mutation has enhanced oncogenic potential (Zhang et al. 2017). In addition, four 
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missense mutations P71R, T231M, E288G, and Q346R within the CSF3R extracellular domain 
have also been identified in CNL/aCML/MPN-U groups (Zhang et al. 2017). 
The activating mutation, T595I, is commonly found in patients with CNL, with the adjacent 
T592A mutation also seen in  CNL (Pardanani et al. 2013). Both T592 and T595 are part of an 
O-linked glycosylation cluster in the extracellular domain adjacent to the transmembrane 
domain, with mutation at these sites hampering O-glycosylation of CSF3R, leading to 
increased receptor dimerization that results in ligand-independent activation (Maxson et al. 
2014). The T595I mutation has also been identified more rarely in atypical chronic 
myelogenous leukemia (aCML) (Maxson et al. 2013), chronic myelomonocytic leukemia 
(CMML) (Mehta et al. 2013), AML (Beekman et al. 2013; Maxson et al. 2013), as well as 
during the initial stages of T-cell precursor T-cell acute lymphoblastic leukemia (ETP-T-ALL) 
(Maxson et al. 2013). CSF3R proteins harbouring these mutations mediated CSF3-independent 
growth of Ba/F3 cells, with constitutive activation of JAK2, SRC, TNK, STAT3 and STAT5 
(Maxson et al. 2013; Mehta et al. 2013), but not AKT and ERK (Mehta et al. 2013).  
An additional CSF3R mutation, N610H was identified in patients with myeloproliferative 
neoplasms (MPNs) (Hughes et al. 2016). N610H and a related N610Q mutation were found to 
highly activate CSF3R, resulting in cytokine independent proliferation and thereby elevating 
the activity of downstream signalling events as confirmed by increased levels of phospho-
STAT3 (Hughes et al. 2016). A different mutation, T617A, was initially identified in a patient 
with AML. Additional reports suggested an alternate T617I mutation in addition to T617A as 
rare, somatic mutations observed in de novo AML (Forbes et al. 2002). The T617A mutation 
was also shown to be the cause for autosomal dominant hereditary neutrophilia, characterized 
by increased numbers of CD34+ precursors that proliferated and differentiated indefinitely in 
the absence of CSF3 (Plo et al. 2009). Lastly, a three nucleotide deletion in-frame mutation, in 
which two amino acids are replaced with an alternative residue, N630K_R631del 
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(N653K_R654del) was observed in MDS, and results in sustained signalling upon ligand 
stimulation (Awaya et al. 2002).  
   “Hyperresponsive” intracellular truncations 
Acquired nonsense mutations in CSF3R have been identified in SCN patients (Dong et al. 
1995a). These mutations result in the truncation of amino acids between 82 and 98 from the 
carboxy-terminus of the receptor (Dong et al. 1995a). Such truncated receptors display normal 
affinity for ligand, but lead to enhanced growth signals with weakened maturation signals 
(Dong et al. 1995a; Dong et al. 1993). When co-expressed with wild-type receptors they also 
act in a dominant-negative manner, enhancing proliferation but inhibiting maturation (Dong et 
al. 1995a). Truncation mutations display increased cell surface receptor expression and ligand 
hypersensitivity, likely because of the loss of motifs necessary for endocytosis and degradation 
(Ward et al. 1999c). SCN patients harbouring these truncating mutations show a strong 
predisposition to both MDS and AML (Welte & Touw 1997). Indeed, CSF3R mutations are 
the most commonly observed in SCN patients that enable transition to AML in (82%) ahead of 
RAS (~50%) and monosomy 7 (Freedman & Alter 2002). However, CSF3R mutations are not 
always seen in AML and can spontaneously disappear and therefore their exact contribution to 
AML remains uncertain.  
Various studies with mouse and cell line models have reported that the truncated Csf3r exert a 
number of effects on myeloid cells. Firstly, truncated Csf3rs result in defective neutrophil 
differentiation and neutropenia under basal conditions, directly contributing to SCN. The 
reduced differentiation is due to loss of sequences within the C-terminal region of the receptor, 
which are essential for signal transduction. One of the important signalling molecules 
associated with this region of the CSF3R is STAT3 (Tian et al. 1994), which has a key role in 
the differentiation and survival of both macrophages and neutrophils (de Koning et al. 2000; 
Shimozaki et al. 1997).  
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Secondly, CSF3R truncations elicit a hyperproliferative phenotype on precursors, explaining 
how SCN patients with these mutations may progress to MDS/AML (Ward 2007). Truncated 
CSF3R receptors display prolonged activation with a reduced “off-rate” (Dong et al. 1998; 
Hermans et al. 1999; Ward et al. 1999c). This is attributed mainly due to impaired 
internalization of the truncated receptor due to the combined loss of a conserved di-leucine 
residue containing motif within Box 3 (van de Geijn et al. 2004; Ward et al. 1999c) and a less 
well defined motif across residues 756 to 769 (van de Geijn et al. 2004). However, the receptor 
truncation also interferes with alternative negative regulatory pathways, such as through loss 
of recruitment sites for two members of the SOCS family, namely CISH (at Y729 and Y744) 
(Hunter et al. 2004) and SOCS3 (at Y729) (van de Geijn et al. 2004), and for the tyrosine 
phosphatases SHP-1 (at an undefined site in C-terminus) (Dong et al. 2001) and SHP-2 (at 
Y724) (van de Geijn et al. 2004). It remains uncertain if expression of truncated CSF3R are 
directly leukemogenic, or rather additional genetic defects are required for transformation to a 
leukemic state (Hermans et al. 1998; Ward 2007). 
   Defective splice variants and pathogenic single nucleotide polymorphisms 
High expression of a CSF3R splice variant triggered by a single base change near the cryptic 
splice donor site has been identified in the blast cells of a de novo AML patient (Dong et al. 
1995b). This encodes a protein with an altered carboxyl terminus due to a change in reading 
frame, with the 130 amino acids from the C-terminus of CSF3R replaced with an alternate 34 
amino acids from another reading frame (Dong et al. 1995b). Finally, a single nucleotide 
polymorphism (SNP) leading to a E785K change in the intracellular region of the receptor was 
observed in almost 6% of the population, and is associated with predisposition to high risk 
MDS, and leads to enhanced signalling in response to CSF3 (Wölfler et al. 2005).  
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   JAK3 in health and disease 
   Structure of JAK3 
Like other JAKs, JAK3 consists of seven JAK homology (Yamaoka et al. 2004) domains 
termed JH1-7, numbered from carboxyl terminus to the amino terminus (JH1-JH7) (Ziemiecki, 
Harpur & Wilks 1994) (Figure 1.5). The JH1 domain corresponds to a tyrosine kinase domain 
possessing a distinctive GXGXXG motif in the nucleotide-binding loop, tyrosine residues in 
the activation loop and a conserved aspartic acid residue important in the phosphotransfer 
reaction within the catalytic loop (Leonard & O'Shea 1998).  
The JH2 or ‘pseudokinase’ domain (PKD) is similar to the kinase domain but lacks key tyrosine 
kinase residues, making it catalytically inactive (Rane & Reddy 2000; Yamaoka et al. 2004). 
However, the PKD domain has a critical negative regulatory function for the kinase domain 
(KD) and also represents a potential docking site for STATs (Chen et al. 2000; Fujitani et al. 
1997; Saharinen, Takaluoma & Silvennoinen 2000). The JH3, JH4 and part of the JH5 domain 
constitute a modified SH2 domain involved in protein-protein interactions (Radtke et al. 2005). 
The amino terminal JH6-JH7 domains constitute a 300 amino acid long FERM (Band-4.1, 
ezrin, radixin and moesin) domain (Girault et al. 1998) that mediates interaction/binding with 
cytokine receptors and positively regulates the catalytic activity of the protein (Zhou et al. 
2001). 
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Figure  1.5:  Structure  of  JAK3  
Schematic  representation  of  the  primary  structure  of  Janus  kinase  3  (JAK3).  Like  other  JAKs,  
JAK3  is  comprised  of  FERM,  SH2-­like,  pseudokinase  and  kinase  domains,  which  relate  to  the  
seven  Janus  homology  (JH)  domains  as  indicated.  The  N-­terminal  FERM  domain  mediates  
cytokine  receptor  binding,  the  FERM  and  the  pseudokinase  domains  have  roles  in  regulating  
the  activity   via   interaction  with   the   catalytic   kinase  domain.  Adapted   from   (Yamaoka  et   al.  
2004)  
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   JAK3 functions 
JAK3 is unique in being predominantly expressed in hematopoietic tissues with constitutive 
high-level expression in NK cells and thymocytes, and is essential for IL2Rγc-mediated 
cytokine signalling (Johnston et al. 1994; Kawamura et al. 1994; Witthuhn et al. 1994). 
   SCID-associated mutations 
The pivotal function of JAK3 in immune development was recognized through the 
identification of a loss-of-function JAK3 mutation in patients with autosomal-recessive SCID 
(Macchi et al. 1995; Russell et al. 1995). The phenotype of these patients was similar to those 
with X-linked SCID, caused by mutations in the IL2Rγc chain (Noguchi et al. 1993), with 
patients harbouring non-functional B cells and lacking T cells and NK cells. Furthermore, a 
patient with a mutation in IL2Rγc chain with a moderate X-SCID phenotype was reported that 
showed partial loss of JAK3 association (Russell et al. 1994). This is consistent with JAK3 
exclusively signalling through the IL2Rγc chain (Russell et al. 1994). 
Defects in JAK3 gene has been reported in patients with autosomal recessive T-B+ SCID 
patients. A point mutation Y100C within the FERM domain of JAK3 causes SCID with 
maternal T cell engraftment, while the compound mutation E481G/del aa 482-596 within the 
JAK3 SH2 domain causes leaky SCID with non-functional T cells in humans (Notarangelo et 
al. 2000). Further, JAK3 SH2 domain mutations R445X and E481fs-P517X causes T-B+ SCID 
(Notarangelo et al. 2000). Similar to these, JAK3 PKD mutations R577W, del aa 590-596, 
Chapter 1 
31 
 
K733fs-A844X and compound mutations Y1023X/L910S (KD mutations) and R445X/C759R 
(SH2/PKD mutations) also causes T-B+SCID (Notarangelo et al. 2000).  
Jak3 knockout mice also developed SCID (Nosaka et al. 1995; Park et al. 1995; Thomis & 
Berg 1997; Thomis et al. 1995), with smaller thymi and slightly smaller spleen, and a profound 
reduction in circulating lymphocytes (Nosaka et al. 1995). Jak3 knockouts developed less 
severe phenotypes compared to human SCID patients (Kisseleva et al. 2002; Levy & Darnell 
Jr 2002; O'Shea, Gadina & Schreiber 2002). Although Jak3 knockout mice have normal 
proportions of thymocytes, they suffered profound loss of early progenitor cells with a 
heightened rate of apoptosis (Baird, Lucas & Berg 2000), associated with concomitant 
downregulation of B cell lymphoma 2 (BCL-2) and upregulation of bcl-2-associated X protein 
(BAX) (Wen et al. 2001). 
   Malignancy-associated mutations 
Activating JAK3 mutations have been detected in several cases of hematopoietic neoplasms, 
specifically Acute Megakaryoblastic Leukemia (AMKL), Natural killer/T-cell lymphoma 
(NKTCL) and T-ALL (Bains et al. 2012; Kiyoi et al. 2007; Koo et al. 2012). These have been 
found in the FERM, SH2 and pseudokinase domains (PKD) (Table 1.2).  
The FERM domain point mutations P132T and P132A have been identified in AMKL patients 
(Constantinescu, Girardot & Pecquet 2008; Riera et al. 2011; Walters et al. 2006). A further 
activating mutation I87T is reported to cause transient myeloproliferative disorder (TMD) (De 
Vita et al. 2007; Kiyoi et al. 2007; Sato et al. 2008). Moreover, three gain-of-function 
mutations, L156P, E183G and R172Q within the FERM domain of JAK3 were reported in 
adult T-cell leukemia/lymphoma (Elliott et al. 2011).  
JAK3 SH2 domain mutation Q501H has been identified in acute megakaryoblastic leukemia 
of Down syndrome (DS-AMKL) patients (Sato et al. 2008). Two JAK3 point mutations within 
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the PKD A572V and V722I, have been identified in AMKL patients (Constantinescu, Girardot 
& Pecquet 2008; Walters et al. 2006), with A572V also reported to cause NKTCL (Koo et al. 
2012). Somatic activating mutation A573V within the PKD was identified in both NKTCL, T-
ALL and AMKL patients (Bains et al. 2012; Degryse et al. 2014; Koo et al. 2012; Malinge et 
al. 2008; Riera et al. 2011; Walters et al. 2006). The A572V and A573V PKD mutations 
resulted in constitutive activation of JAK3 and STAT5 and mediate cytokine-independent 
proliferation when introduced into Ba/F3 cells. JAK3 S789P is a missense mutation found in 
patients with ALL (Mullighan et al. 2009). Three novel JAK3 PKD mutations M576L, V722I 
and A593T were identified in AMKL and transient myeloproliferative disorder (TMD) patients 
(De Vita et al. 2007; Kiyoi et al. 2007; Sato et al. 2008). Another study also reported the 
identification of two other novel PKD mutations of JAK3, R657Q, and V674 in acute 
megakaryoblastic leukemia of Down syndrome (DS-AMKL) patients (Sato et al. 2008). 
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Table  1.2:  Activating  JAK3  mutations  
Activating  JAK3  mutations  reported  in  human  patients  with  various  malignancies.  SH2:  SRC-­
homology  2,  PKD:  protein  kinase  domain,  AMKL:  acute  megakaryoblastic  leukemia,  T-­ALL:  T  
cell   acute   lymphoblastic   leukemia,   NKTCL   :   Natural   killer/T-­cell   lymphoma,   ALL:   acute  
lymphoblastic  leukemia.  
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   Zebrafish as a model 
   Zebrafish overview 
The zebrafish (Danio rerio) is a small tropical fresh water teleost fish belonging to the minnow 
family (Cyprinidae). Compared to other vertebrate models, the zebrafish offers several 
advantages. These include its small size, rapid external development, high fecundity of 200-
300 eggs per week, short generation interval of about 2-3 months and external fertilization that 
enables manipulation of embryos in a petri dish (Berghmans et al. 2005).  Since zebrafish 
embryos are transparent, in vivo visualization of developmental processes and internal organs 
is possible. Lineage-specific transgenic fish lines are also available to mark or manipulate 
specific cells (Amatruda et al. 2002; Smolowitz, Hanley & Richmond 2002; Stern & Zon 
2003). In addition, embryos are permeable to small molecules, facilitating large scale chemical 
screening (Kari, Rodeck & Dicker 2007; Parng et al. 2002). This organism has proven to be an 
excellent vertebrate model to study development, particularly of the hematopoietic system, 
including the molecular mechanisms underpinning human diseases (Stoletov & Klemke 2008). 
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   Zebrafish hematopoiesis 
Like other vertebrates, zebrafish has distinct waves of hematopoiesis (Galloway & Zon 2003). 
Primitive hematopoiesis starts at 13 hours post fertilization (hpf) at two intraembyonic 
locations: the anterior lateral mesoderm (ALM) and the posterior lateral mesoderm (PLM) 
(Carlsson et al. 2007), the latter of which develops into the so-called Intermediate cell mass 
(ICM) at 18 hpf (Figure 1.6). The ALM and PLM contribute to both blood and vascular 
development and express transcription factors for both lineages (Chen & Zon 2009). Primitive 
myeloid cells are generated in the ALM whereas primitive erythrocytes are produced in the 
PLM/ICM (Davidson et al. 2003; Detrich et al. 1995; Liongue et al. 2009a). Around 24 hpf, 
the transient intermediate wave of hematopoiesis starts in the posterior blood island (PBI) 
which generates both erythrocytes and granulocytes.  
The definitive wave of hematopoiesis commences with the generation of multipotent 
hematopoietic stem cells (HSCs) in the ventral wall of dorsal aorta in the aorta-gonad-
mesonephros (Schorpp et al. 2006) region from hemogenic endothelium (Burns et al. 2002; 
Thompson et al. 1998). At 48 hpf, the AGM progenitor cells migrate first to the caudal 
hematopoietic tissue (CHT), equivalent to the mammalian fetal liver, where erythrocytes, 
thrombocytes and myeloid cell lineages are produced. In contrast to mammalian erythrocytes, 
which have a nucleus only during their primitive wave, all zebrafish erythrocytes are nucleated 
(Weinstein et al. 1996). Further, zebrafish thrombocytes are nucleated and appear as aggregates 
in peripheral blood, however, they lack megakaryocytes (Carradice & Lieschke 2008). At 
around 54 hpf, common lymphoid progenitor (CLP) cells migrate from the AGM to thymus, 
where the T cell development commences (Kissa et al. 2008). Around 48 hpf, HSCs migrate 
to the kidney marrow, equivalent to the mammalian bone marrow, which is the primary site for 
definitive hematopoiesis and gives rise to all blood lineages, including B cells starting from 
~20 dpf (Bertrand et al. 2008; Chen & Zon 2009; Kissa et al. 2008; Page et al. 2013). NK cells 
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and a novel population of NK-like cells have been identified in zebrafish although their 
developmental ontogeny remains to be determined (Moore et al. 2016a; Tang et al. 2017).  
Key hematopoietic transcription factors have conserved orthologues in zebrafish. These are 
used to visualise specific cell populations using whole mount in situ hybridisation (WISH) in 
the absence of antibodies used in mammals to identify different subsets of stem cells, 
progenitors, and other hematopoietic cells. The transcription factors scl, lmo2, gata2, fli1 and 
etsrp genes serve as markers of hemangioblasts, the common precursor of blood and 
vasculature, which is derived from lateral mesoderm (cdx4) (Lengerke & Daley 2012; van den 
Akker et al. 2002; Wingert et al. 2007). Early hematopoietic stem cell progenitors also express 
scl (Liao et al. 1998; Patterson et al. 2007; Patterson, Gering & Patient 2005; Pham et al. 2007; 
Sumanas & Lin 2005; Thompson et al. 1998), whilst markers of HSCs during definitive 
hematopoiesis include runx1 and c-myb (Burns et al. 2002; Kalev-Zylinska et al. 2002; Willett 
et al. 2001). The ikaros gene also marks HSCs during early hematopoiesis and later the 
lymphoid progenitors that emerge during definitive hematopoiesis at around 96 hpf (Willett et 
al. 2001) (Figure 1.6). Nascent HSCs in the AGM, as well as thrombocytes express the cd41 
(Kissa et al. 2008). The gata1 gene marks various erythroid progenitors (Long et al. 1997), 
whereas spi1 and c/ebp1 are employed as markers for early myelopoiesis (Lieschke et al. 2002; 
Lyons et al. 2001b). Mature erythrocytes are identified with β-globin and later αe1-globin (Jin 
et al. 2009). The classical zebrafish marker employed for neutrophils is mpo (Bennett et al. 
2001; Lieschke et al. 2001; Liu et al. 1996; Yoong et al. 2007), with fms and l-plastin expressed 
in monocyte/macrophages (Aarts et al. 2004; Bennett et al. 2001; Hall et al. 2007; Herbomel, 
Thisse & Thisse 1999; Le Guyader et al. 2008; Meijer et al. 2008). T cell specific markers, 
such as gata3, ikaros, lck, rag1 and rag2 genes are expressed in the thymus (Trede, Zapata & 
Zon 2001). Other genes, such as l-plastin, lyz and mmp-9 likely mark overlapping myeloid 
populations (Bennett et al. 2001; Hall et al. 2007). Some of the B cell markers include cd37, 
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pax5, cd79a, cd79b,ighz, igic1s1, and igl2v2 whereas NK cell markers include ztb32, nkl.2, 
ccl38.6, il2rb, jak3, nkl.4 and prf1.8 (Tang et al. 2017). 
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Figure  1.6:  Hematopoiesis  in  zebrafish  
Spatial   and   temporal   representation   of   zebrafish   hematopoiesis.   Different   sites   of  
hematopoiesis  and  the  corresponding  cells  produced  are  depicted  in  the  top  panel.  The  green  
area  indicates  the  site  of  primitive  hematopoiesis,  pink  indicating  transient  intermediate  wave  
of   multi-­lineage   hematopoiesis   and   blue   depicting   the   definitive   hematopoiesis.   Important  
hematopoietic  transcription  factors  and  markers  are  listed  in  each  box,  with  their  expression  
pattern  at  various  timeline  shown  in  the  bottom  panel.  Mesoderm  cells  (white  box  and  grey  
arrows)   differentiate   temporally   into   four   progenitor   populations,   ALM,   PLM/ICM,   PBI   and  
AGM.  ALM  is  the  site  for  myeloid  (M)  and  endothelial  (Ec)  cells,  PLM/ICM  being  the  site  for  
erythroid  cells   (E)  and  endothelial   cells.  The  definitive  wave  starts  at  25  hpf  and   the  AGM  
progenitors  (P)  enter  the  circulation  at  33  hpf,  seeding  the  caudal  hematopoietic  tissue  (CHT)  
and  kidney  at  48  hpf.  The  CHT  is  an  intermediate  site  for  blood  development  (erythroid  (E),  
myeloid  (M)  and  thromboid  (T)  lineages),  whereas  the  kidney  marrow  is  the  site  for  all  blood  
cell  development.  The  common   lymphoid  progenitors   (CLPs)  migrate   from   the  AGM  to   the  
thymus  at  54  hpf,  which   is   the  site   for  maturation  of   lymphoid  T  cells.  Abbreviations:  ALM-­  
anterior   lateral  mesoderm,  PLM-­  posterior   lateral  mesoderm,   ICM-­   intermediate   cell  mass,  
PBI-­  posterior  blood  island  and  AGM-­  aorta-­gonad  mesonephrons.  Adapted  from  (Chen  &  Zon  
2009).  
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   Zebrafish cytokine signalling 
Zebrafish and humans share broad conservation of cytokine receptor signalling. A total of 36 
class I cytokine receptors/chains have been identified in zebrafish, 24 of which represent clear 
orthologues for mammalian receptors (Liongue & Ward 2007). These receptors show 
conservation of key domains such as Ig, CHD, FNIII, transmembrane, and intracellular 
domains including the key tyrosine residues for intracellular signal transduction (Liongue et al. 
2009a). Several studies of cytokine receptors show key conservation of function (Liongue et 
al. 2009a; Paffett-Lugassy et al. 2007). Zebrafish CSF3R exhibited a conserved function in 
myeloid development with their knockdown causing severe reduction in neutrophils (Liongue 
et al. 2009a). The zebrafish has two paralogues of IL-2Rγc, il-2rγc.a and il-2rγc.b, with il-
2rγc.a shown to have important role in lymphopoiesis with their inactivating mutations causing 
SCID-like phenotype with reduced T and NK cells, but B cells were present with all other 
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aspects of hematopoiesis being unaffected (Sertori et al. 2016). Zebrafish also has conserved 
downstream cytokine signalling components, including single JAK1 and JAK3 orthologues, 
and been shown to have an evolutionary conserved role of IL-7 signalling in zebrafish T cell 
development. A similar complement of STATs indicating conserved intracellular signalling 
pathways (Iwanami et al. 2011; Liongue et al. 2012). Zebrafish Jak3 was also been shown to 
have a conserved role in lymphopoiesis acting downstream of the Il-2rγc signalling chain 
(Sertori, Ward & Liongue). Functional characterisation of epo and epor has been shown to be 
conserved in mammals with prominent roles in erythropoiesis and their overexpression in 
zebrafish resulted in severe polycythemia (Paffett-Lugassy et al. 2007). 
   Zebrafish models of immunodeficiency 
Due to the applicability of the zebrafish animal model and conservation of blood and immune 
development and the genes controlling it, several zebrafish models of immunodeficiencies have 
been developed (Iwanami et al. 2011; Jung et al. 2016; Langenau & Blackburn 2014). 
The immunocompromised zebrafish model has been generated by utilizing zinc-finger 
nucleases (ZFNs) targeting zebrafish Rag2 with the Rag2E450fs  frameshift mutation resulting 
in reduced functionally mature T and B cell lymphocytes (Tang et al. 2014). This mutant was 
viable and had normal fecundity. Furthermore, ENU mutagenesis and subsequent screening 
identified Ikaros mutant zebrafish that had a severe reduction in rag1+ T cells (Schorpp et al. 
2006). This nonsense mutation instigated in the generation of hypofunctional protein which 
lacked the C-terminal zinc finger at ikaros gene resulting in complete loss of T cell lymphocyte 
population. ENU mutagenesis also revealed the earl gray mutant zebrafish with defective 
pharyngeal arches and devoid of lymphocytes (Trede et al. 2007). Another mutant, van gogh, 
phenotypically resembled the human DiGeorge syndrome. These mutants were devoid of 
thymus or displayed thymic hypoplasia (Piotrowski & Nüsslein-Volhard 2000; Piotrowski et 
al. 1996). 
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A variety of SCID models of zebrafish has been developed. One such model includes Prkdc-
null zebrafish generated by transcription activator like effector nucleases (TALEN) genome 
editing (Jung et al. 2016). This resulted in a complete loss of functional T and B lymphocytes 
and was utilised as an excellent platform for tumor xenograft studies. Warts, 
hypogammaglobulinemia, infections and myelokathexis (WHIM) is a primary 
immunodeficiency (PID) disorder characterized by severe congenital neutropenia and recurrent 
infections. Transgenic expression of CXCR4b–GFP or WHIM–GFP transgenic lines resulted 
in impaired neutrophil mobility and wound recruitment (Walters et al. 2010). Another PID 
model of zebrafish was developed by generating transgenic zebrafish expressing Rac2D57N 
mutation in neutrophils. Rac2 mutant zebrafish were neutropenic with reduced polarity and 
mobility of neutrophils (Deng et al. 2011). 
   Zebrafish models of leukemogenesis 
Zebrafish have been employed as a model of leukemia and other hematopoietic proliferative 
disorders, typically using transgenic approaches (Table 1.3). The first zebrafish model of 
leukemia was generated, by transient expression of a human RUNX1-CBF2T1 transgene, the 
product of the t(8;21) translocation in acute myeloid leukemia in zebrafish embryos (Kalev-
Zylinska et al. 2002). This resulted in disruption of normal hematopoiesis, aberrant circulation, 
internal hemorrhages and cellular dysplasia. The expression of a zebrafish-derived Etv6-Jak2a 
fusion under the control of the zebrafish spi1 promoter, resulted in the expansion of the myeloid 
compartment causing ALL and aCML (Onnebo et al. 2005; Onnebo et al. 2012). 
Various AML models of zebrafish have been developed. The first bona fide zebrafish model 
of AML expressed MOZ/TIF2, the oncogenic product of inv (8)(p11q13) under the control of 
spi1 promoter which led to the development of overt AML with extensive invasion of myeloid 
blast cells within the kidney (Deguchi et al. 2003; Zhuravleva et al. 2008). Expression of the 
human AML-derived MYST3/NCOA2 fusion gene under the control of the spi1 promoter led 
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to the development of AML in  ̴ 1% of embryos, including extensive invasion of kidney by 
myeloid blast cells (Zhuravleva et al. 2008). Overexpression of a mutant human nucleophosmin 
(NPM1) in zebrafish resulted in increased myeloid cell numbers during primitive 
hematopoiesis, especially in a p53 mutant context, with increased numbers of EMPs and HSCs 
in the AGM region (Bolli et al. 2010). Another zebrafish AML model was established by 
expressing a human RUNX1-ET0 translocation fusion gene from a heat shock promoter, which 
resulted in disrupted hematopoiesis, reduction in circulating blast cells, cellular 
immaturity/dysplasia and hemorrhages in the central nervous system (Yeh et al. 2008; Yeh et 
al. 2009). Injection of mRNA encoding AML-derived FLT3-ITD or FLT3-TKD mutants in 
zebrafish led to constitutive activation of downstream signalling pathways, resulting in 
expansion of myeloid cells reminiscent of human AML (He et al. 2014). Transgenic zebrafish 
expressing the mouse Mycn under the control of the zebrafish hsp70 promoter developed many 
aspects of human AML following induction of expression, including enhanced cell 
proliferation and accumulation of immature blasts, increased myelopoiesis and anemia, with 
immature myeloblasts observed in the peripheral blood, kidney marrow, and spleen (Shen et 
al. 2013). A forward genetic screen using zebrafish identified a mutation in Ddx18 that resulted 
in a loss of mature myeloid and erythroid cells due to increased apoptosis and p53-dependent 
G1 arrest. Subsequent screening of AML patients identified four non-synonymous sequence 
variants of DDX18 (Payne et al. 2011).  
A stable zebrafish T-ALL model was generated using chimeric enhanced green fluorescence 
protein (EGFP) fused to mouse c-Myc gene under the control of the zebrafish rag2 promoter 
(Langenau et al. 2003; Mizgirev & Revskoy 2010; Smith et al. 2010). This caused an initial 
expansion of EGFP positive cells in thymus, before hematologic dissemination into a T-ALL. 
To overcome issues related to high early mortality, a conditional cMyc-expressing transgenic 
line was generated using a heat shock-inducible Cre-recombinase, in which the transgene 
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expression could be activated later in development (Feng et al. 2007; Feng et al. 2010; 
Langenau et al. 2005). Loss-of-function PTEN mutations or activating AKT2 induced MYC-
independent T-ALL tumor progression (Gjini et al. 2015; Gutierrez et al. 2011; Gutierrez et al. 
2014). Chen et al. developed transgenic zebrafish overexpressing the intracellular domain of 
human NOTCH1 (ICN1) fused to EGFP,  leading to aggressive oligoclonal T-ALL (Chen et 
al. 2007). Several heritable T-ALL models of zebrafish were generated by employing a 
transgenic line expressing EGFP-positive lymphocytes in a forward genetic screen (Frazer et 
al. 2009). Sabaawy et al. developed the sole model of B-cell precursor ALL (B-ALL) by 
expressing a human ETV6-RUNX1 fusion gene, interfering with the normal B-cell 
development (Sabaawy et al. 2006). About 3% of the transgenic zebrafish carrying these 
mutations developed B-ALL. The PTEN is also frequently mutated in hematological 
malignancies including T-ALL (Gutierrez et al. 2009). Zebrafish Pten−/− mutants showed 
leukemia-like phenotypes, including enhanced proliferation of HSCs within the CHT and 
differentiation arrest of committed progenitors across the erythroid, myeloid, and lymphoid 
lineages (Choorapoikayil et al. 2014; Fu et al. 2010). 
Overexpression of a zebrafish Jak2a V581F mutant based on a recurring somatic gain-of-
function mutation in the JH2 domain of JAK2, causing polycythemia vera (PV), resulted in an 
increase in Stat5.1 phosphorylation, upregulation of major hematopoietic transcription factors, 
and a Stat5.1-dependent increase in erythrocyte numbers at 18 hpf.  This model shared the 
features of human JAK2 V617F PV (Ma et al. 2009). Finally, expression of a constitutively-
active Stat5.1 H298R/N714F mutation also led to myeloid cell expansion, with increased 
number of myeloid, erythroid and B cell lineages (Lewis, Stephenson & Ward 2006). The first 
stable model of MPD-utilized heat shock-inducible Cre/Lox-mediated expression of human 
kRASG12D from the zebrafish β-actin promoter. Whole animal heat shock induction resulted in 
high tumor incidence with short latency, but associated with significant juvenile lethality and 
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a propensity to develop other disorders, like rhabdomyosarcoma, intestinal hyperplasia, and 
malignant peripheral nerve sheath tumor (Le et al. 2007). Expression of human HRASG12V from 
the zebrafish fli1 promoter also recapitulated several pathologic aspects of MPD, including 
defective definitive hematopoiesis, with enhanced proliferation and infiltration of leukocytes 
into the CHT and kidney marrow (Alghisi et al. 2013). Transgenic expression of the systemic 
mastocytosis (SM)-derived KITD816V mutant under the control of the zebrafish β-actin 
promoter recapitulated features of aggressive SM, with infiltration of mast cells into the kidney 
marrow, associated with elevated expression of mast cell proteases, decreased epcam 
expression, and defects in cell-cycle progression, with significantly increased apoptosis (Balci 
et al. 2014). 
Zebrafish carrying a hypomorphic spi1 mutant allele exhibited overproduction of immature 
granulocytes in the CHT by 3 dpf and in the kidney marrow at later time points, which persisted 
to 18 months of age. This was associated with a reduction of lymphoid cells in kidney marrow 
and subsequent accumulation of myeloblasts in the peripheral blood, which closely mimicked 
aspects of human myelodysplastic syndrome (MDS)/AML (Sun et al. 2013). Conditional 
expression of the human NUP98-HOXA9 oncogene under the control of the zebrafish spi1 
promoter was achieved using a Cre/lox-heat shock induction strategy. Heat shock-induced 
expression of NUP98-HOXA9 perturbed hematopoiesis, with enhanced spi1+ myeloid 
precursors at the expense of gata1+ erythroid precursors (Forrester et al. 2011; Ko et al. 2015). 
Mutation of the Ten-Eleven Translocation 2 (TET2) has been observed in MDS (Ko et al. 
2015). A Tet2−/− zebrafish line generated through genome editing demonstrated normal 
embryonic hematopoiesis, but developed a pre-myelodysplasia at 11 months of age. This 
culminated in true MDS at 24 months, characterized by increased progenitor and 
myelomonocytic cell numbers, and decreased erythrocyte cell numbers within the kidney 
marrow (Gjini et al. 2015). The zebrafish crimsonless (Crs) mutant was identified in a forward 
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genetic screen that exhibited phenotypes consistent with MDS, including multilineage 
cytopenia, including decreased hbbe3+ and mpo+ cells, disrupted gata1+ precursors, and cell 
dysplasia. The causal mutation in crs was identified in Hspa9b, encoding a conserved 
mitochondrial matrix chaperone, with the loss-of-function Hspa9bG492E mutation disrupting the 
substrate-binding domain of the protein (Craven et al. 2005). 
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Table  1.3:  Zebrafish  models  of  blood  and  immune  cancers  and  proliferative  
disorders  
Zebrafish  models  of  different  types  of  leukemia  studied  to  date,  with  the  targeting  protein  and  
their  key  phenotypes  shown.  Adapted  from  (Rasighaemi  et  al.  2015)  
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   Genome editing  
High precision genome engineering has become a powerful tool for biological research. 
Strategies for genome editing have proven successful in zebrafish, including ZFN (Miller et al. 
2007; Porteus & Baltimore 2003), TALENs (Christian et al. 2010; Wood et al. 2011), and the 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas system (Deveau, 
Garneau & Moineau 2010; Horvath & Barrangou 2010). These genome editing strategies can 
be used to induce targeted insertions, deletions and other alterations in the zebrafish genome.  
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   Transcription Activator-Like Effector Nucleases  
TALENs are genome editing nucleases that are derived from naturally occurring proteins from 
plant pathogens, called transcription activator-like effector (TALEs). TALENs work in pairs 
and is comprised of a TALE-derived DNA binding domain and a DNA cleavage domain 
(Figure 1.7). The DNA binding domain consists of 12-27 repeats, each composed of 33-35 
amino acids. Each repeat of the TALEN design recognises and binds to a single target DNA 
nucleotide, with two hypervariable amino acids known as the repeat variable di-residues 
(RVDs) determining the base specificity (Bogdanove & Voytas 2011; Deng et al. 2012; Joung 
& Sander 2012). The C-terminal cleavage domain is also composed of a FokI endonuclease, 
that functions only when a pair of TALENs binds to the target DNA, creating a double-stranded 
break  (Cermak et al. 2011). TALENs have been adopted for gene manipulation and to create 
various disease models in a variety of organisms such as mouse-ear cress, rat, zebrafish, fruitfly 
and human cell lines (Bedell et al. 2012; Cermak et al. 2011; Dahlem et al. 2012; Hockemeyer 
et al. 2011; Tesson et al. 2011; Zhang, Ferreira & Schnorrer 2014). TALEN pairs are also 
delivered by injection of encoding mRNAs in zebrafish embryos, and have been used to 
generate a wide variety of mutations. When compared to ZFNs, TALENs are more reliable and 
flexible as they have higher target specificity and so reduced off-target effects (Dahlem et al. 
2012; Mussolino et al. 2011). 
    Clustered Regularly Interspaced Short Palindromic Repeats-Cas system 
The CRISPR-Cas system is derived from the adaptive immune mechanisms of bacteria and 
archaea, which are used to defend against invading exogenous viruses and plasmids (Deveau, 
Garneau & Moineau 2010; Garneau et al. 2010; Horvath & Barrangou 2010). In contrast to 
ZFN and TALENs, which are based on the protein-DNA interaction mediated targeting, 
CRISPR uses RNA-DNA base pairing interactions for target recognition. These adaptive 
systems consist of a Cas9 nuclease and a CRISPR RNA (crRNA) array made of short foreign 
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DNA fragments from the invading viruses/plasmids that are incorporated between the CRISPR 
repeats, which is retained as a memory of previous exposures, and a trans-activating crRNA 
(tracrRNA) that mediates the processing of the crRNA array into short fragments (Garneau et 
al. 2010; Gasiunas et al. 2012). A chimera of the crRNA and transcrRNA has been generated, 
known as the single-guide RNA (sgRNA) for ease of gene manipulation (Jinek et al. 2012). 
The guide sequence within the sgRNA recognizes and binds to a complementary 20 bp DNA 
target adjacent to a protospacer adjacent motif sequence (Jinek et al. 2012) (Figure 1.7). The 
sgRNA directs Cas9 to cleave the target site only if there is an adjacent PAM sequence, NGG, 
and serves as a target identification signal for the Cas9 nucleases (Ran et al. 2013; Sander & 
Joung 2014). The Cas9 then induces a DSB at the RuvC and HNH sites within the target DNA 
strands (Sapranauskas et al. 2011). CRISPR-Cas systems have been successful in creating 
knock-out and knock-in allelles in model organisms such as mouse and zebrafish (Auer et al. 
2014; Chang et al. 2013). CRISPR-Cas9 gene editing has proven to be highly specific, being 
more efficient and easy to customize compared with other approaches. This approach can also 
be used to generate tissue-specific knockouts, transcribing the gRNA ubiquitously using a U6 
promoter, while limiting expression of Cas9 with a tissue-specific promoter (Ablain et al. 
2015). CRISPR can also be multiplexed by injection of multiple sgRNAs, allowing 
simultaneous targeting of multiple genes or locations within a gene. The biggest limitation of 
this methodology is its inability to target all sequences, relying on specific sequence motifs to 
be present. 
   DNA Repair 
The engineered nucleases exploited by genome editing technologies such as TALEN and 
CRISPR act by inducing a DNA double stranded break at a specific sequence of interest (Lones 
et al. 2007), thereby stimulating DNA repair typically via either the error-prone Non-
Homologous End Joining (NHEJ) or error-correcting Homology-Directed Repair (HDR) 
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mechanisms (Figure 1.7). NHEJ occurs in the absence of any repair template, resulting in the 
efficient introduction of insertion or deletion (indel) mutations. NHEJ is primarily aimed at the 
generation of loss-of-function models, with indels introduced in coding exons to disrupt the 
translational reading frame, causing frame shift mutations and premature stop codons (Ran et 
al. 2013; Sander & Joung 2014). In contrast, HDR uses a donor template for repair, which is 
exogenously introduced either as a double-stranded DNA construct or as a single-stranded 
DNA oligonucleotide (ssODN) with flanking insertion sequences in the homology arms. This 
approach can introduce a full range of genetic alterations through recombination of the target 
locus with the repair template (Ran et al. 2013; Sander & Joung 2014).  
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Figure  1.7:  CRISPR  and  TALEN  mediated  genome  editing  
Schematic  representation  of  transcription  activator-­like  effector  nucleases  (TALENs)  (A)  and  
clustered   regularly   interspaced   short   palindromic   repeat   (CRISPR)/CRISPR-­associated  
protein  9  (Cas9)  (B).  These  bind  to  target  DNA  sites  to  deliver  a  double-­strand  break  (Lones  
et  al.  2007).  The  TALENs  work  in  pairs  with  two  DNA-­binding  domains,  arranged  in  an  inverted  
dimer,  which   recognizes  specific   sequences,  while  CRISPR/Cas9  system   recognizes  DNA  
through  an  RNA-­DNA  interaction  between  the  target  site  and  a  CRISPR-­based  synthetic  guide  
RNA.  The  TALENs  possess  a  FokI  nuclease  domain  for  DNA  cleavage,  whereas  the  CRISPR-­
based  guide  RNA  recruits  a  Cas  nuclease  for  the  same  function.  Cas9  uses  its  dual  RuvC  and  
HNH  endonuclease  domains   to  create  cleavage.  The  DSB   is   repaired  by  non-­homologous  
end  joining  (NHEJ)  or  homology-­dependent  repair  (HDR)  (C).  NHEJ  occurs  in  the  absence  of  
donor   template  and  results   in  random  insertions  or  deletions  (indels).   In  HDR,  a   transgene  
donor   DNA   template   can   be   provided,   facilitating   targeted   insertion   or   modification.  
Abbreviations:  sgRNA-­  single-­guide  RNA,  Cas-­  crispr-­associated  system,  PAM-­  protospacer  
adjacent  motifs.  Adapted  from  (Sertori  et  al.  2015).  
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   Rationale, Aims and Hypothesis 
Cytokines play a pivotal role in hematopoiesis and immunity, with perturbations of components 
of cytokine receptor signalling pathway leading to a variety of hematopoietic disorders, 
including immunodeficiencies and malignancies. Zebrafish represent a valuable vertebrate 
organism to model hematopoietic disorders, with high conservation of hematopoiesis as well 
as the relevant genes controlling this process, including cytokine receptor signalling 
components.  
Therefore, the underlying hypothesis of this project was that zebrafish could be used as a model 
for human hematopoietic diseases mediated by mutant cytokine receptor signalling 
components. For this purpose, GCSF-R has been selected as an exemplar of mutations 
impacting on the myeloid lineage and JAK3 as an exemplar for the lymphoid lineage. 
The project pursued two specific aims:  
(i) To investigate the role of G-CSF and GCSF-R in zebrafish myelopoiesis and generate a 
model of neutropenia.  
(ii)  To investigate the role of JAK3 in zebrafish lymphopoiesis and generate models of SCID 
and lymphoid malignancy.
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   Materials 
   Suppliers  
The following companies supplied reagents and equipment used in this work:  
AGRF, Parkville, Vic, Australia  
Ambion, Austin, TX, USA  
Amresco, Solon, OH, USA  
Applied Biosystems, Warrington, UK  
Astral Scientific, Sydney, NSW, Australia  
BDH Laboratory Supplies, Poole, UK  
Beckman Coulter, Lane Cove, NSW, Australia  
Bioline, Sydney, NSW, Australia  
Bio-Rad, Hercules, CA, USA  
Chem-Supply, Port Adelaide, SA, Australia  
Eppendorf, Hamburg, Germany  
GeneCodes, Ann Arbor, MI, USA  
Gene Target Solutions, Dural, NSW, Australia  
Gene Tools, Philomath, OR, USA  
GeneWorks, Thebarton, SA, Australia  
Gilson, Guelph, Canada  
Hitachi, Tokyo, Japan  
Interpath Services, Heidelberg West, Vic, Australia  
Life Technologies, Carlsbad, CA, USA  
Nikon, Tokyo, Japan  
Olympus, Tokyo, Japan  
Promega, Madison, WI, USA  
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Qiagen, Melbourne, Vic, Australia  
Roche Molecular Biochemicals, Indianapolis, IN, USA  
Sigma-Aldrich, Sydney, NSW, Australia  
Thermo Scientific, Waltham, MA, USA  
ToolGen, Seoul, South Korea  
VWR, Murarrie, Qld, Australia  
Westlab group, Ballarat, Vic, Australia  
Zebrafish International Resource Center, Eugene, OR, USA 
   Oligonucleotides  
Oligonucleotide primers were synthesised by Sigma Genosys Products (Table 2.1). 
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Table  2.1:  Oligonucleotides  used  in  this  study    
Ori  =  orientation,  S  =  sense,  AS  =  anti-­sense,  bp  =  base  pairs,  HRM  =  high  resolution  melt,  
HDR  =  homology  directed  repair,  RT-­PCR  =  reverse  transcriptase  polymerase  chain  reaction,  
QRT-­PCR  =  quantitative  reverse  transcriptase  polymerase  chain  reaction.  
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Primer Description Ori Sequence 5`-3` bp Application 
AW024 β-actin F S TGGCATCACACCTTCTAC 18 
QRT-PCR, RT-
PCR 
AW025 β-actin R AS AGACCATCACCAGAGTCC 18 QRT-PCR, RT-PCR 
AW216 T3 N/A AATTAACCCTCACTAAAGGGA 21 Sequencing 
AW217 SP6 N/A AATTAGGTGACACTATAG 18 Sequencing 
AW218 T7 N/A TAATACGACTCACTATAGGG 20 Sequencing 
AW473 csf3r F S GGGAATGTCTACACGCCTGC 20 RT-PCR 
AW537 csf3r R AS TCTCTCAGCCACCGTAGGATTG 22 RT-PCR 
AW553 jak3 F1 S ACAGAGACACAAACCAAGCCAC 22 RT-PCR 
AW554 jak3 R1 AS CAGTTCAGTCCACTCCAGCG 20 RT-PCR 
AW989 jak3 F2 S AACTCAGAGACCACCTTCAGCA 22 RT-PCR 
AW990 jak3 R2 AS ACTTTCACTCCAGATGAGGTCC 22 RT-PCR 
AW1291 M13 F S TGTAAAACGACGGCCAGT 18 Sequencing 
AW1292 M13 rev AS CAGGAAACAGCTATGAC 17 Sequencing 
AW1439 csf3r F2 S CGGAGAAAATAATATACAGGGGG 23 PCR 
AW1440 csf3r R2 AS TAAAGCGACAGTCACCAAAATG 22 PCR 
AW1444 jak3 F3 S CAAAGAGAGTTTTTTTCGGCAC 22 PCR 
AW1445 jak3 R3 AS CTCACTCTCATCTACTTTTTTGCCA 25 PCR 
AW1465 csf3r intron R AS CACAGTGGAATGAACCGCC 19 PCR 
AW1468 jak3 gRNA 1 S TAGGAGATTTGACTCATCAAAC 22 Genome editing 
AW1471 jak3 gRNA 2 AS AAACGTTTGATGAGTCAAATCT 22 Genome editing 
AW1472 csf3r intron 1  F S GCACAATAAGAACGAAATCAAAGG 24 PCR 
AW1473 csf3r intron 1 R AS GGAAACACCGATACACACTCATAC 24 PCR 
AW1504 jak3 A572V F S AGTCTCTTTTCGAAGTGGCCAGTTTGATGAGTCAAATCTCCCACA 45 Cloning 
AW1505 jak3 A572V R AS TGTGGGAGATTTGACTCATCAAACTGGCCACTTCGAAAAGAGACT 45 Cloning 
AW1506 jak3 A573V F S GTCTCTTTTCGAGGCGGTATCCTTGATGAGTCAAA 35 Cloning 
AW1507 jak3 A573V R AS TTTGACTCATCAAGGATACCGCCTCGAAAAGAGAC 35 Cloning 
AW1526 csf3r intron 2  F S GATAATGACTACGGAGACCAGCG 23 PCR 
AW1527 csf3r intron 2 R AS ACAGTGCCGCCGCTCATC 18 PCR 
AW1530 jak3 intron 1 F S AATGCCTCTAAATAAAAGTCAAAATG 26 PCR 
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AW1532 jak3 intron 1 R AS CGGCATAAACCCCATAACAGTC 22 PCR 
AW1603 csf3r intron 3 F S CAACCACACACTAAATATCATGCCC 25 HRM 
AW1604 csf3r intron 3 R AS GTGACCTTCTTGCTGCGAGGCGAC 24 HRM 
AW1607 jak3 intron 2 F S GAGGCTAATAATTCTGACTTTAACTG 26 Sequencing 
AW1608 jak3 intron 2 R AS AGTTACTTACTTTTGGATTTGTGCACAC 28 Sequencing 
AW1645 eef1al1 F S GAGAAGTTCGAGAAGGAAGC  20 QRT-PCR 
AW1646 eef1al1 R AS CGTAGTATTTGTGGTCTCG  19 QRT-PCR 
AW1662 vb1.5/17.5 1st F S AATGGACAGCTTGATAGAACTGAAC 25 RT-PCR 
AW1663 vb1.5/17.5 2nd F S TGCTTATTCAACCGAACAGAAACATTC 27 RT-PCR 
AW1664 vb12 1st F S CAGACACCGTGCTTCAGTCGAG 22 RT-PCR 
AW1665 vb12 2nd F S ACGTTTCATGGCAGTGTTACCTG 23 RT-PCR 
AW1666 vb14.5 1st F S GAATCCAATGTGACGTTAACATGC 24 RT-PCR 
AW1667 vb14.5 2nd F S CATGATCATAAGGACCACTACAG 23 RT-PCR 
AW1668 cb1 1st R AS AAGATGACAAGGCCATACAGTC 22 RT-PCR 
AW1669 cb1 2nd R AS GTCCGCTCTTAGCAATGGTC 20 RT-PCR 
AW1672 igVH1 1st F S GATGGACGTGTTACAATTTGG 21 RT-PCR 
AW1673 igVH1 2nd F S CCTCCTCAGACTCTGTGGTGA 21 RT-PCR 
AW1676 igVH4 1st F S CAAGATGAAGAATGCTCTCTG 21 RT-PCR 
AW1677 igVH4 2nd F S TGTCAAAGTATGGAGTCGA 19 RT-PCR 
AW1678 cm 1st R AS ACATGAAGGTTGCTGATCCAC 21 RT-PCR 
AW1679 cm 2nd R AS TTGCTGATCCACCTTCTAATTC  RT-PCR 
AW1680 jak3 F intron S TTATCCATGTGAATAAATGTTTAATCTTC 29 HRM 
AW1681 jak3 R intron AS CTAATGCCATACACCAAAAGAAGG 24 HRM 
AW1696 nklc 1 F S CCAGCTAAAGCAAAACCC 18 RT-PCR 
AW1697 nklc 1 R AS GGAAAGGTGAAACGGAAG 18 RT-PCR 
AW1698 nklc 2,3 F S TTCATTCATGTTGGGCGTGACA 22 RT-PCR 
AW1699 nklc 2,3 R AS TTGATTTCATCTGGCGTTGAG 21 RT-PCR 
AW1700 nccr F S GGAAGCTGGCAGATCACAACA 21 RT-PCR 
AW1701 nccr R AS ACGGTGTCCCAATGCCT 17 RT-PCR 
AW1823 jak3 A573V long HDR F intron S 
TCTTCTTTTTTCTAGTCTCTTTTCGA
GGCGGTATCCTTGATGAGTCAAATC
TCCCACAGGCACCTTC 
67 HDR 
AW1914 lmo2 F S TTACCTCAGACTGTTTGGTCAGG 23 QRT-PCR 
AW1915 lmo2 R AS CGCACACGCATGGTCATTTC 20 QRT-PCR 
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AW1916 cd4 F S TCTTGCTTGTTGCATTCGCC 20 QRT-PCR 
AW1917 cd4 R AS TCCCTTTGGCTGTTTGTTATTGT 23 QRT-PCR 
AW1918 cd8 F S ACTCTTCTTCGGAGAGGTGAC 21 QRT-PCR 
AW1919 cd8 R AS ACAGGCTTCAGTGTTGTTTGAA 22 QRT-PCR 
AW1920 tcrb F S AGTTGCAGGTGGATATGACCG 21 QRT-PCR 
AW1921 tcrb R AS ATGACAAGGCCATACAGTCCG 21 QRT-PCR 
AW1922 igm F S CCGAATACAGTGCCACAAGC 20 QRT-PCR 
AW1923 igm R AS TCTCCCTGCTATCTTTCCGC 20 QRT-PCR 
AW1924 igd F S TCCTTGCACCATTCTGCTCC 20 QRT-PCR 
AW1925 igd R AS AAAACCCGACACCAGACACA 20 QRT-PCR 
AW1928 cd79a F S GCGAGGGTGTGAAAAACAGT 19 QRT-PCR 
AW1929 cd79a R AS CCCTTTCTGTCTTCCTGTCCA 20 QRT-PCR 
AW1930 pax5 F S AAGGCAGTTACTCCACACCC 20 QRT-PCR 
AW1931 pax5 R AS ACCGTACTCCTGCTGAAACAC 21 QRT-PCR 
AW1932 nklc F S TCATCTCCTCTGCTTGTGCTG 21 QRT-PCR 
AW1933 nklc R AS TTCCTCCTTATTTGCTGTATTGG 23 QRT-PCR 
AW1936 nccrp1 F S TCAGCACAGGTGGTTCACTCTA 22 QRT-PCR 
AW1937 nccrp1 R AS GGCTTTCCTCATACCAGTCTTC 22 QRT-PCR 
AW1938 nkld F S TGGTGAAATCCCAACAGAGCA 21 QRT-PCR 
AW1939 nkld R AS TTTCATCCTGAGTTGCACCA 20 QRT-PCR 
AW2029 mpo F S CAAAGGAACTGCGGGACC 18 Cloning 
AW2030 mpo R AS CAACCTATCGCCATCTCGG 18 Cloning 
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   Plasmids 
TALENS were synthesised by Gene Tools. 
Table  2.2:  Plasmids  used  in  this  study  
  
Plasmid Description Vector Reference 
pA212 lyz pBK-CMV (Liu & Wen 2002) 
pA232 spi1 pBK-CMV (Lieschke et al. 2002) 
pA249 l-plastin pSPORT1 (Herbomel, Thisse & Thisse 1999) 
pA451 rag1 pCR2.1 (Willett, Cherry & Steiner 1997) 
pA455 ikaros pBS KS (Willett et al. 2001) 
pA456 lck pBK-CMV (Langenau et al. 2004) 
pA1075 c-myb pGEM- T easy (Soza-Ried et al. 2010) 
pA1180 jak3 pGEM- T easy This study 
pA1211 tcrα pGEM- T easy (Sertori et al. 2016) 
pA1263 mpo pGEM- T easy This study 
 runx1  (Kalev-Zylinska et al. 2002) 
 csf3r pGEM- T easy (Liongue et al. 2009a) 
pA1104 CRISPR guide RNA empty vector pDR274 (Hwang et al. 2013) 
pA1105 Cas9 RNA pMLM3613 (Hwang et al. 2013) 
pA1190 jak3 gRNA pDR274 This study 
pA1199 jak3 A572V pGEM- T easy This study 
pA1206 jak3 A573V pGEM- T easy This study 
pA1221 csf3r TALEN R1 pBK-CMV This study 
pA1222 csf3r TALEN L1 pBK-CMV This study 
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   Morpholinos 
The following antisense morpholinos (Gene Tools) were used for gene knockdown by targeting 
splice sites. 
Table  2.3:  Morpholinos  used  in  this  study  
Name Sequence (5`-3`) Target 
scrMo CCTCTTACCTCAGTTACAATTTATA  
csf3aMo AAAAACCTCTTGGAACTCACCAGAC csf3a 
csf3bMo CAGGTGTTAGTGTGTATTTACCAGT csf3b 
csf3rMo   TTTGTCTTTACAGATCCGCCAGTTC csf3r 
 
   Antibodies 
Antibodies used in this study includes pSTAT5 (I in 1000) from BD Biosciences and GAPDH 
(1 in 10000) from Sigma. 
   Methods 
   In silico methods 
   Databases 
Databases used were the National Center for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov/) and Ensembl (http://www.ensembl.org) for genomic and other 
sequence data analysis, Zebrafish Information Network (ZFIN) (http://zfin.org/) for zebrafish 
transcript and expression data, and the Universal Protein Resource (UniProt) 
(http://www.uniprot.org/), Zifit Targeter version 4.2 (http://zifit.partners.org/ZiFiT/) for 
designing guide RNAs.  
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   Sequence analysis and alignment  
Sequence analysis, manipulation and assembly were carried out using Sequencher version 
4.10.0 (Gene Codes). ClustalX 2.1 (Jeanmougin et al. 1998) was used to generate protein 
sequence alignments. 
   Primer design 
Oligonucleotides used for PCR were designed using the web program Netprimer 
(http://www.premierbiosoft.com/netprimer/netprlaunch/netprlaunch.html). The primers for 
RT-PCR experiments were designed to flank splice sites to avoid application of contaminating 
genomic DNA. 
   Statistical analysis 
Statistical analysis were performed using GraphPad Prism (Version 7). Data were analyzed for 
significance with a Student’s t-test using Welch's correction where necessary to account for 
variation between the data groups. 
   RNA methods 
   Isolation of total RNA 
Approximately 15-30 zebrafish embryos or dissected adult tissues were homogenized in 1 mL 
Trizol reagent (Life Technologies) and separated into phases with 200 µL chloroform and 
centrifugation at 12000 g for 15 min after 2-3 min incubation. The RNA was extracted from 
the aqueous phase and precipitated by the addition of 500 µL isopropanol and incubation at 
room temperature for 10 min. The RNA was pelleted by centrifugation at 12,000 g for 10 min 
at 4°C, before being washed with 75% (v/v) ethanol and centrifuged at 7,500 g for 5 min at 
4°C. The air dried RNA was resuspended in 30 µL sterile nuclease-free water (Amresco). 
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   In vitro RNA transcription 
To produce digoxigenin (DIG)-labelled RNA for in situ hybridization, 1-2 µg linearized DNA 
or 100-500 ng PCR products were mixed with 2.0 µL 10×DIG labelling mix (Roche), 2.0 µL 
10×Transcription buffer, 1.0 µL RNase inhibitor (20 U/µL), 2.0 µL T7 (20 U/µL) or SP6 (20 
U/µL) polymerase, and the volume adjusted to 20 µL by adding sterile nuclease-free water 
(Amresco). Following incubation at 37oC for 2 h, 2.0 µL of DNase I (10 U/µL) was added and 
the sample incubated at 37oC for a further 15 min to destroy the DNA template. The reaction 
was terminated by the addition of 2.0 µL of 0.2 M EDTA (pH 8.0). The DIG-labelled RNA 
was purified using G-50 gel filtration exclusion microcolumns (GE Health). The column was 
prepared by brief vortexing followed by centrifugation at 735 g for 1 min. The DIG-labelled 
RNA was then applied to the column which had been placed in a sterile 1.5 mL eppendorf tube 
and centrifuged at 735 g for 2 min. The purified RNA was then stored at -20oC.     
To produce capped RNA and poly A tailed for injection, mMessage mMachine Kit T7 Ultra 
(Ambion) was used following the manufacturer's protocol.  Briefly, up to 1 µg of linearized 
template DNA, 10 µL 2×NTP/CAP, 2 µL 10× reaction buffer and 2 µL enzyme mix containing 
either T7 or SP6 polymerase was added to a final volume of 20 µL and incubated at 37oC for 
2 h.  To destroy the template DNA, 1 µL DNaseI was added to the reaction and incubated for 
15 min at 37o C.  Recovery of the RNA was performed using Probe-Quant G-50 micro columns 
(Amersham).  Samples were scaled up to 50 µL with sterile nuclease free water (Amresco) and 
added to the resin bed before subsequent centrifugation at 3,000 rpm for 2 min with the eluate 
stored at -20oC. Alternatively, for uncapped gRNA MegaShortscript T7 (Ambion) was used to 
transcribe the gRNA according to the manufacturer’s protocol and was subsequently recovered 
using the MegaClear kit (Ambion) to remove unincorporated ribo-nucleotides. 
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   Agarose gel electrophoresis 
RNA electrophoresis was performed with a Formaldehyde-Free RNA Gel Kit (Amresco). Gels 
were prepared with 1.2% (w/v) agarose in 1×Formaldehyde-Free RNA Gel Solution according 
to the manufacturer’s instructions. SYBR safe (1:10000 final concentration) (Life 
Technologies) was added to enable visualization of RNA. These gels were subjected to 
electrophoresis in 1×Formaldehyde-Free RNA Gel Running Buffer at 100-110 V for 30 min.   
   DNA methods 
   Reverse transcription 
The iScript cDNA Synthesis Kit was used to generate cDNA from total RNA. Briefly, 500 ng 
total RNA was added to 4 µL 5×iScript Reaction mix and 1 µL iScript Reverse Transcriptase 
(U/µL) and the volume adjusted to 20 µL with sterile nuclease-free water (Amresco). The 
reaction mixture was then incubated at 25oC for 5 min and then 42oC for 30 min for cDNA 
generation followed by 85oC for 5 min to denature the reverse transcriptase. 
   Reverse Transcriptase-Polymerase Chain Reaction 
A 2 µL aliquot of cDNA was used in a PCR reaction containing 12.5 µL Go-Taq mix (Promega) 
and 2.5 µL of each primer (sense and antisense) (10 µM) with the volume adjusted to 25 µL 
with sterile nuclease-free water (Amresco). Typical PCR conditions used initial denaturation 
step of 94°C for 2 min, followed by 35 cycles of 94°C for 1 min, 58°C for 1 min, 72°C for 2 
min, and finally 72°C for 10 min. These typical conditions and cycle numbers were modified 
as necessary.  
   Quantitative Reverse Transcriptase-Polymerase Chain Reaction 
A 2 µl aliquot of cDNA was used in a PCR reaction containing 10 µL 2×SensiMix™ SYBR® 
Low-ROX (Bioline) and 0.8 µL of each primer (10 µM) with the volume adjusted to 20 µL 
 Chapter 2 
66 
 
with sterile nuclease-free water (Amresco). Typical PCR conditions used an initial denaturation 
step of 95ºC for 10 min, followed by 40 cycles of 95ºC for 5 sec, 58ºC for 10 sec then 72ºC for 
20 sec. Fluorescence was subsequently read at after an initial incubation at 95ºC for 1 min, 65-
95ºC for 30 sec per degree. Samples were run in triplicate and data were normalized to ef1a or 
β-actin and fold change was calculated using the ΔΔCt method (Livak & Schmittgen 2001). 
These typical conditions and cycle numbers were modified as necessary. 
   High resolution melt analysis 
High resolution melt (Radtke et al.) analysis was performed using a 10 μL reaction containing 
5 μL Precision Melt Supermix (Biorad), 200 nM each primer (sense and anti-sense), 3.5 μL 
nuclease free water and 0.5 μL genomic DNA, which was were subjected to PCR with CFX96  
with an initial denaturation step 95°C for 2 min, followed by 45 cycles 95°C for 10 sec, primer 
(Tm °C), for 30 sec and 72°C for 30 sec. This was followed by 95°C for 30 sec, 60°C for 1 
min, then 0.2°C temperature increments from 65-95°C for 10 sec/step and fluorescence 
measured and analysed using Precision Melt Analysis Software 1.2 (Bio-Rad).  
   Agarose gel electrophoresis 
Electrophoretic analysis of DNA was performed using 1-3% (w/v) agarose gels containing 
1×TAE buffer (40 mM Tris-HCl, 190 mM glacial acetic acid, 10 mM EDTA; pH 8.0) and 
0.006% (v/v) SYBR safe (Life Technologies). These gels were subjected to electrophoresis in 
1×TAE at 100-110 V for 30-40 min before visualization under UV light. 
     DNA purification 
PCR products were purified using the QIAquick PCR purification kit (Qiagen), following the 
manufacturer’s instructions. DNA fragments were purified from agarose gels using the 
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QIAquick Gel Extraction Kit (Qiagen) following the manufacturer’s protocol, with variation 
at step 13 such that the DNA was eluted with 30 µL nuclease-free water (Amresco). 
   UV Spectrophotometry 
UV spectrophotometry of DNA and RNA samples was performed using a Nanodrop 2000 
(Thermo Scientific) to determine nucleic acid concentrations and purity, using the relationships 
that 1 absorbance unit (260 nm) equals 50 µg/µL DNA and 40 µg/µL RNA and Abs (260 
nm)/Abs (280 nm) ratios = 1.8 for DNA and 2.0 for RNA. 
   Restriction enzyme digests 
Plasmid DNA (typically 1-2 µg) was digested using the required restriction endonucleases 
(Roche) for 2 h, following the manufacturer’s directions for incubation temperature and buffer. 
   Genomic DNA extraction 
Genomic DNA was extracted from embryos or adult zebrafish fin clips using 30 µL QuickExtract 
solution (Epicentre). Samples were incubated at 68ºC for 2 min before vortexing for 30 sec and 
incubating at 98ºC for 2 min. Samples were again vortexed for 30 sec and then centrifuged at 
13,000 rpm for 5 min at 4ºC. 
  Minipreps and midipreps 
Plasmid DNA was prepared with a Wizard Plus Minipreps DNA Purification System Kit 
(Promega), following the manufacturer’s recommendations. The protocol was varied at steps 
1 (centrifugation at 4,000 g for 5 min), as well as steps 5 and 9 (centrifugation at 12,000 g) and 
step 14 (50 µL of nuclease free water was used to elute the DNA at 12,000 g).  Alternatively, 
larger amounts of plasmid DNA were prepared with PureLink® HiPure Plasmid Midiprep Kit 
K210005 (Life Technologies Australia) following the manufacturer’s recommendations, with 
variations at step 1 (centrifugation at 4,800 rpm for 5 min), step 5 (centrifugation at 9,800 rpm), 
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and step 11 (200 µL of preheated water was added). DNA was resuspended in an appropriate 
volume (50-200 µL) of sterile distilled water. 
  DNA sequencing 
Sequencing was carried out on double-stranded plasmid DNA or PCR products 100-1000 bp. 
Reactions contained 3-75 ng template DNA and 0.83 µM oligonucleotide primer in 12 µL 
reactions adjusted with sterile nuclease-free water (Amresco) and sent to the Australian 
Genome Research Facility (AGRF) for sequence analysis. 
  Site Directed Mutagenesis 
QuikChange II site directed mutagenesis (Stratagene) was used for site-specific mutagenesis. 
Briefly, 1 µL PAGE-purified forward and reverse mutagenic primers, 1 µL dsDNA template 
plasmid, 5 µL 10×reaction buffer, 1 µL dNTP mix and 41 µL nuclease free water were mixed 
with 1 µL of PfuUltra DNA polymerase and the reaction mix subjected to thermal cycling. 
Typical conditions included an initial denaturation step of 95°C for 30 sec, followed by 18 
cycles of 95°C for 30 sec, 55°C for 1 min, and finally 68°C for 1 min/kb of plasmid length. 
Following thermal cycling, the reaction mix was placed on ice for 2 min and 1 µL DpnI 
restriction enzyme added and the sample incubated at 37ºC for 1 h to digest the parental 
supercoiled dsDNA, prior to transformation into E.coli.  
   Bacterial methods 
   Bacterial strains and media    
E.coli strain XL 10-Gold endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac Hte Δ(mcrA)183 
Δ(mcrCB-hsdSMR-mrr)173 tetR F'[proAB lacIqZΔM15 Tn10(TetR Amy CmR)] was used for 
plasmid propagation. Clones were grown in 2×YT medium (1.6% (w/v) tryptone, 1.0% (w/v) 
yeast extract, 0.5% (w/v) NaCl) in the presence of appropriate antibiotic (typically 100 µg/mL 
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ampicillin (Amp)), to enable selection of plasmids. Solid media contained 1.6% (w/v) agar and 
30 mg/mL (5-bromo-4-chloro-3-indolyl β-D-galactopyranoside, X-gal), when required for 
blue/white screening. Bacterial infection assays utilised E. coli expressing green fluorescent 
protein (GFP) (#25922GFP, ATCC) propagated in pUCP18-MCSgfpmut3 vector. 
The E. coli – GFP bacteria was grown overnight in tryptic soy media and the broth is subjected 
to spectrophotometer to read the absorbance 600 to determine the CFU. The broth was then 
centrifuged at 1000 g for 1 min and the bacterial pellet resuspended in sterile PBS at a 
concentration of 1x109 CFU/mL. 
   Competent cells 
XL 10-Gold cells were grown in 50 mL LB at 37oC with shaking at 200 rpm until OD600 
reached 0.3-0.6. Cultures were harvested by centrifugation at 4000 rpm for 20 min at 4oC. The 
supernatant was removed and the pellet resuspended in 15 mL of ice-cold buffer RF1 (160 mM 
KCL, 50 mM MnCl2.4H2O, 30 mM CH3CO2K, 10 mM CaCl2.2H2O, 15% (v/v) glycerol) at pH 
5.8. The suspension was incubated on ice for 15 min and centrifuged at 4000 rpm for 10 min 
at 4oC. The pellet was resuspended in 5 mL ice cold buffer RF2 (20 µL/mL 0.5 M MOPS,  20 
mM KCL, 70 mM CaCl2.2H2O, 15% (v/v) glycerol) and incubated on ice for 15 min. The cells 
were aliquoted (100 µL) and frozen with liquid nitrogen and for storage at -80oC. 
   Ligation and transformations 
Linear PCR products were ligated using the pGEM-T easy vector system (Promega) following 
the manufacturer’s recommendations and using a 2:1 ratio of DNA:Vector and an overnight 
incubation at 4oC. Competent XL 10-Gold cells were removed from -80oC freezer and thawed 
on ice.  A 2-5 µl aliquot of the ligation solution was added to 100 µL of competent cells and 
incubated on ice for 15 min before a 45 sec heat-shock at 42oC, after which the tube was placed 
on ice for 3 min.  Following this, a pre-warmed 800 µL aliquot of 2×YT broth was added and 
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the cells were incubated at 37oC for 1 h with shaking at 200 rpm.  Cells were plated onto 2×YT 
plate media containing appropriate antibiotics.  
   Tissue culture applications 
   Cell line maintenance 
Human embryonic kidney cells (HEK 293) were thawed slowly on ice and 1 mL DMEM media 
added before centrifugation at 2,500 rpm for 5 min. The cell pellet was then resuspended in 
fresh DMEM media with 10% FCS, 1% glutathione and 1% penicillin-streptomycin and placed 
in a culture flask, which was maintained at 37°C and 5% (v/v) CO2 in an air-jacketed incubator. 
   Subculturing 
At approximately 80% confluency, cells were subcultured by washing twice with PBS-EDTA 
(1x) (Ameresco) and then trypsinisation with 0.25% (1×) Trypsin–EDTA (Invitrogen) for 3-5 
min at 37°C, to allow the cells to detach. Fresh DMEM media with 10% FCS and 1% 
glutathione was added to these plates before centrifugation at 1,000 g for 5 min. The cell pellet 
was then resuspended in fresh media and the total number of cells determined by 
hemocytometer, with an appropriate amount of cells seeded into a fresh flask. 
   Transfection 
Cells at 70% confluency were transfected using Lipofectamine Transfection Reagent 
(Invitrogen), which is used in a 3:1 ratio to that of DNA construct (µg). The transfecting 
reaction was prepared by making a suspension of 500 µL serum free DMEM media, 5 µg DNA, 
and 15 µL Lipofectamine transfection reagent, which was incubated at room temperature for 
20 min and then slowly added to the cells as droplets. Following 6 h incubation, this was 
replaced with 10 µL DMEM media. Cells were incubated at 37°C for 48 h before they were 
harvested for protein analysis. 
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   Cell freezing 
Prior to freezing, a single cell suspension was prepared by subculturing and the suspension 
transferred to labelled cryovials, which were centrifuged at 1000 g for 5 min, with 300 µL 
freezing mixture (70% DMEM media, 20% FCS and 10% DMSO) added to the cell pellet. The 
cryovials were stored in Mister Frosty™ (Thermo Scientific) overnight at -80oC, before being 
transferred to liquid nitrogen for long term storage. 
   Protein applications 
   Protein isolation 
RIPA lysis buffer (0.5 mL) (Sigma) and phosphatase inhibitor cocktail (5 mg/mL) were added 
to around five million cells harvested using a cell scraper. The harvested cells were resuspended 
by pipetting and further incubated in ice for 5 min and centrifuged at 14,000 g for 15 min at 
4°C. The supernatant was then collected and stored at -80oC for future protein expression 
analysis. 
   Protein concentration determination 
The total protein content was determined using a Pierce-BCA Protein Determination Kit 
(Pierce) following the manufacturer’s instructions, with bovine serum albumin as the standard 
and reading the absorbance at a wavelength of 570 nm using a VICTOR X Multilabel Plate 
Reader (Perkin Elmer). 
   SDS PAGE 
Protein lysates were denatured by adding SDS-PAGE loading buffer (80 mm of 1M Tris HCL 
(pH:6.8), 2% of 20% SDS, 10% of 100% glycerol, 0.0006 % of 0.1% bromo phenol blue), 
which is mixed with β-mercaptomethanol in 4:1 ratio, and heating the mixture for 5 min at 
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100oC followed by immediate cooling on ice for 5 min. The protein is then separated on 4–
20% Mini-PROTEAN® TGX Stain-Free™ Protein Gels from Biorad at a voltage of 30 mA.  
   Western blotting 
Following electrophoresis, proteins were electroblotted to Odyssey nitrocellulose membrane 
(Millennium Science) in 20% (v/v) methanol, 25 mM Tris base, 192 mM glycine, pH 8.0. The 
membranes were then blocked with 5% (w/v) dried milk in 0.1% TBST, pH 7.6 (20 mM Tris 
base, 200 mM NaCl, and 0.05% (v/v) Tween-20), then incubated with primary antibodies (BD 
Biosciences and Sigma) at appropriate concentrations, according to the manufacturer’s 
instruction overnight at 4oC. Membranes were then washed and incubated with HRP secondary 
antibody, and proteins were detected using the Fujitsu imaging system. 
   Zebrafish methods 
   Fish maintenance and embryo collection 
Wild-type and Tg(mpo::GFP)i114 (Renshaw et al. 2006), hereafter called Tg(mpo::GFP), 
zebrafish were maintained in an Aquatic Habitats aquarium system at 28.5oC on a 14 h/10 h 
light/dark cycle and fed twice daily. Embryos were manually spawned and maintained in the 
incubator at 28.5oC in a petri dish containing aquarium water and 0.00005% (w/v) methylene 
blue (Sigma). Water temperature was maintained at 28°C, with pH at 7.0 and conductivity in 
the range of 650-700 µS to ensure optimal breeding conditions. Day and night phases were 
simulated by an automatic cycle of 14 h of light and 10 h of dark. Natural spawning was 
stimulated by the start of the light cycle. Embryos were collected, washed and allowed to 
develop in aquarium water (pH 7 with < 0.02 Tan, < 0.05 nitrite and < 20 ppm nitrate, and 
conductivity 500 µS) at 28ºC.  At 8 h post fertilization (hpf) methylene blue was replaced with 
aquarium water containing 0.003% (w/v) 1-phenyl-2-thio-urea (PTU) to inhibit pigmentation 
to enhance embryo transparency. Embryos were collected at appropriate time points, and 
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anesthetized with 0.4 mg/mL benzocaine before fixation with 4% (w/v) paraformaldehyde 
(PFA) in phosphate-buffered saline (PBS). All experiments were performed under Deakin 
University Animal Welfare Committee guidelines.  
   Microinjection 
Injection needles were drawn on a Flaming brown micropipette puller model P-87 (Sutter 
Instruments) using a heat setting of 339, pull 45, velocity 80 and time 150, from a 1.0 mm 
borosilicate capillary filament (SDR Clinical Technologies), bent by flaming and loaded using 
pipette tips with morpholinos diluted to 1-5 mM in 1×Danieau buffer (58 mM NaCl, 0.7 mM 
KCl, 0.4 mM MgSO4, 0.6 mM CaCl2, 5.0 mM HEPES; pH 9) containing 1% (w/v) phenol red 
or injected with 100 pg/nL mRNA encoding transcription activator-like effector nucleases 
(TALENs) or 100 pg/nL mRNA of Cas9 and 12.5 ng/µL of gRNA for CRISPR . Needles were 
mounted in a MN-151 micromanipulator attached to a SMZ 645 dissecting microscope 
(Nikon). Embryos at the 1 cell stage were held with watchmakers’ forceps and the needle 
positioned so as it entered the yolk between the individual cells.  Typical injection conditions 
included a pulse duration of 0.3 sec and a gas pressure of 400 kPa.  Embryos were subsequently 
allowed to develop on a warming tray at 28°C. 
   Bacterial infection assay 
Embryos at 48 hpf were injected with 2-5 nl of ~109 CFU per mL E. coli expressing GFP into 
the venous return, with bacteria visualized by fluorescence microscopy and imaged using a 
MVX10 camera (Olympus) (Hou et al. 2016). The survival of the infected embryos were 
monitored by regular visual inspection. 
The bacterial load in the infected embryos were determined by homogenising individual 
embryos in 1 mL PBS supplemented with 1% Triton X and plated onto tryptic soy agar plates, 
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which was grown overnight at 37oC. Colonies on each plate were counted manually or using 
Image J cell counter software. 
   LPS injection and wound healing assay 
To simulate an emergency hematopoietic response, 2 dpf embryos were injected with 5 µg/mL 
LPS, as described (Liongue et al. 2009a). Wound-healing assays were performed on 3 dpf 
embryos by excising the end of the caudal tail fin with a scalpel (blade number 21) after 
anaesthesia with 0.1 mg/mL benzocaine, as described (Hall et al. 2007) with the number of the  
neutrophils  migrated  to  the  close  proximity  of  the  wounding  site  was  counted up to 8 h after 
wounding. 
   Pharmacological inhibition 
Embryos at 16 hpf were treated for two hours with the JAK2 inhibitor AG490 (0.91 mM) 
(Changelian et al. 2003; Ma et al. 2007), the PI3K inhibitor LY294002 (1.2217 mM) (Vlahos 
et al. 1994), and the Src kinase inhibitor PP2 (0.076 mM) (Tsai et al. 2005).  
   O-dianisidine staining 
Euthanized embryos were incubated in 0.5 mg/mL O-dianisidine (Sigma-Aldrich) in 40% (v/v) 
ethanol, 6% (v/v) H2O2 (BDH) and 0.01 M NaOH for 15 min in the dark, followed by 3x5 min 
PBS-T washes before fixation in 4% PFA/PBS. 
   Fin clipping 
Individual zebrafish were placed in aquarium water containing 20 µg/mL benzocaine until their 
gills stopped moving, transferred to a glass slide and the tail fin tip cut with a number 10 scalpel 
blade. The zebrafish was placed in aquarium water to recover. 
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   Dissection of adult zebrafish 
Adult fish were euthanized with benzocaine (50 µg/mL) overdose and dissected to collect the 
following organs: skin, muscle, eyes, brain, thymus, kidney, spleen, liver, intestine, oocyte, gall 
bladder, female gonad, and gill. 
   Embryo fixation  
Embryos were euthanized using 0.4 mg/mL benzocaine (Sigma) prior to fixation in 4% (w/v) 
paraformaldehyde (PFA) in phosphate buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 4.3 
mM Na2HPO, 1.47 mM KH2PO4) (PFA/PBS). Fixed embryos were stored at 4°C for at least 1 
day, after which embryos were dehydrated with 100% (v/v) methanol for long-term storage at 
-20°C.  
  Whole mount in situ hybridization (WISH)  
Fixed embryos were rehydrated via a series of 5 min washes in 50% (v/v) methanol, 30% (v/v) 
methanol and PBS-T (PBS plus 0.1% Tween-20) before refixing for 20 min in 4% (v/v) 
PFA/PBS followed by three washes in PBS-T.  Embryos older than 26 hpf were then incubated 
at room temperature in PBS containing proteinase K, 24-36 hpf with 10 µg/mL proteinase K 
for 10 min, 36 hpf-10 dpf with 20 µg/mL proteinase K for 30 min. Hybridization involved 
digoxigenin-labelled antisense RNA probes transcribed from appropriately linearized plasmids 
or pcr products. Embryos were incubated in 500 µl of HYB- (50% (v/v) formamide, 5×sodium 
chloride/sodium citrate (SSC), 0.1% (v/v) Tween-20) for 5 min at 70°C, which was replaced 
with 500 µl of HYB+ (HYB- containing 5 mg/mL ribonucleic acid, 0.05 mg/mL heparin 
(Sigma)) which was incubated at 70°C for at least 3 h. Embryos were bathed in 300 µl of probe 
solution (1/50-1/300 dilution in HYB+) and incubated at 70°C overnight. Probes solutions were 
removed following the incubation and the embryos were washed in 50% (v/v) 
formamide/2×SSC-T for 30 min and 60 min at 70°C. Embryos were then washed for 15 min 
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in 2×SSC-T followed by two x 15 min washes in 0.2×SSC-T also at 70°C. This was followed 
by three room temperature washes in PBS-T followed before incubation in blocking solution 
(0.02% (w/v) bovine serum albumin (BSA), 5% (v/v) fetal calf serum (FCS) in PBS-T) for 2 h 
at room temperature. Following the incubation, embryos were placed into blocking solution 
with (0.15 U/µL) of alkaline phosphatase (AP) conjugated anti-DIG antibody (Roche) and 
incubated at 4°C overnight. Embryos were washed six 15 min in PBS-T at room temperature 
with gentle rocking and then three 5 min washes in staining buffer (0.1 M Tris pH 9.5, 0.05 M 
MgCl2, 0.1 M NaCl, 0.1% (v/v) Tween 20) containing 25 µg/mL levamisol. Following this, 
embryos were stained in staining solution (0.225 mg/mL nitroblue tetrazolium (NBT) and 
0.175 mg/mL 5-bromo,4-chloro,3-indolyl phosphate (BCIP) in staining buffer) appropriately 
at room temperature in the dark for 4 h to 3 d, but normally overnight. Once stained, embryos 
were rinsed in PBS-T and fixed in 4% PFA/PBS. 
  High Resolution WISH 
Fixed embryos were rehydrated via a series of 5 min washes in 75% (v/v) methanol, 50% (v/v) 
methanol, 25% (v/v) methanol and PBS before 4 × 5 min washes in PBS-T. Embryos were then 
incubated at room temperature in PBS-T containing proteinase K, 10 µg/mL proteinase K for 
30 seconds (blastula and gastrula), 1 min (early somitogenesis), 5 min (late somitogenesis), or 
15 min (24 hpf), 36 hpf -10 dpf or with 20×g/mL proteinase K for 30 min (36 hpf -10 dpf) 
before fixing for 20 min in 4% (v/v) PFA/PBS followed by five 5 min washes in PBS-T. 
Embryos were incubated in 800 µL HM+ mix (50% formamide, 5×SSC, 0.1% Tween-20, 9.2 
µL/mL citric acid pH 6, 50 µg/mL heparin, and tRNA 500 µg/mL) for 2-5 h. Embryos were 
then bathed in 200 µL of probe solution (1/50–1/300 dilution in HM mix) and incubated at 
70°C overnight. Probes solution was removed and embryos washed briefly in 100% HM– (50% 
formamide, 5×SSC, 0.1% Tween-20, 9.2 µL/mL citric acid pH 6) and then for 15 min in 75% 
HM–/25% 2×SSC, 50% HM–/50% 2×SSC, 25% HM–/75% 2×SSC and 2×SSC, then twice in 
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0.2×SSC 30 min, then 10 min in 75% 0.2×SSC/25% PBS-T, 50% 0.2×SSC/ 50% PBS-T, 25% 
0.2×SSC/ 75% PBS-T and PBS-T. Embryos were then incubated in PBS-T/ 2% sheep serum/ 
2mg/mL BSA at RT for 3 h then in antibody solution (1:5000 anti-DIG antibody in PBS-T, 2% 
sheep serum, 2 mg/mL BSA pre-absorbed against embryos) at 4°C overnight with agitation. 
Embryos were rinsed in PBS-T then washed six 15 min in PBS-T at room temperature with 
gentle rocking and then three 5 min washes in staining buffer (0.1 M Tris pH 9.5, 0.05 M 
MgCl2, 0.1 M NaCl, 0.1% (v/v) Tween 20) containing 25 µg/mL levamisol. Following this, 
embryos placed in staining solution (nitroblue tetrazolium (NBT) 0.225 mg/mL and 5-
bromo,4-chloro,3-indolyl phosphate (BCIP) 90.175 mg/mL in staining buffer) at room 
temperature in the dark for 4 h-3 d, but normally overnight. Embryos were finally rinsed in 
PBS-T and fixed in 4% PFA/PBS when stained to an appropriate extent. 
  Imaging 
Embryos were visualised using a MVX10 microscope (Olympus) with stage lighting provided 
using LG-PS2 fibre optics light source (Olympus) for light microscopy and fluorescence 
microscopy. Digital images recorded using CellSens Dimension 1.6 software (Olympus) and 
DP72 camera (Olympus). To quantify neutrophil migration, the mean distance of the farthest 
three neutrophils to a point at the dorsal edge of the yolk adjacent to the most caudal extent of 
the eye. 
   Cell analysis 
   Blood and kidney cell preparation 
Blood was collected from 5 dpf embryo by nicking the fin and from adult zebrafish by cutting 
the tail. Alternative adult kidneys were dissected and resuspended in PBS supplemented with 
2 mM EDTA and 2% FCS. The cell suspension was then passed through 40 µm cell strainer. 
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These were placed on slides using a Cytospin funnel (Thermo Fisher Scientific), centrifuged at 
750 rpm for 5 minutes. 
   Histochemical analysis 
Slides were fixed in 100% methanol for 1 min and stained with Giemsa for 20 min. Slides were 
viewed on a Leica DME stereomicroscope and differential counts performed. Images were 
captured on a DFC290 digital camera (Leica) controlled by the Leica Application Suite for 
Windows (Leica Microsystems). 
   Flow cytometry 
Adult kidney cells analyzed using a SSC/FSC with GFP+ cells identified in the FITC channel. 
Apoptosis was determined using an Annexin V-PE/7AAD Apoptosis Detection Kit 
(Biolegend) according to manufacturer’s protocol. A minimum of 100,000 events were 
collected for each sample using FACS-Canto II flow cytometer (BD Biosciences) and analyzed 
using FACSDiva software (v6.0).  For cell sorting, the FACSAria II (BD Biosciences) was 
used to isolate one million cells for other applications. 
 
 
 
 
 
 
 
 79 
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   Introduction 
Colony-stimulating factor 3 (CSF3), also known as granulocyte colony-stimulating factor (G-
CSF), acts via its cognate cell surface receptor CSF3R, or GCSF-R, to exert a key role in both 
developmental and ‘emergency’ granulopoiesis, augmenting the proliferation, differentiation 
and survival of myeloid progenitors and their neutrophilic granulocyte progeny (Liongue et al. 
2009a). Administration of CSF3 leads to neutrophilia in mice and humans (Price, Chatta & 
Dale 1996; Singh et al. 2012). Csf3-/- and Csf3r-/- mice show neutropenia with reduced survival 
of neutrophils and defects in granulocyte-macrophage progenitor (GMP) differentiation with 
reduced number of hematopoietic progenitors (Hermans et al. 2003; Lieschke et al. 1994; Liu 
et al. 1996). Furthermore, myeloid cell migration and wound healing processes are regulated 
by CSF3/CSF3R signals (Eroglu et al. 2004; Kim et al. 2006; Liongue et al. 2009a). 
CSF3 binding triggers CSF3R homodimerization and the activation of associated tyrosine 
kinases, principally JAK2 and LYN (Corey et al. 1994; Nicholson et al. 1995; Tian et al. 1996; 
Ward et al. 1998a; Zhu et al. 2006). These in turn stimulate various intracellular signalling 
cascades, such as signal transducer and activator of transcription (STAT) (Liongue et al. 
2009a), phosphatidylinositol 3-kinase (PI3K)/AKT (Zhu et al. 2006) and mitogen-activated 
protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) (Wang et al. 2008) 
pathways. However, due to a paucity of relevant in vivo studies, it remains unclear how these 
pathways regulate the broad spectrum of biological activities promoted by CSF3. 
Neutropenia occurs as sporadic and autosomal dominant forms, as well as a characteristic of a 
range of other disorders (Ward & Dale 2009). In patients with severe congenital neutropenia 
(SCN), levels of circulating neutrophils are extremely low (<0.5×109/l), with reduced 
neutrophil survival and typically increased numbers of myeloid progenitors (Berliner 2008; 
Germeshausen, Ballmaier & Welte 2007). Since neutrophils represent an essential component 
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of host defence against bacteria, neutropenia patients suffer repeated episodes of opportunistic 
bacterial infections that are potentially life threatening (Berliner 2008; Ward & Dale 2009). 
SCN patients additionally exhibit an enhanced risk of developing myelodysplastic syndrome 
(MDS) and/or acute myeloid leukemia (AML) with poor prognosis for long-term survival 
(Germeshausen, Ballmaier & Welte 2007; Rosenberg et al. 2008). CSF3 is utilized clinically 
to successfully treat the majority of neutropenia patients, but a group remain unresponsive to 
this therapy (Dale et al. 2006). Within this patient cohort “crippling” mutations within the 
extracellular domain of CSF3R have been identified. Most of these “crippling” mutations 
truncate the CSF3R protein prior to the transmembrane domain, thereby resulting in a form of 
the receptor unable to transmit intracellular signals (Liongue et al. 2009b). No animal model 
of this class of mutations has been created. 
Zebrafish has been shown to possess a CSF3R homologue, Csf3r, with a conserved function in 
early myelopoiesis (Liongue et al. 2009a). It also has two paralogues for CSF3, Csf3a and 
Csf3b (Stachura et al. 2013), which appear to have arisen from gene duplication during teleost 
evolution and share low sequence conservation, but display similar predicted structure and 
ligand-receptor interaction sites as their mammalian counterparts. Moreover, both Csf3a and 
Csf3b vary in their spatio-temporal expression patterns and have different effects on 
myelopoiesis and hematopoietic stem cells. Both signals through a single Csf3r, supporting 
hematopoietic stem and progenitor cell development and expansion, in addition to their role in 
neutrophilic or granulocytic expansion (Stachura et al. 2013). However, their physiological 
roles have not been fully determined. The aim of this Chapter was to investigate CSF3R 
signalling in zebrafish myelopoiesis, and to generate a zebrafish model of neutropenia based 
on a relevant human mutation. 
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   Functional analysis of CSF3R signalling in early zebrafish hematopoiesis 
   Analysis of CSF3 and CSF3R in zebrafish myelopoiesis 
Morpholino mediated knockdown of zebrafish csf3r resulted in a reduction of total myeloid 
cells during primitive hematopoiesis (Liongue et al. 2009a). To investigate the ligand 
specificity of Csf3r-mediated myelopoiesis, zebrafish csf3a, csf3b, and csf3r were knocked 
down in Tg (mpo::GFP) embryos with the splice-site targeting morpholinos csf3aMo, csf3bMo, 
and csf3rMo, respectively, at concentrations previously shown to give effective knockdown 
(data not shown). Knockdown of either csf3a or csf3b resulted in a significant decrease in mpo+ 
myeloid cells at 22 hpf compared to control scrambled morpholino (scrMo) injected embryos 
(Figure 3.1 A-C, E), although not as severe as observed in embryos injected with csf3rMo 
(Figure 3.1 A, D, E). A migration defect in early myeloid cells has also been observed in csf3r 
ablated embryos (Liongue et al. 2009a). The csf3aMo produced a more severe defect in 
neutrophil migration than the csf3bMo, although the csf3rMo again elicited the greatest effects 
(Figure 3.1 A-D, F).   
   Analysis of Csf3 and Csf3r in neutrophil migration and emergency myelopoiesis 
Zebrafish Csf3r has also been shown to influence myeloid cell migration in response to 
wounding (Liongue et al. 2009a). To investigate the ligand-specificity of this effect, a 
wounding assay was performed on Tg (mpo::GFP) embryos injected with scrMo, csf3aMo, 
csf3bMo, and csf3rMo. In control scrMo-injected embryos, mpo+ cells migrated to the site of 
wounding peaking at 2 hours post wounding (hpw) and sustained at 8 hpw (Figure 3.2 A-C, 
M). Injection of csf3aMo injection did not affect the kinetics of neutrophil recruitment, with 
comparable levels of neutrophils migrating to the injury as those of the control scrMo injected 
embryos (Figure 3.2 D-F, M). In contrast, embryos injected with csf3bMo showed reduced 
initial neutrophil migration following wounding, but numbers were slightly heightened at 8 
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hpw in comparison to controls (Figure 3.2 G-I, M). Embryos injected with csf3rMo showed a 
severe defect in neutrophil migration, with few cells migrating to the wounding site and low 
retention, indicating that csf3r plays a crucial role in mediating the migration and retention of 
neutrophils in this injury model (Figure 3.2 J-M). Although the neutrophil numbers are 
decreased in csf3rMo injected embryos, the effects on migration were proportionally greater 
with no clear peak in the neutrophil migration in response to wounding in these embryos 
compared to their controls. 
An ‘emergency’ response was stimulated by injection of lipopolysaccharide (LPS). LPS 
strongly induced expression of csf3a (Figure 3.3 A) but only produced a small increase in 
expression of csf3b (Figure 3.3 B). The csf3a morphants showed an almost complete abrogation 
of the LPS stimulated expression of both genes, with csf3b morphants showing a lesser but still 
significant abrogation of LPS-induced csf3a expression only (Figure 3.3 A-B), indicating that 
csf3b contributes to LPS mediated increase in csf3a expression. 
   Analysis of downstream signalling pathways in early myeloid cells. 
Key pathways downstream of Csf3r were investigated by treating embryos with specific 
inhibitors. Embryos treated with a JAK2 inhibitor (AG490) or PI3K inhibitor (LY294002) 
showed a significant reduction in the number of mpo+ cells at 22 hpf (Figure 3.4 A), which 
also displayed reduced migration compared to control DMSO treated embryos (Figure 3.4 B).  
To understand the role of these signalling components in neutrophil migration, a wounding 
assay was performed. Neutrophil migration peaked in control (DMSO treated) embryos at 2 
hpw with sustained retention at the site of injury at 8 hpw (Figure 3.5 A-C, M). Embryos treated 
with the JAK2 (AG490) inhibitor showed similar recruitment of neutrophils to the wounding 
site but neutrophil retention was decreased (Figure 3.5 D-F, M). In contrast, the PI3K inhibitor 
(LY294002) hampered the initial neutrophil recruitment, but the numbers eventually increased 
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to be similar to control embryos at 8 hpw (Figure 3.5 G-I, M). The SRC inhibitor (PP2) did not 
significantly influence recruitment or retention of neutrophils to the wounding site (Figure 3.5 
J-M).  
The effect of downstream signalling on emergency granulopoiesis was examined by LPS 
injection following inhibitor treatment in Tg (mpo::GFP) embryos. Control embryos showed 
an increase in neutrophil number in response to LPS, which was comparable for those treated 
with the JAK2 inhibitor (AG490) (Figure 3.6 A-D, I). However, both PI3K (LY294002) and 
SRC (PP2) inhibitors blocked this LPS-induced increase in neutrophils (Figure 3.6 E-I) as the 
number of mpo+ cells in embryos treated with and without LPS was the same, indicating a role 
for PI3K and SRC kinases in emergency granulopoiesis.  
   Impact of neutropenia-associated CSF3R mutations on zebrafish 
hematopoiesis 
   Generation of a csf3r mutant zebrafish based on neutropenia-associated mutations 
A variety of truncating mutations within the extracellular region of the human CSF3R have 
been described that are associated with SCN and chronic idiopathic neutropenia (CIN) (Figure 
3.7 A). To generate similar variants of zebrafish Csf3r, TALEN-mediated genome editing was 
employed to target csf3r exon 13 as this region lacked the necessary PAM sequence for 
CRISPR-mediated genome editing, which encodes the most membrane-proximal fibronectin 
type III-like domain of the extracellular region (Figure 3.7 B-C). TALEN injected embryos 
were raised to adulthood and crossed with wild-type fish. The F1 progeny was screened for 
mutations by restriction fragment length polymorphisms (RFLP) with TaqI that were 
confirmed by sequencing. This identified two mutant alleles, mdu5 and mdu6, representing 13 
bp and 11 bp deletions, respectively (Figure 3.7 D). Each caused a frameshift that introduced 
a premature stop codon, leading to truncated Csf3r proteins lacking all transmembrane and 
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intracellular sequences. Fish carrying these alleles were outcrossed twice with heterozygote 
progeny incrossed to generate homozygote mutants for further analysis. 
   Reduced numbers of neutrophils in csf3r mutants 
The effects of csf3r mutations on primitive hematopoiesis were first assessed. Compared with 
wild-type embryos, homozygous csf3rmdu5/mdu5 mutant embryos showed a modest reduction in 
the myeloid progenitor marker spi1 (Figure 3.8 A-C). Notably, an almost complete loss in csf3r 
expression was observed at all-time points (Figure 3.8 D-I), most likely due to the non-sense 
decay. Analysis with markers for mature myeloid cells demonstrated a substantial decrease in 
mpo+ granulocyte cells (Figure 3.8 J-L) and a smaller, but still significant, reduction in the 
lyz+ leukocyte cell population (Figure 3.8 M-O). In contrast, the l-plastin+ macrophage cell 
population was not affected (Figure 3.8 P-R). The mpo+ and lyz+ myeloid cell populations 
also showed a migration defect (Figure 3.8 J-K, Figure 3.8 M-N), previously noted in csf3r 
knockdown embryos (Liongue et al. 2009a). Similar results were obtained with homozygous 
csf3rmdu6/mdu6 mutants, with no difference noted between heterozygote mutants and wild-types, 
suggesting that CSF3R heterodimers between mutant and wild-type were not biologically 
significant (data not shown). 
With regards to definitive hematopoiesis, no difference was observed in expression of the HSC 
markers c-myb (Figure 3.9 A-C) or runx1 (Figure 3.9 D-F) at 3.5 dpf between wild-type and 
homozygous csf3rmdu5/mdu5 or csf3rmdu6/mdu6 mutants. However, the negligible csf3r expression 
(Figure 3.9 G-I) and significantly decreased mpo+ cells (Figure 3.9 J-L) persisted in 
csf3rmdu5/mdu5 embryos at later time-points, with heterozygote mpo+ cell numbers again similar 
to that of wild-types (data not shown). In contrast, there was no difference between wild-type 
and csf3rmdu5/mdu5 mutants in the number of lyz+  cells (Figure 3.9 M-O), l-plastin+ cells (Figure 
3.9 P-R) cells, the area of expression of the lymphoid cell marker rag1 (Figure 3.9 S-U), or in 
staining of hemoglobinized red blood cells with O-dianisidine (Figure 3.9 V-W). The 
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csf3rmdu6/mdu6 mutant produced similar results for mpo, lyz and rag1 (data not shown). Analysis 
of blood smears at 5 dpf confirmed a significant reduction in the number of circulating 
neutrophils in csf3rmdu5/mdu5 mutants (Figure 3.9 X-Z).  
Analysis of adult homozygous csf3rmdu5/mdu5 fish revealed that the number of circulating blood 
neutrophils remained markedly reduced relative to their wild-type siblings (Figure 3.10 A-C). 
A significantly decreased neutrophil population was also observed in the kidney of 
csf3rmdu5/mdu5 fish, but these were well differentiated, with hypersegmented neutrophils 
observed while erythroid numbers were slightly elevated most likely due to a compensatory 
shift between the two lineages (Figure 3.10 D-F). FACS analysis of fish carrying the 
csf3rmdu5/mdu5 allele on the Tg (mpo::GFP) background identified a decrease in both the total 
myeloid (Figure 3.10 G-I) and mpo+ (Figure 3.10 J-L) populations. Histochemical staining of 
sorted myeloid cells demonstrated an increase in hypersegmented neutrophils in csf3rmdu5/mdu5 
fish (Figure 3.10 M-O).  
   Truncation of zebrafish Csf3r leads to functional deficiencies 
A range of functional responses were also analysed in the csf3r mutants. Responsiveness to 
Csf3 was examined by injection of csf3a mRNA, which elicited a substantial increase in mpo+ 
cells in wild-type embryos as described (Liongue et al. 2009a), which was not observed in 
csf3rmdu5/mdu5 mutant embryos (Figure 3.11 A). Next, LPS injection was used as a model of 
emergency granulopoiesis, which also resulted in an increase in mpo+ cells in wild-type 
embryos but not in csf3rmdu5/mdu5 or csf3rmdu6/mdu6 mutant embryos (Figure 3.11 B). In response 
to wounding, csf3rmdu5/mdu5 mutant embryos displayed reduced migration of mpo+ cells 
compared to wild-type embryos (Figure 3.11 C). Although the total number of mpo+ cells were 
decreased in csf3rmdu5/mdu5 mutant embryos, there is proportionally greater migration defect 
with a complete lack of clear peak in the neutrophil migration in these mutant embryos 
compared to wild-type embryos in response to wounding. Embryos were also subjected to 
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infection with fluorescent E. coli. Bacterial numbers increased more rapidly in csf3rmdu5/mdu5 
mutants compared to wild-type embryos, which reached statistical significance at 16 h post 
infection (Figure 3.11 D), with this increase also evident by fluorescence microscopy (Figure 
3.11 E-F). This was reflected in significantly greater mortality of bacterial-infected 
csf3rmdu5/mdu5 mutants compared to wild-type embryos (Figure 3.11 G). Consistent with this, 
close monitoring of csf3rmdu5/mdu5 and csf3rmdu6/mdu6 mutants revealed a reduced survival of 
juveniles under normal husbandry conditions compared to wild-types (Figure 3.11 H). Finally, 
analysis of the myeloid cell population in the adult kidney marrow identified normal 
myeloperoxidase staining but increased vacuoles (Figure 3.11 I), and significantly higher levels 
of apoptosis (Figure 3.11 J-L), in the csf3rmdu5/mdu5 mutants. 
   Discussion 
Hematopoiesis is strongly conserved between humans and zebrafish (Rasighaemi et al. 2015), 
which extends to the cytokine signalling networks controlling it (Liongue & Ward 2007). 
Zebrafish has been shown to possess a conserved CSF3R that contributes to steady state and 
emergency myelopoiesis during embryogenesis (Galdames et al. 2014; Liongue et al. 2009a; 
Stachura et al. 2013), although unlike mammals zebrafish possess two ligands for CSF3R with 
distinct properties (Stachura et al. 2013). This Chapter aimed to extend our understanding of 
Csf3r signalling pathway in zebrafish myelopoiesis and generate a zebrafish model of 
neutropenia. Firstly, it investigated the function of the two zebrafish ligands for Csf3r in steady 
state and emergency myelopoiesis during embryogenesis and probed the role of key signalling 
pathways. Secondly, the function of zebrafish Csf3r was further explored in both embryonic 
and adult myelopoiesis using genome editing, to generate zebrafish carrying a neutropenia-
associated CSF3R mutation. 
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   Analysis of Csf3r signalling pathway components in early myelopoiesis and 
myeloid cell function 
Mammals possess a single ligand for CSF3R, encoded by the CSF3 gene. However, previous 
studies had identified two zebrafish paralogues of the CSF3 gene, csf3a and csf3b, which 
appear to have evolved through gene duplication, with the products of both shown to signal 
through Csf3r (Stachura et al. 2013). The function of each ligand was further investigated using 
validated splice site targeting morpholinos. Knockdown of either csf3a or csf3b resulted in 
decreased myeloid cells during primitive hematopoiesis compared to scrMo injected controls, 
although csf3r knockdown caused the greatest effect. In addition, both csf3aMo and csf3bMo 
injected embryos displayed neutrophil migration defects but those injected with csf3aMo 
showed more severe effects. This indicates a differential but additive role of csf3a and csf3b in 
early myeloid cell migration. Once again embryos injected with csf3rMo displayed the greatest 
migration defect suggesting both ligands contribute independently. In contrast, csf3a 
morphants showed robust neutrophil trafficking in response to wounding with their retention 
comparable to control scrMo injected embryos. In contrast, csf3b morphants showed reduced 
initial neutrophil migration, but with good retention at later times post wounding. Notably, 
csf3r morphants showed the most severe defects, with both recruitment and retention affected. 
Analysis of downstream signalling pathways using specific inhibitors revealed that both JAK2 
and PI3K pathways were involved in early myelopoiesis and myeloid cell migration, with  
JAK2 in particular important in migration and PI3K in myelopoiesis. The JAK2 inhibitor did 
not influence the initial kinetics of recruitment in response to wounding, but caused decreased 
retention at later time points. In contrast, the PI3K inhibitor resulted in delayed and decreased 
recruitment at the injury but with good retention, while a SRC inhibitor did not influence 
neutrophil recruitment. Collectively, this suggests that Csf3b may have a predominant role in 
the first hours following wounding with PI3K involvement, whereas retention may involve 
both ligands acting redundantly through Csf3r via JAK2. Analysis of ‘emergency’ responses 
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with LPS injection demonstrated that csf3a was most strongly induced by LPS with csf3a 
morphants showing abrogation of the LPS-stimulated increase in csf3a and csf3b expression, 
in contrast to csf3b morphants, in which still showed significant LPS-mediated effects. The 
JAK2 inhibitor failed to affect LPS-mediated granulopoiesis, while PI3K and SRC inhibitors 
blocked this effect. This suggests that Csf3a is the key mediator of emergency responses, with 
emergency granulopoiesis requiring signalling via PI3K and SRC. 
Other studies in zebrafish have demonstrated that PI3K regulates cell protrusion and polarity 
during random motility of zebrafish neutrophils and is necessary for the directed migration of 
zebrafish neutrophils during early development and in response to wounding (Yoo et al. 2010). 
This is consistent with the results presented in this Chapter. Developmental migration and 
wound-induced retention of myeloid cells was also found to be reduced by a JAK2 inhibitor 
identifying another pathway involved in this process in vivo. A member of the SRC kinase 
family, LYN, has been identified as a physiological redox sensor detecting wound-derived 
H2O2 and mediating initial recruitment of neutrophils (Yoo et al. 2011). However, a SRC 
inhibitor failed to cause significant change in neutrophil migration. The reason for this 
discrepancy remains unclear. 
   Generation of model of SCN unresponsive to CSF3 
Neutropenic patients have been identified with two major classes of CSF3R mutations 
(Germeshausen, Ballmaier & Welte 2007; Ward 2007). One class represents acquired 
mutations that cause truncation of the intracellular domain of the receptor leading to sustained 
signalling responses. These appear to contribute to the strong predisposition of these 
neutropenia patients to MDS/AML, but their contribution to neutropenia is likely only minor 
(Liongue & Ward 2014). The other class of mutation includes generally constitutive mutations 
within the extracellular domain of the receptor resulting in hyporesponsive forms of the 
receptor, which have been reported in patients with SCN and CIN unresponsive to normal 
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CSF3 therapy (Ward 2007). This Chapter also details the generation and characterisation of 
zebrafish Csf3r mutants that recapitulate unresponsive neutropenia alleles. 
Several mutant alleles of zebrafish Csf3r were generated that resulted in complete truncation 
of the transmembrane and intracellular region, thereby mimicking neutropenia-associated 
mutations (Germeshausen, Ballmaier & Welte 2007; Palmblad & Papadaki 2008), particularly 
a CIN mutation (Papadaki et al. 2004). These mutants were phenotypically normal, but 
homozygote mutants displayed reduced numbers of neutrophils during both primitive and 
definitive hematopoiesis, which continued to adulthood where fewer neutrophils were 
observed in both blood and kidney marrow. Neutrophils from adult csf3r mutants showed 
normal myeloperoxidase staining but were hypersegmented when compared to those from 
wild-type fish.   
The zebrafish csf3r mutants displayed various functional deficits. They were resistant to LPS-
induced myelopoiesis and showed a reduced neutrophil migration to sites of wounding. 
Furthermore, the mutants were more susceptible to bacterial infection with increased bacterial 
load and decreased survival, while their overall survival was also reduced. Their myeloid cells 
also exhibited reduced survival in adult mutants. These phenotypes were comparable to several 
observed in Csf3-/- (Lieschke et al. 1994) and Csf3r-/-  (Hermans et al. 2003; Liu et al. 1996) 
mice and in Csf3r morphant (Liongue et al. 2009a) and csf3r mutant (Pazhakh et al. 2017) 
zebrafish, suggesting these likely represent null alleles. Finally, zebrafish Csf3r mutants were 
unresponsive to Csf3. Collectively, these phenotypes were also consistent with neutropenic 
patients harbouring these mutations (Bartels et al. 2016; Donadieu et al. 2011), establishing a 
bona fide model of neutropenia unresponsive to CSF3.   
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Figure  3.1:  CSF3  and  CSF3R  in  granulopoiesis    
A-­D.  Fluorescent  microscopy  images  of  22  hpf  Tg  (mpo::GFP)  embryos  injected  with  either  
scrMo  (A),  csf3aMo  (B),  csf3bMo  (C)  or  csf3rMo  (D).    
E-­F.  Quantitation  of  mpo+  cell  number  for  the  whole  embryo  (E)  and  relative  migration  of  these  
cells  (F)  in  embryos  injected  with  the  indicated  morpholinos,  with  mean  and  SEM  displayed  in  
red  and  level  of  statistical  significance  (****p  <  0.0001)  shown  (n>26).  
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Figure  3.2:  CSF3  and  CSF3R  in  neutrophil  migration  
A-­L.  Fluorescent  microscopy  of  3  dpf  zebrafish  Tg  (mpo::GFP)  embryos  injected  with  either  
scrMo   (A-­C),  cs3faMo   (D-­F),  csf3bMo   (G-­I),   or  csf3rMo   (J-­L)   subjected   to  wounding   (blue  
dotted  line)  and  imaged  at  the  times  indicated  post  wounding.  
M.  Quantitation  of  mpo+  cells  at  the  site  of  wounding  in  embryos  injected  with  the  indicated  
morpholinos  with  mean  and  SEM  displayed  in  solid  lines  and  level  of  statistical-­significance  
(****p  <  0.0001,  **p<0.01,  *p<0.05)  shown  (n=30).  
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Figure  3.3:  Interplay  between  CSF3  and  emergency  granulopoiesis  
A-­B.  Analysis  of  control  (scr),  csf3a  or  csf3b  morpholino  (Mo)-­injected  embryos  at  56  hpf  with  
or  without  LPS  injection  at  48  hpf  for  expression  of  csf3a  (A)  and  csf3b  (B)  by  qRT-­PCR,  with  
mean   and   SEM   displayed   in   solid   lines   and   level   of   statistical   significance   (***p   <   0.001,  
**p<0.01,  *p<0.05,  ns  not  significant)  shown.  
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Figure  3.4:  CSF3R  pathways  in  myelopoiesis  
A-­B.  Quantitation  of  mpo+  cells  in  embryos  treated  with  either  DMSO  or  the  inhibitors  AG490,  
or  LY294002  (A).  Quantitation  of  relative  migration  of  mpo+  cells  in  embryos  treated  with  either  
DMSO   or   the   indicated   inhibitors   (B),   with   mean   and   SEM   displayed   in   red   and   level   of  
statistical  significance  (****p  <  0.0001,  ***p  <  0.001,  **p<0.01)  shown  (n>30).  
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Figure  3.5:  CSF3R  pathways  in  neutrophil  migration  
A-­L.  Fluorescent  microscopy  of  3  dpf  Tg  (mpo::GFP)  embryos  treated  with  either  DMSO  (A-­
C),  or  the  inhibitors  AG490  (D-­F),  LY294002  (G-­I),  or  PP2  (J-­L)  subjected  to  wounding  (blue  
dotted  line)  and  imaged  at  the  times  indicated  post  wounding.  
M.  Quantitation  of  mpo+  cells  at  the  site  of  wounding  in  embryos  treated,  with  either  DMSO  or  
the  inhibitors  indicated  with  mean  and  SEM  displayed  in  solid  lines  and  statistically-­significant  
differences  (*p  <  0.05)  shown  (n=30).  
Chapter 3 
100 
 
  
  
  
Chapter 3 
101 
 
Figure  3.6:  CSF3R  pathways  in  emergency  myelopoiesis  
A-­H.  Fluorescent  microscopy  images  of  3  dpf  Tg  (mpo::GFP)  embryo  injected  with  LPS  and  
pretreated  with  either  DMSO  (A-­B),  or  the  inhibitors  AG490  (C-­D),  LY294002  (E-­F),  or  PP2  
(G-­H).    
I.  Quantitation  of  mpo+  cells  in  embryos  injected  with  LPS  and  pretreated  with  either  DMSO  
or   the   inhibitors   indicated   with   mean   and   SEM   shown   in   red   and   statistically-­significant  
differences  (**p  <  0.01,  *p<0.05)  shown  (n>25).  
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Figure  3.7:  Targeting  Csf3r  with  TALENs  and  identification  of  mutant  alleles  
A.  The  CSF3R  and   its  perturbation   in  neutropenia.  Schematic   representation  of   the  Csf3r,  
showing  the  N-­terminal  leader  sequence  (open  triangle),  followed  by  the  extracellular  region  
comprising  immunoglobulin  domain  (red),  four  conserved  cysteines  (thin  lines)  and  W-­S-­X-­W-­
S   motif   (thick   line)   within   the   cytokine   receptor   homology   domain   (orange)   and   three  
fibronectin  type  III-­like  domains  (green),  the  transmembrane  domain  (blue),  as  well  as  Box  1-­
3  (numbered  grey  rectangles)  within  the  cytoplasmic  region  (pink),  which  also  includes  four  
tyrosine  (Y)  residues.  The  exon  boundaries  of  the  zebrafish  Csf3r  are  shown  with  the  dotted  
vertical  lines,  with  the  relative  positions  of  human  CSF3R  extracellular  truncations  associated  
with  SCN  or  CIN  indicated  above  with  dark  blue  arrows  and  the  mutation  generated  in  this  
study  by  blue  arrow.    
B-­C.   Genome   targeting   of   zebrafish   csf3r.   Schematic   representation   of   the   intron/exon  
structure  of  part  of  the  csf3r  gene  (B).  Exons  are  represented  as  numbered  boxes  colored  as  
described   in   panel   A,   with   the   introns   represented   with   solid   lines   and   spanning   primers  
indicated  by  arrows.  Targeting  of  exon  13  with  a  TALEN  pair   (C).  The   relevant  nucleotide  
sequence   is   shown,   with   its   targeting   by   left   and   right   TALENs   indicated   and   the   TaqI  
restriction  site  italicized  and  underlined.    
D.  The  csf3r  mutant  alleles  generated.  Sequence  of  homozygous  wild-­type  (wt)  and  mutant  
csf3r  alleles  (mdu5  and  mdu6),  with  respective  translations  shown  below.  The  csf3rmdu5  allele  
represents  a  13  bp  deletion  and  the  csf3rmdu6  allele  an  11  bp  deletion,  both  of  which  cause  a  
frameshift  resulting  in  a  small  number  of  residues  translated  from  an  alternative  reading  frame,  
followed  by  a  stop  codon  that  truncates  at  the  C-­terminus  of  the  third  fibronectin  type  III-­like  
domain.  
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Figure  3.8:  Effect  of  Csf3r  mutation  on  primitive  myelopoiesis  
Homozygous  wild-­type  (wt)  and  csf3rmdu5/mdu5  (mdu5)  embryos  were  subjected  to  WISH  with  
spi1  at  16  hpf  (A-­B),  csf3r  at  18  hpf  (D-­E)  and  22  hpf  (G-­H)  (using  HR  WISH),  and  mpo  (J-­K),  
lyz  (M-­N)  and  l-­plastin  (P-­Q)  at  22  hpf.  Individual  embryos  were  assessed  for  the  number  of  
spi1+   (C),  csf3r+  (F,I),  mpo+   (L),   lyz+   (O)  and   l-­plastin+   (R)  cells,  with   the  mean  and  SEM  
shown  in  red  and  level  of  statistical-­significance  indicated  (****  p<0.0001,  ***  p<0.001,  ns  not  
significant).  The  dotted  light  blue  lines  demarcate  the  extent  of  migration  of  mpo+  and  lyz+  cell  
populations,   (n=30,   the   results  have  been  showed   from   individual  experiments,  which  was  
confirmed  in  an  additional  experiment).  
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Figure  3.9:  Effect  of  Csf3r  mutation  on  definitive  myelopoiesis  
Homozygous  wild-­type  (wt)  and  csf3rmdu5/mdu5  (mdu5)  and  csf3rmdu6mdu6  (mdu6)  embryos  were  
subjected  to  WISH  with  c-­myb  (A-­C)  and  runx1  (D-­F)  at  3.5  dpf,  csf3r  at  4  dpf  (G-­H)  (using  HR  
WISH),  mpo  (J-­K),  lyz  (M-­N),  l-­plastin  (P-­Q)  and  rag1  (S-­T)  or  whole  embryo  staining  with  O-­
dianisidine   (V-­W)   at   5   dpf,   or   were   subjected   blood   analysis   at   5   dpf   (X-­Y)   (100   X  
magnification)   (Abbreviations:   e:   erythrocyte,   l:   lymphocyte,   n:   neutrophil,   p:   precursor).  
Individual  embryos  was  assessed  for  the  number  of  csf3r+  (I),  mpo+  (L),  lyz+  (O)  and  l-­plastin+  
(R)  cells,  the  area  of  staining  for  rag1,  expressed  as  ratio  to  eye  size  averaged  for  individual  
embryos  (U),  or  blood  differential  counts  (Z),  with  mean  and  SEM  shown  in  red  and  level  of  
statistical-­significance  indicated  (****  p<0.0001,  ***  p<0.001,  ns  not  significant)  (n=30  for  WISH  
and  n=5  for  blood  smear,  the  results  have  been  showed  from  individual  experiments,  which  
was  confirmed  in  an  additional  experiment).    
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Figure  3.10:  Effect  of  Csf3r  mutation  on  adult  hematopoiesis  
A-­F,  M-­O.  Histological  analysis  of  adult  blood  and  kidney  cells.  Imaging  (A-­B,  D-­E,  M-­N)  (100  
X  magnification)  and  quantitation  of   indicated  cell  populations   (C,  F,  O)  of  Giemsa  stained  
blood   (A-­C),   kidney   (D-­F)   and   sorted   kidney   myeloid   cells   (M-­O)   from   wild-­type   (wt)   and  
csf3rmdu5/mdu5   (mdu5)   adult   fish,   with   hypersegmented   neutrophils   indicated   with   arrows  
(Abbreviations:  e:  erythrocyte,  eo:  eosinophil,  l:  lymphocyte,  n:  neutrophil,  p:  precursor)  (n=5).  
G-­L.  FACS  analysis  of  myeloid  cells.  Analysis  of  kidney  myeloid  (G-­H)  and  GFP+  neutrophil  
(J-­K)  populations  of  wild-­type   (wt)  and  csf3rmdu5/mdu5   (mdu5)  adult   fish,  and   their   respective  
quantitation   (I,   L),   with   mean   and   SEM   shown   in   red   and   level   of   statistical-­significance  
indicated  (****  p<0.0001,  ***  p<0.001,  **  p<0.01,  n/s  not  significant)  (n=5).  
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Figure  3.11:  Functional  analysis  of  Csf3r  mutants  
A.  Response  to  exogenous  Csf3.  Wild-­type  (wt)  and  csf3rmdu5/mdu5  (mdu5)  embryos  at  the  1-­8  
cell  stage  were  either  left  uninjected  or  injected  with  csf3a  mRNA  (+csf3a)  and  analysed  at  48  
h  with  mpo,  with  the  number  of  mpo+  cells  in  individual  embryos  enumerated,  with  mean  and  
SEM  in  red  and  level  of  statistical-­significance  indicated  (****  p<0.0001,  ***  p<0.001,  **  p<0.01,  
n/s  not  significant)  (n=30).  
B.  Response  to  LPS  injection.  Wild-­type  (wt),  csf3rmdu5/mdu5  (mdu5)  and  csf3rmdu6/mdu6  (mdu6)  
embryos  at  48  hpf  were  either  left  uninjected  or  injected  with  LPS  (+LPS)  and  analyzed  8  h  
later  with  mpo  as  described  for  panel  A,  (n=30).  
C.  Response  to  wounding.  Quantitation  of  myeloid  cell  recruitment  at  the  indicated  hours  post  
wounding  (hpw)  in  wild-­type  (wt)  and  csf3rmdu5/mdu5  (mdu5)  embryos,  showing  mean  and  SEM  
using  mpo  and  analyzed  as  described  for  panel  A,  (n=30,  the  neutrophils  migrated  to  the  close  
proximity  of  the  wounding  site  was  counted).  
D-­G.  Response  to  bacterial  infection.  Wild-­type  (wt)  and  csf3rmdu5/mdu5  (mdu5)  embryos  at  72  
hpf  were  injected  with  PBS  or  fluorescent  E.  coli  (+bact).  The  bacterial  load  was  enumerated  
by   plate-­counting   (D),   (n=10),   with   mean   and   SEM   shown   in   red,   and   visualized   by  
fluorescence  microscopy  (E-­F),  at  the  indicated  hours  post  infection  (hpi)  and  displayed  as  a  
Kaplan-­Meier   plot   (G),   (n=30).   (****   p<0.0001,   ***   p<0.001,   **   p<0.01,   *   p<0.05,   n/s   not  
significant).  
H.  Relative   juvenile   survival.  Wild-­type   (wt),  csf3rmdu5/mdu5   (mdu5)   and  csf3rmdu6/mdu6   (mdu6)  
juveniles  were  placed   in   tanks  on  the  standard  recirculating  aquarium  system,  and  survival  
monitored  and  displayed  as  a  Kaplan-­Meier  plot,  (n=30).  (***  p<0.001,  n/s  not  significant).  
I-­L.  Analysis  of  adult  kidney  myeloid  cells.  Staining  of  sorted  myeloid  cells  for  myeloperoxidase  
(I)  (100  X  magnification)  and  analysis  of  myeloid  cells  for  apoptosis  using  Annexin  V/7-­AAD  
staining  (J-­K),  with  quantitation  of  early  (AnnV  +/7-­AAD  -­)  and    late  (AnnV  +/7-­AAD  +)  cells  
from   wild-­type(wt)   and   csf3rmdu5/mdu5   (mdu5)   fish   (L),   (n=5).   (**   p<0.01,   *   p<0.05,   n/s   not  
significant).  
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Chapter 4: Role of JAK3 in zebrafish lymphopoiesis: toward 
models of SCID and T cell leukemia 
Chapter 4 
114 
 
   Introduction 
Janus kinases (JAKs) are tyrosine kinases that have key roles downstream of cytokine receptors 
in transmitting signals controlling critical cell processes such as proliferation, survival and 
differentiation (Rane & Reddy 2000). The activity of these kinases is regulated through 
tyrosine phosphorylation that is initiated by the binding of a cytokine to its cognate receptor, 
thereby triggering structural changes that mediates trans auto-phosphorylation of the JAKs 
(Feng et al. 1997). JAKs have been shown to play crucial roles in blood and immune cell 
development (Yamaoka et al. 2004). Dysregulation of JAKs is associated with a variety of 
diseases, with loss-of-function mutations associated with various immune deficiency 
syndromes. Conversely, aberrant activation of JAKs, such as by point mutations in the 
regulatory pseudokinase domain or gene fusions, are key drivers of proliferative disorders and 
cancers, including leukemia (Babon et al. 2014; Laurence et al. 2012). 
Of the four mammalian JAKs, JAK3 is unique in having restricted expression in hematopoietic 
cells, particularly within the lymphoid compartment. Therefore, perturbations in JAK3 affects 
only lymphoid cells. Furthermore, JAK3 specifically associates with the common IL2Rγc chain 
that is shared by the receptors of several cytokines important for lymphopoiesis, specifically 
IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 (Johnston et al. 1994; Kawamura et al. 1994; Witthuhn 
et al. 1994). Inactivating mutations in JAK3 cause autosomal Severe Combined Immune 
Deficiency (SCID) characterised by a lack of T and NK cells and non-functional B cells, due 
to loss of function for all of these receptors (Macchi et al. 1995; Notarangelo et al. 2001; Russell 
et al. 1995). A myriad of such mutations have been identified in different patients, such as a 
frame shift mutation in the SH2 domain and a non-sense mutation in the pseudokinase domain 
associated with SCID (Russell et al. 1995), a frame shift mutation in the FERM domain causing 
SCID with maternal T cell engraftment (Cacalano et al. 1999), a E481G substitution mutation 
in the SH2 domain leading to a milder SCID phenotype with non-functional T cells, compound  
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C759R and R445X mutation within the pseudokinase domain and SH2 domain respectively, 
and a homozygous 21 base pair deletion (Δ 1861-1881) and 5 base pair deletion (Δ 1537-1541) 
mutations within the kinase domain causing T-B+ SCID (Candotti et al. 1997).  
Constitutively-activating mutations in JAK3 have been reported in cases of Natural Killer T 
cell lymphoma (NKTCL) (Koo et al. 2012), cutaneous T cell lymphoma (Kameda et al. 2010), 
acute megakaryoblastic leukemia (AMKL) (Walters et al. 2006) and T cell acute lymphoblastic 
leukemia (T-ALL) (Bains et al. 2012; Zhang et al. 2012) in humans. Two common mutations 
A572V and A573V are reported to cause NKTCL (Koo et al. 2012), T-ALL (Bains et al. 2012; 
Degryse et al. 2014) and AMKL (Malinge et al. 2008; Walters et al. 2006) in humans. These 
mutations are found within the pseudokinase regulatory domain (PKD), causing JAK3 to be 
constitutively-activated and able to mediate receptor-independent proliferation of NK and T 
cells. There are several other constitutively-activating mutations within the JAK3 PKD, such 
as R657Q that has been identified in T-ALL patients (Bains et al. 2012) and AMKL associated 
V722I mutation that confers growth factor independent proliferation in Ba/F3 cells (Walters et 
al. 2006). The JAK3 P132T mutation found within the FERM domain has also been reported 
in AMKL (Walters et al. 2006). The aim of this Chapter was to characterise the function of 
zebrafish Jak3. This involved analysing its pattern of expression, as well as generating mutants 
based on those found in SCID and T-cell lymphoma as potential models of these diseases. 
   Expression of zebrafish jak3 
In mammals JAK3 is specifically expressed in lymphoid cells (Park et al. 1995; Suzuki et al. 
2000). The expression profile of zebrafish jak3 during embryogenesis was analysed using 
WISH. No specific staining was observed at 3 dpf with an anti-sense jak3 probe (Figure 4.1 A) 
or at earlier time-points (data not shown). However, specific bilateral staining was observed 
within the thymus from 4 dpf (Figure 4.1 C) and continuing to 8 dpf (Figure 4.1 D-H), which 
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was not seen with the sense probe (Figure 4.1 B and data not shown). The staining in the head 
of zebrafish embryos stained with anti-sense jak3 probe at 5 dpf, 6 dpf and 7 dpf was also 
observed in their sense embryos indicating non-specific staining. Expression of jak3 in adult 
zebrafish was analysed by RT-PCR using primers specific for jak3. This showed highest jak3 
expression in the kidney and spleen, which represent major lymphoid organs (Figure 4.1 I). 
   Generation and analysis of JAK3 knockout zebrafish 
   Generation of JAK3 knockout zebrafish 
A variety of loss-of-function mutations of JAK3 have been identified in autosomal recessive 
SCID in humans. These mutations are scattered through all functional domains of JAK3 protein 
with PKD being a prime hot spot for mutations (Notarangelo et al. 2001) (Figure 4.2 A). To 
generate similar alleles of zebrafish jak3, the CRISPR genome editing technique was employed 
to target exon 13 of the zebrafish jak3 gene, which encodes the PKD (Figure 4.2 B).  
One-cell stage zebrafish embryos were injected with in vitro transcribed mRNA encoding 
sgRNA specific for jak3 exon 13 and Cas9 (Figure 4.2 C), and raised to adulthood. The progeny 
of potential F0 founders were screened by High Resolution Melt analysis, followed by 
sequencing. This identified two mutant alleles, mdu9 and mdu10, which carried an 11 bp 
insertion and a 4 bp deletion at the target site respectively. Both of these mutations each 
introduce a premature stop codon, leading to a Jak3 protein truncated in the PKD (Figure 4.2 
D). Fish carrying these alleles were outcrossed twice to dilute potential off-targetting, with 
heterozygote F2 mutants in-crossed to generate both heterozygote and homozygote F3 mutants 
for further analysis in comparison to wild-type siblings. 
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   Phenotypic analysis of zebrafish carrying SCID-derived JAK3 mutation 
   Analysis of embryonic hematopoiesis 
Embryos were first analysed for the effect of Jak3 mutations on definitive hematopoiesis using 
WISH. This revealed reduced area of staining with ikaros, a marker of early lymphoid cells 
(Van Parijs et al. 1999), at 3.5 dpf in homozygous mdu9 (jak3mdu9/mdu9) mutants compared to 
wild-type siblings (jak3wt/wt) (Figure 4.3 A-C). This was sustained at 5 dpf (Figure 4.3 D-F), at 
which time reduced staining was also observed with rag1 (Figure 4.3 G-I), lck (Figure 4.3 J-
L) and tcrα (Figure 4.3 M-O), markers of more mature lymphocytes (Danilova et al. 2004; 
Langenau et al. 2004), in jak3mdu9/mdu9 compared to jak3wt/wt embryos. However, there was no 
difference in the number of cells staining with lyz (Figure 4.3 P-R), a leukocyte marker (Van 
Parijs et al. 1999) or mpo (Figure 4.3 S-U), a neutrophil marker (Van Parijs et al. 1999), 
between jak3wt/wt and jak3mdu9/mdu9 embryos. A similar result of reduced rag1 staining in the 
thymus was obtained with homozygous jak3mdu10/mdu10 mutants with jak3wt/mdu10 heterozygotes 
similar to wild-type embryos (Figure 4.4 A-D). 
   Analysis of larval hematopoiesis 
The effect of Jak3 mutations on later lymphopoiesis was investigated by RT-PCR on 28 dpf 
jak3wt/wt, jak3mdu9/mdu9 and jak3mdu10/mdu10 larvae using primers specific for T cell and B cell 
rearrangements as described (Petrie-Hanson, Hohn & Hanson 2009; Schorpp et al. 2006) 
(Figure 4.5 A). Both homozygous wild-type (jak3wt/wt) and heterozygote (jak3wt/mdu9) 
individuals showed normal T and B cell rearrangement, while jak3mdu9/mdu9 larvae showed no T 
cell rearrangement and variable rearrangement of B cells (Figure 4.5 A). In contrast, 
jak3mdu10/mdu10 larvae displayed complete loss of B cell rearrangement in both heterozygote and 
homozygote mutants.  
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Further, quantitative real-time PCR (qPCR) analysis was performed using a broad range of 
genes marking HSCs, T cells (cd4, cd8, tcrb), B cells (igm, igd, cd79a, pax5), NK cells (nklc, 
nkld, nccrp1) (Moore et al. 2016a) and red blood cells (hbb) (Figure 4.5 B). This revealed 
significant reduction in expression of T cell markers and one NK cell marker in jak3mdu9/mdu9 
compared to jak3wt/wt juveniles, whereas markers of HSCs, B cells and RBC were not 
significantly altered (Figure 4.5 B).  
   Survival analysis 
No adult jak3mdu9/mdu9 or jak3mdu10/mdu10 fish were identified at 3 months of age. Therefore, the 
relative survival rate of jak3wt/wt compared to heterozygote and homozygote fish jak3mdu9/mdu9 
and jak3mdu10/mdu10 was investigated by following the progeny of heterozygote in-crosses by 
genotyping at various ages. During embryogenesis, a Mendelian ratio of wild-type, 
heterozygote and homozygote mutant zebrafish was observed. However, zebrafish carrying 
homozygote mdu9 and mdu10 alleles were at less than the expected Mendelian ratio from 28 
days post fertilization indicating a survival defect. Heterozygote mutants displayed similar 
survival rates to wild-types and survived to adulthood (Figure 4.6).  
   Generation and analysis of T cell lymphoma-derived constitutively-activated 
JAK3 mutants 
The constitutive activation of JAK3 results in different types of lymphoproliferative 
malignancies. Two such mutations of JAK3, A572V and A573V, which are associated with 
NKTCL and AMKL in humans (Koo et al. 2012; Malinge et al. 2008). Here we analysed the 
effect of these mutations on zebrafish lymphopoiesis. 
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   In vitro analysis of mutant JAK3. 
Protein alignment of human and zebrafish JAK3 proteins revealed high conservation overall, 
including the residues adjacent to A572V and A573V within the PKD domain (Figure 4.7 A). 
To analyse the effect of JAK3 mutations A572V and A573V in vitro, sequences encoding wild-
type zebrafish Jak3 along with variants carrying A572V and A573V mutations were 
synthesized and cloned into pBK-CMV. These plasmids were transfected into human HEK293 
cells along with an expression vector containing the zebrafish Stat5.1 gene. After 48 h, total 
protein was extracted and analysed by Western blot using an anti-phospho-STAT5 antibody 
(Figure 4.7 B). No phospho-STAT5 was observed in untransfected HEK293 cells, those 
transfected with Stat5.1 alone, or empty pBK-CMV vector plus Stat5.1. In contrast, cells 
transfected with wild-type Jak3 plus Stat5.1 showed strong phosphorylation. Cells transfected 
with Jak3 A572V had reduced levels of phospho-STAT5 compared to wild-type but levels 
were increased with Jak3 A573V. Analysis with anti-GAPDH antibody confirmed equivalent 
loading in each case (Figure 4.7 B).  
To confirm these effects in vivo, one-cell stage wild-type zebrafish embryos were injected with 
in vitro transcribed mRNA encoding Jak3 A572V or A573V and subjected to WISH with rag1 
at 5 dpf to detect mature T cell lymphocytes. This analysis revealed that embryos injected with 
Jak3 A573V but not A572V mRNA showed increased expression of rag1 (Figure 4.7 D-F), 
when compared to control embryos (Figure 4.7 C, F).  
   Generation of zebrafish carrying T cell lymphoma-derived JAK3 mutation 
The in vitro data suggested that zebrafish Jak3 A573V mutation resulted in increased activity, 
and the in vivo data correlated this with an increase in T cells. Therefore, a homology directed 
repair (HDR) strategy was used to reproduce this mutation, employing the same CRISPR 
sgRNA as used for generating the SCID-derived JAK3 mutants targeting exon 13, along with 
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an appropriate HDR template. This template was a 67 bp single stranded oligonucleotide 
containing nucleotide changes to elicit a A573V mutation in the coding sequence, as well as 
changes to the PAM motif to destroy CRISPR recognition, and to introduce a restriction 
enzyme site (BciVI) for RFLP screening (Figure 4.8 B-C). Injected embryos were raised to 
adulthood for screening, which identified zebrafish carrying an allele encoding constitutively 
active Jak3 A573V (ca), which was further outcrossed for two generations, with a subsequent 
incross to generate heterozygote (wt/ca) and homozygote (ca/ca) alleles of the Jak3 A573V 
mutation (Figure 4.8 D).   
   Phenotypic analysis of zebrafish T cell lymphoma-derived mutants  
   Phenotypic analysis of zebrafish carrying T cell lymphoma-derived JAK3 
mutation during embryogenesis 
To investigate the effect of Jak3 A573V mutation on embryonic lymphopoiesis, wild-type 
(jak3wt/wt), heterozygote (jak3wt/ca) and homozygote (jak3ca/ca) were subjected to WISH. Both 
jak3wt/ca and jak3ca/ca embryos showed a significant increase in expression of the early lymphoid 
marker ikaros at 3.5 dpf (Figure 4.9 A-D). This was also observed at 5 dpf (Figure 4.9 E-H), 
with a similar increase evident in expression of the mature lymphocyte markers rag1 (Figure 
4.9 I-L), lck (Figure 4.9 M-P) and tcrα (Figure 4.9 Q-T). In contrast, the number of lyz+ 
myeloid cells (Figure 4.9 U-X), mpo+ neutrophils (Figure 4.9 Y-B’) and the extent of O-
dianisidine staining of red blood cells (Figure 4.9 C’-E’) was not significantly different 
between jak3wt/wt, jak3wt/ca and jak3ca/ca embryos. Analysis of blood smears at 5 dpf confirmed 
a significantly increased lymphocyte population in jak3wt/ca and jak3ca/ca embryos in 
comparison to those of their jak3wt/wt siblings (Figure 4.9 F’-I’). 
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   Analysis of constitutively active JAK3 mutants during larval stage 
To examine the effects of Jak3 A573V mutation at the larval stage, RT-PCR on 28 dpf jak3wt/wt, 
jak3wt/ca and jak3ca/ca larvae was performed using primers specific for T cell and B cell 
rearrangements (Petrie-Hanson, Hohn & Hanson 2009; Schorpp et al. 2006) (Figure 4.10 A). 
Both jak3wt/ca and jak3ca/ca individuals showed normal T cell and B cell rearrangement (Figure 
4.10 A). Further analysis was performed with qPCR using a broad range of genes marking 
HSCs (lmo2), T cells (cd4, cd8, tcrb), B cells (igm, igd, cd79a, pax5), NK cells (nklc, nkld, 
nccrp1) (Moore et al. 2016a) and red blood cells (hbb) (Figure 4.5 B). This revealed both 
jak3wt/ca and jak3ca/ca larvae displayed significantly increased expression of markers for T cells, 
whereas markers of HSCs, B cells, NK cells and RBC were not significantly altered (Figure 
4.10 B). This indicated that the Jak3 A573V allele produces a sustained increase in T cells. 
   Analysis of constitutively-active JAK3 mutants in the adult 
The blood from adult jak3wt/wt, jak3wt/ca and jak3ca/ca zebrafish was analysed by cytology (Figure 
4.11 A-C) and quantified by differential counting (Figure 4.11 D). This revealed a significant 
increase in circulating lymphocyte numbers in jak3wt/ca and jak3ca/ca in comparison to jak3wt/wt 
fish. The kidney was similarly analysed, which also showed a significant increase in 
lymphocyte numbers in both jak3wt/ca and jak3ca/ca in comparison to jak3wt/wt fish (Figure 4.11 
E-H). Kidney cells were also subjected to flow cytometry analysis, with the lymphocyte (Figure 
4.11 I-K, M) and precursor (Figure 4.11 I-K, N) populations both increased significantly in 
jak3wt/ca and jak3ca/ca in comparison to jak3wt/wt. In contrast, the erythrocyte and myeloid (Figure 
4.11 I-K, L) populations showed no statistically significant alterations. 
   Survival analysis 
The relative survival rate of jak3wt/wt, jak3wt/ca and jak3ca/ca was investigated. Progeny of 
homozygous jak3wt/wt and jak3ca/ca incrosses and outcrosses of homozygous jak3wt/wt and 
Chapter 4 
122 
 
jak3ca/ca giving jak3 wt/ca were counted at each week post fertilisation. Following embryogenesis 
until 3 weeks post fertilisation (wpf) good survival of jak3wt/wt,  jak3wt/ca and jak3ca/ca zebrafish 
was observed, with a drop in survival seen for jak3ca/ca after 3 wpf, with a 51.4% survival defect 
observed in ca/ca at 12 wpf, whereas jak3wt/ca fish displayed similar survival rate to jak3wt/wt 
and survived to adulthood (Figure 4.11 O). 
   Discussion 
Lymphoid development relies heavily on the IL-2R family of cytokine receptors, including IL-
2R, IL-4R, IL-7R, IL-9R, IL-15R and IL-21R (Liao, Lin & Leonard 2013; Malek 2008; Meazza 
et al. 2011; Rochman, Spolski & Leonard 2009), each of which shares the common IL2Rγc 
that signals via JAK3, as well as a ligand-specific chain that signals through JAK1 and 
sometimes a third receptor chain (Lai et al. 2013; Malek & Castro 2010). Loss-of-function 
mutations of several of these components, including JAK3, are associated with SCID in 
humans and mice (Candotti et al. 1997; Macchi et al. 1995; Nosaka et al. 1995; Notarangelo et 
al. 2001; Park et al. 1995). Activating mutations in JAK3 (or JAK1) are also associated with 
lymphoid malignancy (Mullighan et al. 2009). Zebrafish possesses many of the constituent 
chains of the IL-2R family, including a duplicated Il2rγc (Liongue & Ward 2007)  and a single 
Jak3 (Liongue et al. 2012), and is therefore suitable to model these human diseases . 
This Chapter aimed to generate specific mutants of zebrafish Jak3 based on those seen in 
human SCID and T cell lymphoma. A CRISPR-Cas genome editing strategy was used to create 
an inactivating mutation in zebrafish Jak3 and in combination with HDR to generate a 
constitutively-activated zebrafish Jak3 A573V mutation based on a mutation commonly found 
in T cell lymphoma. These mutants were broadly characterised during embryonic, larval and 
where possible-adult hematopoiesis. Collectively, this Chapter has successfully generated a 
model of SCID and a model of expanding T lymphopoiesis in zebrafish. 
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   Generation of zebrafish model of SCID via inactivating JAK3 mutation 
SCID related JAK3 mutations are found throughout the JAK3 protein, with truncating 
mutations typically resulting in T-B+NK- SCID in humans (Roberts et al. 2004). The strong 
identity between humans and zebrafish JAK3 proteins suggested likely functional 
conservation, which was reinforced by the observation that zebrafish jak3 expression was 
enriched in lymphoid tissues. Therefore, zebrafish lines were generated carrying an inactivating 
mutation in the pseudokinase domain of Jak3 similar to those seen in human SCID. These 
mutants displayed a severe reduction in T cell lymphocytes during embryonic hematopoiesis, 
which continued into the larvae stage at which time NK cells were also reduced albeit to a 
lesser extent, whereas B cell numbers were unaffected. A similar phenotype of T cell reduction 
were also observed in Jak3-/- (Nosaka et al. 1995) and Il2rγc-/- mice (Cao et al. 1995), in another 
zebrafish jak3 mutant (Iwanami et al. 2011) and as well as a zebrafish in which il2rγc.a was 
ablated (Sertori et al. 2016) confirming a conserved role of Jak3 downstream of IL2Rγc in 
zebrafish lymphopoiesis. The jak3 mutant zebrafish created here failed to reach adulthood, 
which impeded further analysis including of B cell function. Presumably, this was due to 
increased susceptibility to infection in a manner similar to human SCID patients (Bortin & 
Rimm 1977; Stephan et al. 1993). It is hoped that enhancement of husbandry conditions, 
including raising fish in sterile conditions, can overcome this issue. A previous zebrafish jak3-
/- has been described to survive to 49 dpf but no adult details were shown (Iwanami et al. 2011).  
   Jak3 A573V mutant model of zebrafish based on T cell lymphoma-derived 
mutation in humans 
Cases of T cell lymphoma in humans are associated with a myriad of mutations, with JAK3 
mutations, including A572V and A573V, being common mutations (Bains et al. 2012). The 
sequence around A572V and A573V was conserved between zebrafish and humans. 
Heterologous expression of the A573V mutant form of Jak3 resulted in increased Stat5 
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phosphorylation compared to the wild-type, with this mutant also able to partially rescue the 
loss of T lymphocytes in il2rγc.a ablated zebrafish (Sertori et al. 2016). Therefore, a CRISPR 
mediated homology-directed repair strategy was used to generate a zebrafish Jak3 A573V 
mutant.  
Detailed analysis revealed elevated levels of T lymphocytes during definitive hematopoiesis in 
both heterozygote (jak3wt/ca) and homozygote (jak3ca/ca) A573V mutants. This was revealed by 
increased expression of the key T cell markers ikaros, rag1, tcrα, and lck, and analysis of blood 
smears from 5 dpf embryos that confirmed increased T cell numbers in jak3wt/ca and jak3ca/ca 
mutants in comparison to that of jak3wt/wt. Larval stages also demonstrated elevated T cells in 
jak3wt/ca and jak3ca/ca Jak3 A573V mutants as determined by qRT-PCR of T cell markers. 
Zebrafish carrying the A573V mutation survived to adulthood with jak3wt/ca heterozygotes 
showing survival rates comparable to that of jak3wt/wt, while jak3ca/ca showed a reduced 
survival. Adult mutants also possessed increased T cell numbers in adult blood and kidney 
analysis. Flow cytometry analysis of kidney marrow demonstrated an increase in total 
lymphoid population in jak3wt/ca and jak3ca/ca, along with an increase in precursors. This is 
consistent with a lymphoproliferative disorder rather than T cell lymphoma. Clone analysis of 
these mutants at later ages should be performed to check for progression to T cell malignancy. 
Cells expressing both A572V and A573V JAK3 mutants showed ligand independent 
proliferation and increased phosphorylation of downstream signalling components 
(Bouchekioua et al. 2014; Degryse et al. 2014; Quintás-Cardama et al. 2011). Mice transplanted 
with mouse bone marrow cells expressing the JAK3 A573V mutation by retroviral tranduction 
of murine stem cell virus  developed a lymphoproliferative disorder with increased T cells that 
later progressed to T-ALL (Degryse et al. 2014). Mice transplanted with human bone marrow 
cells expressing Jak3 A572V mutation also exhibited in proliferation of CD8+ T cells and 
Chapter 4 
125 
 
megakaryocytes (Malinge et al. 2012). In contrast to the Jak3 A573V mutation, the Jak3 
A572V mutation did not show a similar effect in zebrafish. Transient expression of Jak3 
A572V in HEK cells did not lead to phosphorylation of STAT5 and failed to increase T cell 
numbers in embryos. Although amino acid positions 572 and 573 are highly conserved, it is 
possible that they require interactions with other parts of the Jak3 which are not conserved 
meaning the A572V mutation no longer leads to constitutive activation. 
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Figure  4.1:  Expression  of  zebrafish  Jak3  during  embryogenesis  and  in  adult  
tissues  
A-­H.  Wild  type  embryos  were  fixed  and  subjected  to  WISH  with  sense  (S)  and  anti-­sense  (AS)  
jak3  probes  at  indicated  time  points.  Staining  in  the  thymus  is  indicated  with  blue  arrow  heads.  
Embryos  shown  as  lateral  (A-­G),  or  dorsal  (H)  view,  with  anterior  to  the  left  (n=30).    
I.  RT-­PCR  of  total  RNA  extracted  from  the  indicated  adult  tissues  with  jak3  primers,  along  with  
β-­actin  as  a  loading  control.  RT-­negative  controls  yielded  no  products  (data  not  shown).  
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Figure  4.2:  Generation  of  zebrafish  carrying  SCID-­derived  JAK3  mutations  
A.  JAK3  structure  and   its  perturbations   in  human  SCID.  Schematic   representation  of  JAK3  
with   their   domains,   N-­terminal   FERM   domain   (pink),   SH2   domain   (green),   pseudokinase  
domain  PKD   (red)   and   kinase  domain   (blue).   The   relative   positions  of   human  SCID   JAK3  
mutations  are  denoted  by  purple  arrows.  
B-­C.  Genome  targeting  of  zebrafish  jak3.  Exon-­intron  structure  of  the  target  site  with  spanning  
primers   indicated  by  black  arrows  (Fwd  =  F,  Rvs  =  R)  (B).  Exons  are  shown  as  numbered  
boxes  and  coloured  based  on  the  domain  and  intron  represented  as  solid  lines  and  the  relative  
position  of  SCID-­derived  mutation  reproduced  in  zebrafish  denoted  by  pink  arrow.  CRISPR-­
Cas9  targeting  (C)  The  nucleotide  sequence  for  the  target  site  and  sgRNA  are  shown  in  purple  
text,  target  site  shown  in  pink  text  with  PAM  sequence  shown  in  brown  text.  
D.  The  zebrafish   jak3  mutant  alleles  generated.  The  nucleotide  sequence  of  genomic  DNA  
from  zebrafish  carrying  homozygous  wild-­type  (wt)  and  mutant  (mdu9  and  mdu10)  jak3  alleles  
are   shown   with   their   protein   translations   displayed   below   in   black   text.   The  mdu9   allele  
represents  an  11  bp  insertion  and  the  mdu10  allele  a  4  bp  deletion,  both  resulting  in  frameshifts  
that  introduce  a  stop  codon  in  the  pseudokinase  domain.  
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Figure  4.3:  Phenotypic  analysis  of  zebrafish  carrying  SCID-­derived  JAK3  
mutations  
Wild-­type  (wt/wt)  and  jak3mdu9/mdu9  (mdu9/mdu9)  embryos  were  subjected  to  WISH  with  ikaros  
at  3.5  dpf  (A-­B)  and  5  dpf  (D-­E),  rag1  (G-­H),  lck  (J-­K),  tcrα  (M-­N),  lyz  (P-­Q)  and  mpo  (S-­T)  at  
5  dpf.  Staining   in   the   thymus   is   indicated  with  blue  arrow  heads.   Individual   embryos  were  
assessed  for  the  area  of  expression  for  ikaros  (C,  F),  rag1  (I),  lck  (L)  and  tcrα  (O),  expressed  
as  ratio  to  eye  size  averaged  for  individual  embryos,  or  the  number  of  lyz+  (R)  and  mpo+  (U)  
cells,  with   the  mean  and  SEM  shown   in   red  and   level  of  statistical-­significance  differences  
indicated   (****   p<0.0001,   ns   not   significant)   (n=30,   the   results   have   been   showed   from  
individual  experiments,  which  was  confirmed  in  an  additional  experiment).    
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Figure  4.4:  Phenotypic  analysis  of  zebrafish  carrying  alternate  SCID-­derived  
JAK3  mutation  
Wild-­type  (wt/wt),  heterozygote  (wt/mdu10)  and  homozygote  (mdu10/mdu10)  mutant  embryos  
were  subjected  to  WISH  with  rag1  (A-­C)  at  5  dpf.  Individual  embryos  were  assessed  for  the  
area  of  expression  for  rag1,  expressed  as  ratio  to  eye  size  averaged  for  individual  embryos  
(D),  with  the  mean  and  SEM  shown  in  red  and  level  of  statistical-­significance  indicated  (***  
p<0.001,  ns  not  significant)  (n>30).  
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Figure  4.5:  Effect  of  SCID-­derived  JAK3  mutations  on  zebrafish  larval  T,  B  and  
NK  cells    
A.   Total   RNA   from   28   dpf   wild-­type   (wt/wt),   jak3mdu9/mdu9   (mdu9/mdu9)   and   jak3mdu10/mdu10  
(mdu10/mdu10)  was  subjected  to  RT-­PCR  with  primers  specific  for  T  cell  receptor  (TCR)  β-­
chain  (v(d)j-­cβ  vb1.5,  vb12,  vb14.5)  and  B  cell  Ig  heavy  chain  (igVH1,  igVH4)  rearrangements  
and  β-­actin  as  the  control.  RT-­negative  controls  yielded  no  products  (data  not  shown)  (n=2).  
  
B.  Total  RNA  from  homozygous  wild-­type  (wt/wt),  and  jak3mdu9  (mdu9/mdu9)  were  subjected  
to  QRT-­PCR  analysis  with  hematopoietic  stem  cell  marker  (lmo2),  T  cell  specific  markers  (cd4,  
cd8,  tcrb),  B  cell  markers  (igm,  igd,  cd79,  pax5),  NK  cell  specific  markers  (nccrp1,  nklc  and  
nkld)   and   the   red   blood   cell   marker   (hbb).   Data   is   represented   as   relative   fold   change  
compared  to  homozygous  wild-­type  (wt/wt)  with  mean  and  SEM  shown  in  red  and  statistical  
significance  compared  for  their  Cq  values  normalised  (relative  to  control  β-­actin)  and  indicated  
(**p<0.01,  *p<0.05,  ns  not  significant)  (n=3).  
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Figure  4.6:  Relative  survival  of  mutants    
Progeny  of  F2  heterozygote  incrosses  of  jak3  wt/mdu9  and  jak3  wt/mdu10  were  raised  under  normal  
husbandry   conditions.   At   indicated   time   points,   these   embryos   (n>24)   were   genotyped   to  
determine   the   frequency   of  wild-­type   (wt),   heterozygote   and   homozygote   fish   jak3mdu9  and  
jak3mdu10  were  plotted  in  binomial  line  as  ratio  of  wild-­type  versus  heterozygote  (blue  line),  (A)  
both  homozygote  mdu9  and  mdu10  data  points  combined  and  plotted  versus  to  heterozygote  
(green  line)  (n=30).  
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Figure  4.7:  Conservation  of  T  cell  lymphoma-­derived  JAK3  mutations  in  
zebrafish  and  the  effect  of  this  mutation  on  STAT5  activation  and  T  cell  
production  
A.  Conservation  of  human  and  zebrafish  JAK3.  Human  and  zebrafish  JAK3  were  aligned  using  
CLUSTAL  X.  The   residues  are  colour-­coded,  with  similar   residues  coloured   the  same  and  
conservation   indicated   (*   -­   identical,   :   -­   highly   similar,   .   -­   similar).   The   position   of   human  
mutation  A572V  and  A573V  are  indicated  with  purple  arrows,  with  their  zebrafish  equivalent  
denoted  by  pink  arrows.  
B.  Western  blot  analysis  using  anti-­phospho  STAT5  antibody  of  HEK  cells  (control)  or  those  
transfected  with  Stat5.1,  wild-­type  Jak3  +  Stat5.1,  Jak3  A572V  +  Stat5.1  and  Jak3  A573V  +  
Stat5.1.  Empty  vector  with  Stat5.1  and  untransfected  HEK  cells  shown  as  negative  controls.  
C-­F.  Embryos,  either  uninjected   (C)  or   injected  with  mRNA  encoding  Jak3  A572V   (D)  and  
A573V  (E)  were  subjected  to  WISH  with  rag1,  with  the  area  of  rag1  expression  presented  as  
ratio  to  eye  size  averaged  for  individual  embryos  (F)  determined  for  individual  embryos  with  
mean  and  SEM  shown   in  red  and   level  of  statistical-­significance   indicated  (*p<0.05,  ns  not  
significant)  (n=30).  
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Figure  4.8:  Generation  of  zebrafish  carrying  T  cell  lymphoma-­derived  JAK3  
allele  
A.  JAK3  structure  and  its  perturbations  in  human  T  cell  lymphoma.  Schematic  representation  
of   JAK3   with   their   domains,   N-­terminal   FERM   domain   (pink),   SH2   domain   (green),  
pseudokinase  domain  PKD  (red)  and  kinase  domain  (blue).  The  relative  positions  of  human  T  
cell   lymphoma,  NKTCL   and  AMKL  mutations   including   JAK3  A573V   is   denoted   by   purple  
arrows.  
B-­C.  Genome  targeting  of  zebrafish  jak3:  exon-­intron  structure  of  the  target  site  with  primers  
spanning  indicated  by  black  arrows.  (B)  Exons  are  shown  as  numbered  boxes  and  coloured  
based   on   the   domain   and   intron   represented   as   solid   lines,   with   zebrafish   Jak3   A573V  
mutation  denoted  by  pink  arrow.  (C)  The  nucleotide  sequence  for  target  site,  sgRNA  and  HDR  
repair   template  are  shown  in  purple  text,  with  PAM  sequence  shown  in  brown  text  and  the  
corresponding  mutation  based  nucleotide  changes  and  target  site  denoted  in  pink  text.  
D.  The  jak3  mutant  alleles  generated  in  zebrafish.  The  nucleotide  sequence  of  homozygous  
wild-­type  (wt/wt)  and  heterozygous  (wt/ca)  and  homozygous  (ca/ca)  mutant  are  shown  with  
their  protein  translations  shown  below  in  black  text.    
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Figure  4.9:  Phenotypic  analysis  of  zebrafish  carrying  T  cell  lymphoma-­derived  
JAK3  allele  
Embryos  homozygous  for  JAK3  wild-­type  (jak3wt/wt),  JAK3  A573V  (jak3ca/ca)    or  heterozygote  
JAK3  A573V  (jak3wt/ca)    were  subjected  to  WISH  with  ikaros  at  3.5  dpf  (A-­C)  and  5  dpf  (E-­G),  
rag1  (I-­K),  lck  (M-­O),  tcrα  (Q-­S),  lyz  (U-­W),  mpo  (Y-­A’),  and  O-­dianisidine  (C’-­E’)  at  5  dpf,  or  
blood   analysis   performed   at   5   dpf   (F’-­H’)   (100   X  magnification).   Individual   embryos   were  
assessed  for  area  of  staining  with  ikaros  (D,  H),  rag1  (L),  lck  (P)  and  tcrα  (T),  expressed  as  
ratio   to  eye  size  averaged   for   individual  embryos  or   total  number  of   lyz+   (X)  and  mpo+   (B’)  
cells,   or   blood   differential   counts   (I’)   with   the   mean   and   SEM   shown   in   red   and   level   of  
statistical-­significance   indicated  (****  p<0.0001,  ns  not  significant)   (n=30   for  WISH  analysis  
and  n=5  for  blood  smear).    
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Figure  4.10:  Effect  of  T  cell  lymphoma-­derived  JAK3  mutation  on  larval  
hematopoiesis  
A.   Total   RNA   from   28   dpf   homozygote   wild-­type   (jak3wt/wt),   heterozygote   (jak3wt/ca)   and  
homozygote  (jak3ca/ca)  was  subjected  to  RT-­PCR  with  primers  specific  for  T  cell  receptor  (TCR)  
β-­chain   (v(d)j-­cβ   vb1.5,   vb12,   vb14.5)   and   B   cell   Ig   heavy   chain   (igVH1,   igVH4)  
rearrangements  and  β-­actin  as  the  control.  RT-­negative  controls  yielded  no  products  (data  not  
shown)  (n=2).  
B.  Total  RNA  from  homozygous  wild-­type  (jak3wt/wt),  heterozygote  (jak3wt/ca)  and  homozygote  
(jak3ca/ca)  were  subjected  to  QRT-­PCR  analysis  with  hematopoietic  stem  cell  marker  (lmo2),  T  
cell  specific  markers  (cd4,  cd8,  tcrb),  B  cell  markers  (igm,  igd,  cd79  and  pax5),  NK  cell  specific  
markers   (nccrp1,   nklc,   nkld)   and  marker   for   red   blood   cells   (hbb).  Data   is   represented   as  
relative  fold  change  compared  to  homozygous  wild-­type  (wt/wt)  with  mean  and  SEM  shown  in  
red   and   statistical   significance   compared   for   their   normalised   cq   values   (cq   values   were  
normalised  to  their  control  β-­actin)  and  indicated  (**p<0.01,  *p<0.05,  ns  not  significant)  (n=3).  
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Figure  4.11:  Effect  of  T  cell  lymphoma-­derived  JAK3  mutation  on  adult  
hematopoiesis  
A-­D,  E-­H.  Histological  analysis  of  adult  blood  and  kidney  cells.  Giemsa  stained  blood  cells  (A-­
C),   and   kidney   cells   (E-­G)   of   wild-­type   (jak3wt/wt),  heterozygote   (jak3wt/ca)  and   homozygote  
(jak3ca/ca)   are   shown   with   differential   counts   for   blood   (D)   and   kidney   (H)   performed  
(Abbreviations:  e:  erythrocyte,  eo:  eosinophil,   l:   lymphocyte,  n:  neutrophil,  p:  precursor,  m:  
macrophage)  (n=5,  100  X  magnification).  
I-­N.  FACS  analysis  of  different  blood  cell  populations  –  erythrocytes,  myeloid,  lymphoid  and  
precursors  for  wild-­type  (jak3wt/wt)  (I),  heterozygote  (jak3wt/ca)  (J)  and  homozygote  (jak3ca/ca)  (K)  
were   performed,   with   their   respective   quantification   for   myeloid   (L),   lymphoid   (M)   and  
precursors  (N)  plotted,  with  mean  and  SEM  shown  in  red  and  level  of  statistical-­significance  
indicated  (***p<0.001,  **p<0.01,  *p<0.05,  ns  not  significant)  (n=5).  
O.  Percent  survival  of  wild-­type  (jak3wt/wt),  heterozygote  (jak3wt/ca)  and  homozygote  (jak3ca/ca)  
juvenile  zebrafish.  The  zebrafish  juveniles  were  kept  in  aquarium  under  standard  conditions,  
survival  monitored  weekly  and  plotted  as  Kaplan-­Meier  plot  with  level  of  statistical-­significance  
indicated  (***p<0.001)  (n=35).  
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   Introduction 
Zebrafish has proven to be an excellent model for investigating hematopoiesis and 
hematopoietic disease (Jing & Zon 2011; Rasighaemi et al. 2015). This is underpinned by 
conservation of relevant developmental processes and the genes controlling them. For example, 
hematopoiesis occurs in multiple overlapping waves in both zebrafish and humans to generate 
a similar repertoire of blood and immune cells (Chen & Zon 2009; Ellett & Lieschke 2010; 
Jagannathan-Bogdan & Zon 2013). In addition, hematopoiesis has been shown to require 
equivalent transcription factors (Chen & Zon 2009; Davidson & Zon 2004; Song et al. 2004), 
and a similar network of cytokines, receptors and downstream JAK-STAT signalling 
components (Chen & Zon 2009; Hou et al. 2002; Langenau et al. 2003; Liongue et al. 2012; 
Liongue & Ward 2007; Lyons et al. 2001a; Willett et al. 2001).  
Studies have been performed on several cytokine receptor pathways in zebrafish, for example 
EPO/EPOR  and the downstream tyrosine kinase JAK2 . Both epor (Paffett-Lugassy et al. 
2007) and jak2a (Oates et al. 1999) were found to be expressed in hematopoietic sites 
throughout development. Morpholino-mediated ablation of either epo (Chu et al. 2007) or epor 
(Paffett-Lugassy et al. 2007) blocked definitive erythropoiesis, while injection of epo mRNA 
in zebrafish embryos resulted in severe polycythemia (Paffett-Lugassy et al. 2007). Similarly, 
knockdown of jak2a by morpholino (Ma et al. 2007) or shRNA (Sung et al. 2009) also resulted 
in significant reduction of definitive erythropoiesis. These studies have confirmed a conserved 
role for EPO/EPOR/JAK2 signalling in mammalian erythropoiesis.  
Other research has investigated the pathogenic consequences of perturbed cytokine 
receptor/JAK/STAT signalling in zebrafish. For example, expression of a gain-of-function 
mutant of zebrafish Jak2a (V581F) based on the polycythemia vera-associated JAK2 V617F 
mutant resulted in enhanced erythropoiesis in zebrafish embryos (Ma et al. 2009), which was 
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also observed following expression of constitutively-activated forms of Stat5.1 (N646H and 
H298R/N714F) (Lewis, Stephenson & Ward 2006). Expression of Tel-Jak2a fusion proteins 
based on those seen in T-ALL and atypical CML also resulted in perturbation in embryonic 
lymphoid and myeloid populations respectively (Onnebo et al. 2005; Onnebo et al. 2012). 
Therefore, zebrafish represents a useful and relevant model for investigating cytokine receptor 
components and their role in hematopoiesis and disease.  
However, many of the studies published to date have used transient approaches, such as 
overexpression via injection of DNA or RNA, or knockdown via injection of morpholinos or 
shRNA. Furthermore, overexpression is not physiological, while morpholino gene knockdown 
technology gives incomplete knock down and off-target effects (Eisen & Smith 2008; Ekker 
2004; Robu et al. 2007). In contrast, genome-editing technology can provide a more definitive 
analysis with specific targeting of genes in situ, the effects of which can be assessed across the 
lifespan (Sertori et al. 2015). This thesis has used genome-editing approaches in concert with 
other methodologies to explore the function of a cytokine receptor (CSF3R) and a downstream 
JAK (JAK3) in hematopoiesis and to develop models of neutropenia, SCID and T cell 
lymphoma based on clinically relevant mutations in these genes. This Chapter explores the key 
findings and places them in a broader perspective, as well as discussing further directions from 
this work. 
   CSF3R signalling in myeloid biology and disease 
Neutrophils play a key role in defence against bacterial and fungal pathogens throughout life 
(Smith 1994). Coupled with their short survival time, this means they must be constantly 
produced via a process of myelopoiesis, which occurs in several phases across the life span 
(Bardoel et al. 2014; Pillay et al. 2010). Myelopoiesis in humans and mice is mediated by 
several cytokines, with CSF3 and its receptor CSF3R playing key roles (Panopoulos & 
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Watowich 2008) both developmentally and as part of an emergency response (Touw & van de 
Geijn 2007). CSF3R signalling can also modulate key neutrophil functions like adhesion (Yuo 
et al. 1989), phagocytosis (Höglund, Håkansson & Venge 1997), degranulation (De Haas et al. 
1994), chemokinesis (Yong 1996) and super oxide burst (Yuo et al. 1989). CSF3R activates a 
range of intracellular pathways, with JAK2 and the SRC kinase LYN considered the key 
cytoplasmic protein tyrosine kinases acting downstream of this receptor (Corey et al. 1994; 
Nicholson et al. 1995; Tian et al. 1996; Ward et al. 1998a; Zhu et al. 2006). These kinases serve 
to phosphorylate tyrosine residues within the intracellular region of the CSF3R to mediate a 
range of signalling pathways that drive key cellular outcomes, such as proliferation, 
differentiation and activation (Touw & van de Geijn 2007).  
Perturbation of CSF3R signaling can result in various myeloid disorders including neutropenia, 
myeloproliferative disorders and leukemias (Liongue & Ward 2014). Most CSF3R mutations 
are somatic rather than inherited, and while some are associated with neutropenia, their major 
role appear to be driving the development of malignancies like AML, CNL or MDS through 
enhanced responsiveness to ligand stimulation by CSF3 (Klein 2011; Xia et al. 2009). 
However, a variety of inactivating extracellular mutations are directly involved in the etiology 
of neutropenia (Liongue & Ward 2014; Ward et al. 1999b). 
Chapter 3 described the investigation of the role of CSF3R signalling in zebrafish 
myelopoiesis, including the involvement of its two ligands and key downstream pathways in 
normal and emergency myelopoiesis in embryonic zebrafish. It also detailed the generation of 
zebrafish with a mutated CSF3R similar to that observed in neutropenic patients non-
responsive to CSF3, which were characterised from embryogenesis through to adulthood.  
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   Role in embryonic myelopoiesis 
The role of CSF3/CSF3R signalling in mammalian embryonic myelopoiesis – particularly 
primitive myelopoiesis has not been extensively studied. However, zebrafish CSF3R has been 
previously shown to play an important role in embryonic myelopoiesis using a morpholino-
mediated knockdown approach (Liongue & Ward 2007). This was confirmed in Chapter 3 with 
csf3rMo injected embryos exhibiting severely reduced mpo+ myeloid cells and zebrafish csf3r 
extracellular mutants showing reduced neutrophils during embryogenesis. Decreased adult 
neutrophils were also seen in csf3r mutants consistent with recently described csf3r knockouts 
that introduced early stop codons in the N-terminal immunoglobulin (Ig) domain (Pazhakh et 
al. 2017). Importantly, our zebrafish csf3r mutants possessed a number of relevant functional 
deficits that were not observed in this study. 
Zebrafish possesses two paralogues of CSF3, encoded by csf3a and csf3b, which were 
generated during the teleost-specific whole genome duplication (Stachura et al. 2013). Previous 
studies have shown that Csf3a and Csf3b both signal through the single zebrafish Csf3r but 
differ in their temporal expression during embryogenesis and spatial expression in adult 
zebrafish (Stachura et al. 2013). Chapter 3 showed that knockdown of either csf3a or csf3b 
caused a significant reduction in mpo+ myeloid cells, the latter confirming an earlier study 
showing that csf3b morphants exhibited decreased neutrophil numbers (Galdames et al. 2014).  
However, this was not as severe as the reduction seen in csf3r morphants or mutants, which 
indicates that both csf3a and csf3b contribute to embryonic neutrophil production.  
Treatment of zebrafish embryos with JAK2 or PI3K inhibitors also resulted in a significant 
reduction in the mpo+ cells. This indicates that JAK2 and PI3K contribute to embryonic 
myelopoiesis downstream of Csf3r. 
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   Role in steady-state myelopoiesis 
In humans, CSF3R is expressed on myeloid progenitor cells in the bone marrow and CD34+ 
cells within peripheral blood of humans (Tsuji & Ebihara 2001), with their predominant 
expression being on cells of the neutrophilic lineage (Ema et al. 1990; Metcalf 1989). The 
regulatory role of CSF3 in human granulopoiesis has been well documented where it has been 
shown to influence the production, survival and function of neutrophils (Roberts 2005; Wright 
et al. 2015). Csf3 and Csf3r deficient mice exhibited reduced numbers of neutrophils (Lieschke 
et al. 1994; Liu et al. 1996), with Csf3-deficient mice shown to be more susceptible to bacterial 
infections (Lieschke et al. 1994). Csf3 knockout mice also had significantly fewer myeloid 
precursor cells in their bone marrow with this phenotype shown to be rescued by CSF3 
administration (Lieschke et al. 1994).  
Chicken also possess a conserved CSF3, previously called myelomonocytic growth factors 
(MGF) (Gibson, Kaiser & Fife 2009), and CSF3R (Kaiser et al. 2005). Chicken MGF was 
identified due to its role in inducing the production of macrophage and granulocyte-like 
colonies from myeloblasts (Leutz, Beug & Graf 1984). Chicken CSF3 has been shown to 
regulate maturation and function of their neutrophil equivalent, the heterophil, where CSF3R 
is hypothesised to be expressed (Gibson, Kaiser & Fife 2009). Collectively, this suggests a 
conserved role of both in myeloid progenitors and along the neutrophil lineage. 
The Csf3r mutant zebrafish allowed the effects of Csf3r in adulthood to be studied, which was 
not possible with morpholino-based studies. Reduced neutrophil numbers were seen in adult 
blood and kidney consistent with a recently described Csf3r knockout zebrafish model 
(Pazhakh et al. 2017). Neutrophils from Csf3r-deficient zebrafish possessed normal 
myeloperoxidase staining consistent with other studies suggesting normal neutrophil function 
in the absence of CSF3R in mice (Liu et al. 1996). In fact the neutrophils were shown to be 
hypersegmented, which is an interesting finding that warrants further analysis. There were also 
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more vacuoles in the neutrophils of Csf3r-deficient zebrafish compared to wild-types. Studies 
have reported the presence of many vacuoles in human neutrophils during chronic infection 
(McCall et al. 1969; Segal 2005). It is possible this is also the case for mutant fish, which also 
displayed reduced overall survival. 
Csf3r ablation did not entirely deplete the neutrophil population, suggesting that other 
cytokines are involved in neutrophil production and homeostasis in zebrafish as is the case in 
mammals. Myelopoiesis is known to be regulated by network of cytokines and growth factors, 
with signalling via CSF1R, CSF2R, IL-3R, IL-6R and TPOR all contributing to neutrophil 
production (Dalrymple et al. 1995; Romani et al. 1996; Seymour et al. 1997) with several of 
these shown to compensate for the loss of CSF3R signals (Hibbs et al. 2007). Of these, CSF1R, 
IL-6R and TPOR are shown to be conserved in zebrafish (Liongue & Ward 2007; Parichy et 
al. 2000), with Csf1r shown to play a role in embryonic macrophage function (Herbomel, 
Thisse & Thisse 2001) and both Tpo (Svoboda et al. 2014) and Tpor (Lin et al. 2017) shown 
to act on hematopoietic progenitors and thrombocytes. 
   Role in emergency myelopoiesis 
Emergency myelopoiesis in humans occurs in response to infection or inflammation, and is 
mediated by a range of cytokines. However, administration of CSF3 alone is able to drive the 
proliferation of progenitor cells and direct differentiation into granulocytes (Claus 2015). 
Emergency expansion of granulocytic lineages also occur in response to infection in zebrafish 
(Hall et al. 2012; Hou et al. 2016). In order to gain additional insight into the response of 
CSF3R signalling in emergency myelopoiesis, injection with bacterial LPS was used to 
simulate a bacterial infection (Liongue et al. 2009a; Phelps, Runft & Neely 2009). LPS 
stimulation has been shown to significantly increase csf3a expression as well as the number of 
csf3r+ cells, with csf3r morpholinos able to block this response (Liongue et al. 2009a). The 
results of Chapter 3 demonstrated that LPS also increased the expression of csf3b but to a more 
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modest extent. In addition csf3a morphants were resistant to the LPS stimulated expression of 
both csf3a and csf3b genes in zebrafish, with csf3b morphants exhibiting a milder response. 
Collectively, this indicates the particular importance of the csf3a-encoded ligand in zebrafish 
emergency responses.  
SRC and PI3K inhibitors both blocked the LPS-mediated increase in neutrophils, while the 
JAK2 inhibitor had no effect. This indicates SRC and PI3K, but not JAK2 have non-
redundancy role in this process, presumably downstream of CSF3R. CSF3R has been shown 
to activate LYN, which in turn triggers the multiple signalling pathways downstream including 
both the PI3K-AKT and ERK-MAPK pathways (Shimoda et al. 1994; Wang et al. 2008; Zhu 
et al. 2006). Studies with LYN deficient cells have identified a key role for this kinase in 
CSF3R-mediated cell proliferation (Corey et al. 1998), consistent with the results reported here. 
A CSF3R W650R mutant that failed to activate JAK2 also did not elicit proliferative signalling 
(Barge et al. 1996). However, Jak2 knockout mice showed similar numbers of CFU-G, 
suggesting JAK2 is not crucial for CSF3R-mediated cell growth (Grisouard et al. 2014), again 
consistent with the inhibitor studies.  
   Role in neutrophil function 
Neutrophils represent the first line of defence against bacterial and fungal infection (Segal 
2005). This requires a number of different functions. These include the ability to be released 
from the bone marrow into blood and their migration to sites of inflammation or infection, 
where they actively kill pathogens by a number of mechanisms including phagocytosis, 
respiratory bursts and netolysis (Mayadas, Cullere & Lowell 2014). Csf3 plays a indispensable 
role in steady-state neutrophil trafficking in mice (Basu et al. 2002) and also has been shown 
to promote key neutrophil functions, including chemotaxis, phagocytosis, respiratory burst, 
bactericidal/fungicidal activity and survival (Dale et al. 1995). 
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Previous studies have identified a role of CSF3R in myeloid cell migration during early 
development (Liongue et al. 2009a). Morpholino-mediated knockdown revealed both csf3a and 
csf3b contributed to myeloid cell migration during embryogenesis. Other experiments 
demonstrated that morpholino-mediated ablation of csf3b, and not csf3a, resulted in reduced 
neutrophil recruitment at the wounding site with better retention at the injury. This is in 
agreement with a study with csf3b morphants displaying a defective  neutrophil migration in 
an alternate wounding model (Galdames et al. 2014). However, ablation of Csf3r more 
significantly impacted on neutrophil recruitment and their extended retention at the injury, as 
previously described (Liongue et al. 2009a), suggesting csf3a may also play an additive role. 
Use of specific inhibitors demonstrated that PI3K was important for neutrophil recruitment, 
while JAK2 was not required for recruitment but was potentially involved in neutrophil 
retention at the injury. The former is consistent with another zebrafish study showing that PI3K 
impacts on cell protrusion and polarity of zebrafish neutrophils in response to wounding (Yoo 
et al. 2010). Other research has suggested that neutrophil migration to wounding in zebrafish 
is dependent on CXCL18 and CXCR2 (de Oliveira et al. 2013; Deng et al. 2013). However, 
how these chemokines relate to CSF3R/PI3K signalling remains to be determined. Neutrophil 
recruitment to the sites of infection or wounding varies with location and intensity of the 
damage, happening through extracellular matrix for mild proximal lesions, but from the CHT 
through the bloodstream for severe damage (Galdames et al. 2014). The lesions that were 
introduced in this study represented severe damage, and so presumably neutrophil recruitment 
from the CHT via bloodstream. Further analysis of milder lesions would provide further 
insights. 
The function of CSF3R signalling has been examined using various infection models in mice. 
Csf3 knockout mice showed a severely impaired response to infection with Listeria 
monocytogenes compared to wild-type mice, with diminished infection-driven granulopoiesis 
Chapter 5 
157 
 
leading to reduced neutrophils and a delayed increase in monocytes (Lieschke et al. 1994). 
Bronchopulmonary infection of Csf3 knockout mice with Pseudomonas aeruginosa resulted 
in reduced release of neutrophils into the blood with elevated numbers of apoptotic neutrophils 
in the lungs (Gregory et al. 2007). The E. coli infection studies performed in the Csf3r deficient 
zebrafish in Chapter 3 displayed similar immune deficits with increased bacterial load and 
reduced survival compared to wild-type embryos. 
It has been reported that both Csf3 and Csf3r knockout mice show reduced neutrophil survival 
(Basu et al. 2002; Liu et al. 1996). Studies have been done to understand the apoptotic 
mechanism of neutrophils in these animals, which revealed the overexpression of anti-
apoptotic gene bcl2 in Csf3 knockout mice did not increase neutrophil numbers indicating that 
the survival defect likely occurs before the emergence of committed progenitors and mature 
neutrophils (Molineux 2002). Consistent with this, the kidney myeloid cells from Csf3r mutant 
zebrafish displayed increased apoptosis. 
   Further analyses  
Much remains to be investigated about CSF3R signalling pathways in vivo. This study has 
revealed detailed insights into the role of the alternate Csf3 ligands, csf3a and csf3b, along with 
downstream signalling pathway in embryonic hematopoiesis, during both steady state and 
emergency conditions. Generation of csf3a and csf3b knockout zebrafish will allow more 
detailed analysis of the functional split between these ligands especially in adult myelopoiesis. 
Investigating the role of downstream pathways (JAK2, PI3K and SRC) in adult zebrafish is 
more problematic since these molecules play wider roles. However, specific expression of 
dominant-negative and/or activating mutations using lineage-specific transgenesis or genome 
editing in myeloid cells would be informative. Zebrafish also provides the opportunity to 
investigate the intracellular tyrosine residues of CSF3R with HDR strategies available to 
mutate these individually, or in various combinations, to phenylalanine. These could be used 
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to study the specific roles of each in mediating myelopoiesis, and also in CSF3R-mediated 
migration, survival and responses to infection. Also the CSF3R knockout model generated in 
this study is useful to explore alternative approaches to restore neutrophil numbers, which will 
help in identifying specific drugs that might be developed for personalised medicine 
application. 
   Neutropenia models 
Chapter 3 established a zebrafish model that recapitulated human neutropenia unresponsive to 
CSF3. These Csf3r deficient mutants displayed decreased levels of neutrophils during primitive 
and definitive hematopoiesis, which continued to adulthood. The mutant zebrafish showed 
decreased overall survival and increased susceptibility to bacterial infection, with increased 
bacterial load and reduced survival in comparison to their control embryos. Injection of csf3a 
mRNA into these mutant zebrafish Csf3r failed to elicit a response.  
Mutations in a number of other genes, including ELANE, GFI1, HAX1, G6PC3, WAS and TAZ 
also contribute to the etiology of neutropenia (Xia et al. 2009). In addition, neutropenia 
develops as a phenotype associated with other granulocytic disorders with mutations in other 
genes like AP3B1, LYST, VPS13B, SLC37A4, CXCR4 and TAZ (Donadieu et al. 2011). Several 
of these genes have been studied in mice. For example, mice lacking G6pc3 developed 
neutropenia with their neutrophils showing defects in functions such as respiratory burst, 
chemotaxis and calcium flux, with enhanced neutrophil apoptosis, leading to increased 
susceptibility to bacterial infections (Cheung et al. 2007). Gfi1 knockout mice developed 
neutropenia due to an imbalance in granulocyte/monocyte ratio with enhanced monocyte 
differentiation at the expense of granulopoiesis (Zarebski et al. 2008). Mouse Slc37a4 
knockouts exhibited neutropenia and abrogated neutrophil trafficking (Chen et al. 2003), while 
Cxcr4 knockout mice displayed reduced myelopoiesis in fetal liver and complete absence of 
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myelopoiesis in bone marrow (Ma et al. 1998; Nagasawa et al. 1996). A dog model of Vps13b 
deficiency has also been identified, characterised by an absence of segmented neutrophils 
(Shearman & Wilton 2011).  
The role of these and other neutropenia-related genes could also be examined in zebrafish. 
Indeed, a zebrafish model of WHIM syndrome has been developed with mutation of the cxcr4 
gene, which resulted in severely reduced neutrophils during definitive hematopoiesis (Walters 
et al. 2010). This confirms that zebrafish represents an attractive avenue for future research in 
this area. 
   JAK3 as a two faced player in lymphoid development and disease 
JAK3 has been shown to be essential for signalling downstream of the IL-2 family of cytokines 
through its interaction with the IL-2Rγc chain, where it mediates activation of downstream 
pathways important for cell proliferation, differentiation and survival, including STAT5, AKT 
and ERK1/2 (Lai et al. 2013; Malek & Castro 2010; Rochman, Spolski & Leonard 2009). 
Inactivating mutations of JAK3 causes SCID in humans and mice (Nosaka et al. 1995; Russell 
et al. 1995). Conversely, activating JAK3 mutations are associated with several human 
hematological malignancies, including acute megakaryoblastic leukemia (AMKL), natural-
killer T-cell lymphoma (NKTCL), mantle cell lymphoma, Burkitt’s lymphoma, and T cell 
acute lymphoblastic leukemia (T-ALL) (Degryse et al. 2014; Koo et al. 2012; Walters et al. 
2006). 
Chapter 4 detailed the investigation of the role of JAK3 in lymphopoiesis and lymphopoietic 
disease. It described the generation of zebrafish harbouring Jak3 mutations based on the 
inactivating mutations seen in SCID and the constitutively active mutations seen in T cell 
lymphoma, as well as characterisation of blood and immune cells in zebrafish carrying these 
Jak3 alleles. 
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   Role in lymphopoiesis  
JAK3 is predominantly expressed within lymphoid cells in mammals. Zebrafish jak3 was found 
be expressed in the thymus during embryogenesis, with higher expression observed in the 
spleen, kidney, and gills, confirming predominantly lymphoid expression (Gurniak & Berg 
1996; Lai et al. 1995). There was also high sequence conservation between zebrafish Jak3 and 
its mammalian counterparts (Liongue et al. 2012). Collectively, this suggests a similar 
biological role across vertebrates.  JAK3 binds to IL2Rγc, the common signalling chain of IL-
2R, IL-4R, IL-7R, IL-9R, IL-15R and IL-21R, and transduces signals which are important for 
the development and function of immune cells (Alves, Arosa & van Lier 2007; Malek 2008; 
Meazza et al. 2011; Spolski & Leonard 2008). Lack of JAK3 abrogates the signalling from 
each of these receptors resulting in defective immune cell development and activation. 
Inactivating mutations in JAK3 result in autosomal recessive SCID with severely reduced T 
and NK cells as well as B cells that are non-functional (Macchi et al. 1995; Russell et al. 1995). 
This is very similar to the X-linked recessive SCID resulting from mutations in IL2Rγc-chain 
(Noguchi et al. 1993). Both Jak3 and Il-2rγc knockout mice also developed SCID, but with 
markedly reduced T, NK and B cells (Nosaka et al. 1995; Park et al. 1995; Thomis & Berg 
1997; Thomis et al. 1995). The variation in B cell numbers between mice and humans has been 
attributed to IL-7 being a pre-B cell growth factor in mice but not in humans (Puel et al. 1998).  
A loss-of-function Jak3 mutant in zebrafish has been described, which showed reduced T cell 
numbers during embryogenesis and in larvae, however the effects on B cells and NK cells were 
not characterised (Iwanami et al. 2011). Another study also reported zebrafish Jak3 knockout 
mutant, which showed depletion of T and NK cells (Moore et al. 2016b). In this study, 
inactivating mutations of zebrafish Jak3 were generated by CRISPR genome editing targeting 
of the PKD to create truncation mutants similar to those observed in some cases of human 
SCID (Macchi et al. 1995). These fish developed a phenotype similar to human SCID with 
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severe depletion of T cells and some reduction in NK cells, but normal levels of B cells. The 
homozygote mutant zebrafish generated in this study displayed poor survival, preventing 
analysis of adults.  
   Role in lymphoid malignancy 
Activating alleles of JAK3 cause severe disruption to normal T and NK cell development in 
humans (Bains et al. 2012; Bellanger et al. 2014; Koo et al. 2012). Most of these mutations are 
within the pseudokinase domain of JAK3, disrupting the crucial auto-regulatory interaction 
between the kinase and pseudokinase domains resulting in constitutive phosphorylation of 
tyrosine 980 within the activation loop and so constitutive-activation, leading to 
phosphorylation of downstream STAT3, STAT5, ERK1/2 and AKT (Bouchekioua et al. 2014). 
Inhibition of JAK3 kinase activity blocked the activation of these downstream targets 
confirming its central role (Bouchekioua et al. 2014). Interestingly, JAK1 has been shown to 
have a crucial role in the transforming properties of JAK3 A573V presumably through trans-
activation (Degryse et al. 2014).  
The JAK3 A572V and A573V mutations have been implicated in malignant hematopoietic 
disorders like AMKL (Malinge et al. 2008), T-cell ALL (Bains et al. 2012), T cell 
prolymphocytic leukemia (Bellanger et al. 2014) and NKTCL (Koo et al. 2012), being 
collectively reported in 21% of NKTCL and 7% of T-ALL. Mouse models generated by 
retroviral transduction of mouse bone marrow cells expressing JAK3 A572V followed by 
transplantation into lethally irradiated mice were characterised with megakaryocytic 
hyperplasia or lymphoproliferative disorders (Cornejo, Boggon & Mercher 2009; Cornejo et 
al. 2009),  including a T-ALL like disease, with ligand-independent proliferation of these T 
cells (Degryse et al. 2014). Mice transplanted with NKTCL patient cells harbouring the JAK3 
A573V mutation showed tumor cell dissemination throughout the bone marrow, spleen and 
kidney (Bouchekioua et al. 2014).  
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As detailed in Chapter 4, introduction of the A573V mutation into zebrafish Jak3 resulted in 
enhanced activation of STAT5 when transfected into HEK 293 cells, and increased T cells 
when injected into zebrafish embryos. CRISPR genome editing with HDR allowed the 
production of zebrafish carrying a Jak3 A573V encoding mutation. These showed elevated T 
cells starting during embryogenesis and continuing to adulthood. Both heterozygote and 
homozygote zebrafish Jak3 A573V mutants displayed T cell lymphoproliferative disorder 
rather than a lymphoid malignancy. There are several explanations for this phenotype. For 
example, the model generated here is more physiological in which the mutation is present in 
the endogenous Jak3 rather than being overexpressed as is likely in the mouse retroviral 
transduction studies. Moreover, similar to humans (Bains et al. 2012; Bellanger et al. 2014; 
Degryse et al. 2014), additional cooperating mutations might be required in these zebrafish 
mutants for their leukemic transformation.    
   Future directions 
Much work remains to fully characterise the zebrafish Jak3 mutants based on inactivating 
versions found in SCID and activating versions found in hematopoietic malignancy. The SCID-
associated Jak3 mutants failed to survive to adulthood. Therefore, better aquarium conditions 
or inducible ablation of Jak3 is required to complete the analysis of these mutant fish (Hans et 
al. 2009; Maddison, Lu & Chen 2011; Mosimann et al. 2011). Measures to reduce the immune 
burden for these immunodeficient zebrafish, could include individual housing in static tanks, 
separated from other fish, use of antibiotic cocktails to reduce the vulnerability of the bacterial 
infection or the generation of gnotobiotic zebrafish lines harbouring these mutations (Pham et 
al. 2008). If such measures enable them reach adulthood, further studies would include analysis 
of the adult zebrafish lymphocyte populations, including FACS, testing susceptibility to 
infections such as influenza (Goody, Sullivan & Kim 2014) and xenotransplantation studies 
(Eguiara et al. 2011; Konantz et al. 2012).  
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JAK3 is an integral part of IL2Rγc mediated cytokine signaling, and therefore functional 
characterisation of downstream signalling components would provide additional insights. This 
can be achieved by heterozygous ablation of Il2rγc in heterozygous Jak3 zebrafish mutants, 
which might produce milder SCID-like phenotype. However, compensation assays involving 
Jak3 A573V heterozygotes and homozygotes in parallel with ablation of either Il2rγc or Stat5.1 
and Stat5.2 is an interesting study that could provide more information about the contribution 
of each of these signalling component in lymphopoiesis.  
The complete functional analysis of the Jak3 A573V mutant was hampered due to time 
constraints. More detailed analysis of different lymphoid populations in the adult could use 
antibodies validated in previous studies performed on zebrafish and channel catfish for T cells 
(anti-Cd4, anti-Cd8) (Taylor et al. 2016; Yoon et al. 2015), B cells (anti-Igm, anti-Cd3) (Taylor 
et al. 2016) or NK cells (anti-Nkp46) (Jung et al. 2016). Recent studies have reported the 
identification of a novel NK-like cell population in addition to NK cells in zebrafish (Tang et 
al. 2017). Use of both NK cell and NK-like cell specific markers would allow clarification of 
how both populations are affected. In addition, the constitutively-activating Jak3 A573V 
mutants could be combined with other mutations observed in human lymphoid malignancy, to 
see if they collectively can lead to a fully malignant phenotype.  
 Further, studies could include analysis of other signaling pathways. The activation status could 
be analysed by using phospho-specific antibodies, which has been successfully used in 
zebrafish for STAT3 (Jung et al. 2015), STAT5 (Sertori et al. 2016), ERK  (Nagasawa-­‐‑Masuda 
& Terai 2016), PI3K  (Jung et al. 2015), and AKT (Sasore & Kennedy 2014). This would 
provide important mechanistic information. Analysis of their role in zebrafish lymphopoiesis 
could be achieved by using specific inhibitors, which has been a successful approach.  
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This study has demonstrated the effect of the JAK3 A573V allele on hematopoiesis. However, 
other constitutively-activating alleles of JAK3 has been reported in humans to cause 
hematological malignancy, which include V722I, P132T, M576L, M511I, A593T R657Q, 
L156P and Q501H (Elliott et al. 2011; Kiyoi et al. 2007; Malinge et al. 2008; Walters et al. 
2006; Yamashita et al. 2010). Generating zebrafish models of these mutations will provide 
insight into the relative contribution of each of these mutations in disease pathogenesis. 
Animal models are an alternate platform to study potential inhibitors. For example, a pan-JAK 
inhibitor was shown to be efficacious in inhibiting the expansion of murine CD8+ T cells 
expressing constitutively active mutation JAK3 A572V in vitro (Cornejo et al. 2009). Studies 
also report the efficient inhibition of constitutively activated JAK3 mutation M511I mediated 
T cell proliferation by tofacitinib in mice expressing the primary transplanted cells (Degryse et 
al. 2014). Therefore, the human T cell lymphoma-based zebrafish model generated in this study 
is useful for analysing other potential JAK3 inhibitors. 
   Conservation of cytokine signalling in lymphoid development 
The generation, proliferation and differentiation of immune cells is strongly regulated by 
cytokines sharing the IL2Rγc-chain as part of their receptor complex. This chain is associated 
with JAK3 that signals via STAT5, PI3K and IRS to mediate its effects (Lai et al. 2013; Malek 
& Castro 2010). Disruption of several of these signalling component impairs normal lymphoid 
development in humans (Figure 5.1).  
Mutations in IL2Rγc in humans are reported to cause SCID with very low numbers of T cells 
and NK cells, with relative high numbers of B cells that are non-functional (Puck et al. 1997). 
Mice lacking Il2rγc also displayed SCID with similar reduction in T and NK cells with B cells 
also reduced (Suzuki et al. 2000). Inactivating mutations in Il2rγc.a also caused a SCID 
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phenotype in zebrafish, with reduced T and NK cells, but normal B cells (Sertori et al. 2016), 
like in humans. 
SCID patients harbouring mutations in IL-7 receptor alpha chain has been found to have T-
B+NK+ SCID phenotype (Puel et al. 1998; Roifman et al. 2000). Mice with IL-7 and IL-7R 
deficiency possesed reduced levels of T and B cells (Peschon et al. 1994; von Freeden-Jeffry 
et al. 1995), with IL-7R deficient mice having normal NK cell levels (He & Malek 1996). 
Zebrafish carrying an inactivating mutation of Il-7 displayed reduced T cells, but unaffected B 
cells again similar to humans, with NK cells not characterised in this study (Iwanami et al. 
2011). 
JAK3 mutations also results in T-B+NK- SCID in humans (Macchi et al. 1995). Mice deficient 
with Jak3 showed a reduction in T and B cells (Suzuki et al. 2000). Again zebrafish, with 
inactivating Jak3 mutations showed a similar SCID phenotype to humans with reduced T and 
NK cells with B cells unaffected. 
Patients with biallelic JAK1 have been described, with these individuals being 
immunodeficient and susceptible to infection (Eletto et al. 2016). Mice lacking Jak1 developed 
SCID, but suffered postnatal death due to neurological defects (Rodig et al. 1998). Similarly, 
zebrafish lacking Jak1 displayed reduced T cell numbers (Iwanami et al. 2011). 
Human STAT5B mutation also causes immunodeficiency with a decrease in CD4+ CD25+ T 
cells with variable levels of T, B and NK cells (Kofoed et al. 2003). Studies in mice show that 
neither Stat5a nor Stat5b were not essential for T and B cell development (Imada et al. 1998; 
Moriggl et al. 1999). However, ablation of both Stat5a and Stat5b resulted in decreased T cells 
and NK cells (Imada et al. 1998; Nakajima et al. 1997). However, loss-of-function mutations 
of either Stat5.1 or Stat5.2 cause lymphopenia in zebrafish with a reduction in total T cell 
numbers (data not shown).   
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Figure  5.1:  Conservation  of  cytokine  receptor  signalling  pathways  in  immune  
development.  
Schematic  representation  of  the  signaling  by  IL-­2R  family  in  humans  and  zebrafish,  showing  
the  individual  signaling  components  and  how  their  mutation  contributes  to  SCID/lymphopenia.  
SCID  -­  Severe  combined   immunodeficiency,   IL   -­   Interleukin,  STAT/Stat   -­  signal   transducer  
and  activator  of  transcription,  JAK  -­  Janus  kinase.  
 
 
 
 
 
 
 
 
 
Chapter 5 
167 
 
 
 
  
   Zebrafish models of SCID and their application 
Several zebrafish immunodeficiency models have now been developed. The zebrafish 
rag1t26683 mutant generated by ENU mutagenesis showed a significant reduction of T and B 
lymphocytes with a complete block of igm rearrangement along with reduced non-specific 
cytotoxic cells (NCC) and NK cells significantly increased granulocyte populations, 
representing a T-B-NK+ SCID (Petrie-Hanson, Hohn & Hanson 2009; Wienholds et al. 2002). 
A zebrafish rag2E450fs mutant generated by ZFN genome editing displayed reduced functionally 
mature T and B cell lymphocytes, with a complete lack of tcrb rearranged T cells and severely 
depleted igm rearranged B cells in the kidney marrow representing a T-B-NK+ SCID. These 
mutants were viable and had normal fecundity, and have been exploited for engrafting cancer 
tumour, hematopoietic and muscle stem cells (Moore et al. 2016a; Tang et al. 2014). A line of 
prkdc-null zebrafish generated by TALEN genome editing survived to adulthood but possessed 
decreased lymphocytes in the peripheral blood, kidney and spleen, with rearrangement of tcrβ 
or ighm abrogated but with comparable expression of NK cell markers (Jung et al. 2016). This 
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T-B-NK+ SCID model also served as excellent platform for tumor xenograft studies. Recently 
the rag2-/- line has been shown to have enhanced imaging capabilities when crossed with the 
casper mutant (Tang et al. 2016). This creates an exciting platform to determine the 
transforming potential of various hematopoietic cancer and for compound screening to test 
their in vivo efficacy.  
The zebrafish SCID model generated in this study based on Jak3 inactivation could also be 
useful for transplantation studies, if appropriate husbandry conditions can be established. It is 
especially attractive in this regard since it will have reduced NK-mediated immune rejection 
compared to other SCID models (rag1-/-and rag2-/-) (Kroemer et al. 2008). 
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